var title_f30_36_31296="Perforated hard palate";
var content_f30_36_31296=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital syphilis: Perforated hard palate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with congenital syphilis has developed a perforation of hard palate due to gummatous destruction. These destructive tumors can also attack the skin, long bones, eyes, mucous membranes, throat, liver, or stomach lining.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: the Public Health Image Library, Centers for Disease Control and Prevention. Photo by Susan Lindsley.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31296=[""].join("\n");
var outline_f30_36_31296=null;
var title_f30_36_31297="Lower extremity nerve roots";
var content_f30_36_31297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nerve roots and peripheral nerves corresponding to the principal movements of the lower extremity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 564px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The letters labeling the movements proceed in order from proximal to distal down the front of the limb, and then repeat from proximal to distal down the back of the limb. The nerve roots and peripheral nerves corresponding to each movement are listed below.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figure redrawn with permission from Gelb, DJ. The Neurologic Examination. In: Introduction to Clinical Neurology. Woburn, MA, Butterworth-Heinemann 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31297=[""].join("\n");
var outline_f30_36_31297=null;
var title_f30_36_31298="Chest radiograph TTN";
var content_f30_36_31298=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest radiograph of an infant with transient tachypnea of the newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 547px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figures A and B are radiographs of infants with transient tachypnea of the newborn (TTN). They demonstrate areas of diffuse infiltrates in the lung field and perihilar streaking indicative of retained lung fluid, consistent with the diagnosis of TTN.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Richard Martin and Firas Saker.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31298=[""].join("\n");
var outline_f30_36_31298=null;
var title_f30_36_31299="LS adult 45 yrs";
var content_f30_36_31299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus (LS) adult 45 yrs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoASkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDF1MMvmBJJDEpbtjJzx+fFVtLnkknklt1LEELI27O6QdTj8h+FR6xdzm+IEgRZGY4AxkZ4ye9JqNv9j0+0lR0aOVjstwdrl+PmbH1qGtdD109EXrmSWW3nUtGJsn94c8kjpkdfaqkMBtISv71pMAkjnB9z6VLpcMs6mOYxll+cyFiAo7gDpntmpJr+EBkn8zd9+KIEcj1b8KiwLQzgkU4d4DJ9oB5Z2xn8PSi+Mxj2iR5BgDcxC7W64A9Pepr/AFAzzSyQ28UUMfRHONpPf1NZtw5dla3ABcDcxzgN61JpFEt7KtvAAXeS4xwv3lC98+hqsbqcorRy7CxwG7kf0o8ieQFY2LS9PNV9qlcHIIxzVW5tlEjAbC+QMhiB+FXbQFuTpHO5YzS7E7KmeapTzXrt5JkXZFznNQTQsbgItw8q8AsMgD2pl3CEHlQXBZv7wxtJ96a0Ha+o28llgz57By3bdjFRq73MgY7k78NgHjiq6SSW+75VLHjk5qNTcSkGSGRo1/gRu9SVqakV08DYjZjtPDnn9KkmWa0/fm5kZwwYL/CT61WUGe3MsSCOLHyg9TUlvdOGhjkBaUjHPNDI3NiK5l1CISxOqSAcbiQuaSKCSSdRcOd7dgc7TVRba8itkmgUBBxwRkfhW5psKyKsjqWccnn2pp2BqxALG7t54YZXaSFMthWyAa3o7ILCiXM6rG5AcscY9qn0+zWRUl35U8471ZtLZJLiSKZJNy4bLdBnsBWnLfUi+hRubW5thMbMOIwpbdnaNvsT1/CuYnim+ZFLiRzgsG+VhXqGrWCExtKHICjYuAVC444rl9QeOFbo/wBmB3dFSGfcV8kg8tgcHNEotChPqctbyeTAytExk5UjOOaWye6gdQpLkgY3nKg/So7y2u45wHYpld+D1PNVpH8pJBJJI8gIGxRxj61Bq9TTN7JCjIZVJzk7fWq77pQZI53Eh5xuIH4+tZmFV0aWKVVA42561Z+2JLGY44VHGM+n1oRLVjUWby9uLrLEAcHFPmkluEAjkbj73OD+FVrVJiFXy49rkbN7BR6ZJPAFJLdOJZLUyRqdxDMPnXI7Ajr9ab0QJamiv2mKEHBm2njcT/Ol07USxdOQ/YBeB71Tsb5YUZYledsfMB0+nNTpDNcqJ4olUAncu4Bx9BUja7l2ACN1LSy7gOXY4z7ADjNXlunnEcTrLkfN5nQCodPuHZkhud5kGBvJyMewq8ksMzywGE7B9w5xj3pEWKt1cwrH5bNLIoHBXgD8Kr3Ezyyxo4MMR6gDH6VJIYg5TbtVTxk5plyxMTCQN5qt3PapbGlYgni82fMasIQerE8ewqTUNkKRrbyysrLkqRjnvioHctHiXeDgEA8Ef4Vbu4RbQwNCxKsmWKEZz75pFlGbzUt0aIyZY43bjVW2aY3ILTMcenFXbm9lbTBbPOzpG+4LgYUn6daht5Y3t5FdFMoAIdmxxnnFMfQSa9cXYYZIJHU/zro/tlz/AM+kH/fRrBwrRGLyiVaUHP8AEBW95UP/ADxuP+/lV6kSt0OWvn827hdoyriUu0W7hU7KSO+f6UydhLMJrxnWJOEK9M+g9qx5rqcXU0rD/j5ckn+6var007TQoq7fLQAR4PJA/iPvWrS1M10NKG42hY5fMDTEBADzj3HaqN0kksswiZTcH5dsXf8ALtTJbiOTfFbSO02ACdvQd+e1WY7mONBbRFYFjOWmTiUnoeetQ1rYpPTQiJh06Paqj7SRgyMc49cgjg9qjjkhZi935jRAlRHEcFse/pTL6SHdiG1m2oCWdju692PqaSHzZbd5kmhAzt2t948c4Boa1KjqhssksaI5geFGJVAepprFJhGiZifGXkk6AVIL8RjEyKMDILck57j0qpevYzxJ5hZMdSKXoXbqMngKAmG4JjPQgYBqpNcRJCIo0LTE/M55ApZUETHz0mCkDEajt6n61WlJdTIkaxxr/B6/WgbGFRuwhMr55YfdHtVxHneLyTCsZX/loT8wqOKa62AwxpCOoIGasWMQZjJcv83TB7/hQnroHTUht3SCQxuWZCQRz0NbVnGl4zNmOMLzubrn29TVWCGJ5A0Ks/Tr29a67RfDrzG3lQExk5ZSMbaajfRENpbi6PoEkqiQgs248eorrY/D7R2cSyW4jdhkZGCa6bSLOMRpDGyMYznA78d6vDRytwLia42LjlCvyr9K7VhkkefLFNs46PSvIaOWND5aEhlVgC3atPSbW8vrkw6fpoeQgFmOMoK2riGGIyt5DeX0BU856g81iatqljpNmtz5Vi3mMS7R37O4Cjg4UDHX15rRUbC9s57bm5NpdwjFNReziEeCB5wDEdux79zWBqmkW92hFxI5ZVLb2PUfhXms/iq71GSRrLVrLSoR9y4mtfNkzkfLvwSo6nn0ro5PGb6fEjy3ej6rbtna6ys5C5A3OFUbTnOATTcITNfY1adrnMavbRwTnYN2RwW4rmbmW6guXhtFUu4wef8APNdrN4ptdWuGS3jt7S6DZjjjySx7Nkk/lWJeafLuZWEasrFmYn5sn8K4Zx5XY7E31MK0uJbcSm4l8tyNhWRR0PXHvU1qJoHO14zG5zmReCPWnG1KXZjaZACPlLoXGP6VFIyo7COZCi8BWHp3xUuOlxrcmyX+WGRmycAN8ua0FieKCNRFtOMnJ3DHrWEbrz9qnh8/eHQCr0LOm6IS71PG8dqhFl6N5EmACIIyc9cM3+ArR+zpbzo5iwx5U5IPtkVj2TRxXIa8Vpxggqj4JPbmtBgshR45NhH8D8n8KGJ7muJ5TPGyEecDxjkP/gKtvIZIPNZIxIjbThs8+mKzUmlt3MhAMePmABx+lSW9xJNJ5skaKScK2eCPfjipZLVgdkln27G8wDlhyAParlv5dymGJMg53dM/4Uk9zEQ5kfEeNqnPGPQmsh7p7J8wEdeCDkClYVr7GheqgiaMyRs+NwOTk/jWf5zTWyReYAx4II4H41eW4afEs6R/N94svr0qgXltpMbSyA8jt7VLfQqKFhspklIibcpOWQnGR7HrUaeXJO6lASG4HYVpxXMkswED/OF3YBwfpWK0vlaoxK5+fBXNUh6s2NiS6k8cSE5CAY4Cgdc10ez/AK+P++q5nSFD6qTHuTc+M5JGD2Nd/wD2bae3/f01rFXMZu2h4uyPczy27OfO6Fecu390D1qlLDcx30doyPFcZ2mMnG31yexrLie7FwbmGRo1JO07/mPPPuK0tKsHnk3MXnlb/lmCf/Hia1m0RBO3kaW6SG0TTokQlGJPlDJY+570+ztwIzI8aNITj5yQR7j6VpwRTrHgeVC0akdefoPWoo3jRj+78x2yOehOP8aydjVbEFwIy7byzN1OxuMf1qGPFozusZ2dQpPNT3+LWQASCSToAo+Ws9ZvLmd7pGkmccKOAtF7FxCe5jZRkBpgOScfKO2KrXLW0i4Ks0x58wHoPTFSXMfnM7TFFY8fL0H4CqMolXGY3EeMEtwCfYUNWHe+gwy4mMcUjyyNxzzSCKWQENwo5wP8KteYkaxDO2TquACR+FV5DJJI+RsQcEryT70WtqxD7QXLsF3kxjgAGrDW4jK+Y+WznB9Kj0zcz/LxGnHzdc100WnRXkkaQwyPMx71KV0Ddty94SsI727iRYWKlhkk9u9ep26eQVhiTgnjYKo+D/DsemwCW+Y78AhQOBXVxiIBZ1wsYOBuBGa78NTcVzM8zE105WWxFYusdwFTiZhhiExxnoff6VeaDcT59yrKQTjk8egqNbfeyyBQoB/jGOD6CnLBKsrCd5HhLbgq5AT8P611HFuQ3qLLFHGxEkZI2gtgFscD6+teZ+NNfiS4uV1SZZrGMFTZiJljRwfukpz2z0I55r06502JYnaazc4IJEsh2ke+D+tcxqlhbPZahp8Ol2LCVMM1myu2OCAC3O4fXnpUq50UXFO7PJHa2a3kmht5VtHiVrezeYKH7lj6jkkZ55qS7ud2gwwz/wBpHTFkWOWCeRShXaCcmPB4OSB7CtBNO0qHTlsYrjxRHNaSGVrYIskKserbeSp4wfpWddzafcu9m6m4MgwjGIRumOWL9M5HHNJwUdj04zc9+hDoVpZWN2k+kXEd1CifOxuhHLJnOGHXZgdq6W2XTtVtmMOqRfaFOGIYvuI6npkc5rmLS7uryMaVaWEI01pOkfB54+UnqePU03+1tI0G7lttLsvOckjfMmGVs4AYjg498VjKmrW6Fu8nfqaGr2awTears8RwpY5UkVhX9oXnD2aiRk42HkH2rbF6b5Y2mVInbJMaNv5HY44zQ9mGjMUUKLIOyggtnvXNKPKx2aRzEl2HgET2awN0ZlB5x60QJNsffD8nVTkitO90ufSIHeeJWZ/kIYE7D65HFVNOjlkgkcTDev8AyxkI2j3HepavuJOy0HIYGTKk5xyQecj2pxAwMSOsxG7DGpbV4EPlybYnHV2OMntzUUzrG+HVZVY/f/8Ar1m0XFl203BzK53mP7wLkh60EXbIm8qnmHOQc4BrGt97u8YdyfvBQeCP8au25jkKRzGRQGw+4nj6VLQ3Y1hJEiiOZ1Kjqx5496zri3Nv5tzCUZC3y7TvwcZ79aQvJb7WjLltxVXI/SrUChwA65lH8EgwPwpWJ63LFrIWtVWZ45fMTcpPROe9QSwGQGTPmlDn92Rj6D2pIGktN9vtQKTkKQMEex/wqEPHb3TRM7NHJgoN2NjGla7EmXrCSW4uGmEZLoNhRBgLjjmq1/pskeoHcdrS/MQOq59RUMUUn9oSJGxO3PzIdoI9aZesJshp2Z43VQ2SSQfQ+1NK5V7M1LWJobywljbbvHmMDyvHGcV2v9tn0tP+/ArjEeNWTyhuJXahznvzW19li/56Wv8A3ya2W2hzy1epwFnp8fmHBM7IPmklIAUD09fauhgs5oo0MMiADJYIMmQH17VGlvHHL5u6Iuj5KemKmkckLKAkSFiOSAx/AU2upS7IqTWxcGRpgkpPAY4AqNI44kDyhn5ITjr2zTriVXbb5UmQMsWbkn+lVWiuY41k85dxyBzyorO2poldCyyTXcjR4QIhyCBjJNVpVj+ZpJ/3uQN4GMD/ABpk04jEiqTIeCdp6fWs+SV5JQq7Y4hySPWqtYdr7CvJBbyuAZXuC2R3wPequpI90AHkJGOxxir/ANkjMJEbu/IyQv8AImqnkMH46DrmqTtoS9WULa0ZJMQxkk9GPOavwL5QPm7WYnBPUirawSgiNGfaevHJ/CtW1tZJFWDyURVOSWX5j9ai1iuYraXEk06qYgqk5zjFe0+GNLs4bWCW2ilV1HzF8Hd+GK4bwxoE1zeASxMIFIyx44r1RNtpCiwEADjIrfDQ1uzixk9FFFxrVGhBnYGIjpjqKz5XtY4xFcYa127V8zO046VDe6i4iKhxGEB3hl6j1z0rPs5RrCReUFeSNtx2kuQe3y4wK7XI4I031NbTk8rzPLaZ4gflR3LKPTGc4rWE0gKySNG44/dbtxB9TnjFZhtScO8kaRj5mEnzEn1AHSp5dQRUjaIhcZG/ZgZyfXtVE8t2TGOc7lt52aPt+5UY+uM5rnHW+i1Nxaate2bY2mJLcsjn1JxjmtfVNYufsebSaOK5U4Z0XGPf0Nc9pfjSJtQMV3qskl3I+0xGABG55O7I28Ukrm0IySbsGo2d8iK+n3ujQ3yLsnuTvjuNuTwT0/PNY8mgS/Z3Vn33ExIbz4g7TA84Q/xd/pXef2lDqKPbxQtbtINpkJ25H1xzmqxsppppBqckRKriNJpiuP8Ad44+oxRZXszWFaSR5+3hiSw0W4S1PlMrGZYZHUDoeBnB/AdTXEz6dJawPKYbtGeMnKQblyegYjt1r2XUriH/AIR/yLiRpJEJVJWAJX2BI57c15zpt3cyX9zFaX0lvIFJ3qdgGAc5PatJqPQ3oznK7Ob0uO1srWO4gibzAxNwAcBh06H39q6zS7aPUjFNGQqY45B4rmpbSzUxTyR3TZ4+ZgT5mTlgB2+tWdOutR0++Yw2bXMUzYCqMHHfaPauarCL1OtXa8zb8S6eYLRyAssTKc7W5H1BrjpLAS23mQfeDcAjBr0CxjstSJUXL43bJVbrGe4IPpUOuaD9mDSQlXjVuqgq2PVfUVyyi079DNStp1PO4hcQzbbiTYGHQ9CPQ1b/ALLSNDvIXd84XdgN3rRu9LeRTIqFgTj6/wD16owyQwRz2t8jlWYMhY/dGMY//VWaVxuTM21kiBcMGDrzHluv4/nV1pG3bgPOSU5Ch8sppJbb5YzbANGo/iOQackfnBW81ImB5zwPpntScSuZFpZJ0tCGDtbq2Bu5KMR0yalDzGFnlcSZGVYfMQKiWH93tllG2ROHBOM+9V4GEDRxvC0ZUndKjEB8/wD1qTVxRNS7Y3Vnbh4fLEY2ebk/N9fSqNzMJI1Uou+E8sBjd7VYsh5Fu3mMJbZnIJjwSD6+uKYir5ojHkqzZO+XIEg7A+/0qGrj0RWmupDgK0jBvmT37Hp1qOJhLeyB1YszI/Bx04I9Pxp9sVjAjuCuXl27TwE9fpUd4z2Wpvgo6jCDyzgexBq1Hqw5tbG9pu1ppJGaNfKTcTz8x9K0ftx/ufqax9KkM8109wm6RygG7nAzyRjvXbfYIP8Anr/441aW0MZPXU49ltYbgiVpAwJ6HO70qeOFpYnZ0RADuCjO7A/lWRJdOzYBZ5NxwpT7vNWG86fGyR2kPBG7JI96G0zW1iswYmQ7SYsZbn+dQMfPlG12SBuMDIz/AFrSmt7WCGSNrab7Uo+Zs7gPb0FVWWRrRA4jgQc7mf5jx2z/ACFNRE5ozjYSQTEFwgLfdPp6mpri5s7e38kRGe43ZyDlAKrX00KPtjDSkjpnr7nPSq0aXM6Msq4jH8EQxn6k9qGlHcfM5Ik8+6mcLK4UHpGh5UfhUkkMs0oVBtHQgcn8T61e0jTVaVVZAq46J6+9d+vhi2g04PPcBXZQwVWBBz29RSV5aRJlJR3OJ0+FomXKndn71dj4U0uOe+8xlLIPmJJ7/WrXh3wreXVyr+WBCDwG5z+Fd/ZaWtrKsJRJVxyVXgH146VVOjJ6swr4iMVZbleGAJGAAu0DOSSoP4Y5olkVWKqquoHO87dp9qsXiRI6KxY8ZJGSW+lQXUEjwxyPE53P8zytsU47V18tkeepXKm5ZpFU2uUA3M4kA/nx6VYtrG2dRILjYgy/zSE4P4DipNNVUcmNrY7vvLBmTZj3NSPMkdyAs1uVAwSWyfpwKtK+pTb2RY3wyALE25RjO2EnnuQWIqjIU8z93EityCBKv4jbg4p1xIZJFT93sI5GQSfw/rVh4lEacrDv+VGc5X9KGOOhlSPb2DxyXGmT3LPIBhJCAR+JxWQ88bardNZ6GftKAzlGaNkx0HzA8c/WtLU9c0m1Ror64j1BsFSschiB46H2rjobizsblZdPt41VSVKh5GJzznkenFUpJbnTCDlqd/o4vFsnuRZWuyQglFYqVOe2D+uKzdavWmmSCSSWHJ2mSVvOjDZ6EdT+dVrDVtNd4EnsbhZ/+fiKRQOf72enUc0ajcyi+msJZlguXGzE+CjL7uOBSnG60MopqWqOe1acjztkOlvBE2FktL7ZkjjGyQggnr0/GsPxRrFzDpv2a4sbq181AY5XgyGT2cdaqeKUlgmAGiRrNZtiS6tZw8Mq+ndc4PY9ulZWmXcC2ct3Ya0+ntExmSyb5G35wNjHiQnvjGKqC0OtK1n0Op8NX63C2KvbeayK2143GQMdzj69aiawnS7l1BllltCDsKgqTnsO1YC+asloYTdzM+6W5Ag27XY8jI4P4V1X/CQappETqIxdW6fIjiJjsGMjA6/mKym76HSlbWPU5OL7Rb67cMJDYeaTIomTLOP7pP0966a01B760UN5nlr1wCoPuM1qaMLLxFH5k8ttczKh3RSw5yT1G7PB/Crslo0N8LXTtOnEKOqmPqhQjkbz1xwK55aqw5TV7NamRLpd5HbebCN0T5OCw5+nNZE2kpfwGcuUlUEAbeQK9El0ItFJGkMsQRsgSJgg/wCe4rLaxXTsvcRoZDk4IJz71jyu5ipJ7bnlV1az6fOyRTkZ7A5Vvw7Uy3mErsqgJMTkqT8rfSu112O21Jvni+YgAMOOPr1rjtS0ww8xeYuxvlcHJFCfQGmty+sc9nCLtcSwsCChwceuRSEyXdqzQqojLZGTkA1UXVQ86GZQpON+0YVqs3EPz+dZuyxyc4H3c+h96UohHzGrG0Vxm5jeEuNpeJh+fTikSNZiyRzHdGOFL7SSPrWhvkuNMbzcMI2xjHOf60jWtsACriQ43cj26Z9aVrl3MNpI1glbYi3SqRsYH95757GsyW5lktknlI3jA57YrpJDaiQuQqJINhRs5B7HPpXL6tZpHJOsrBgp+VozlWB6EGnaxLOy8OoNSmuLhZEiAIB81sDkZA+uRW19vb+6/wD30K4/wrG/9illYybpgpwcZruP7LH/ADxX9K0ZkvMoy3D3ckgdLW1BTbvcYOBWfL5METwROkkrNkODjI/pUErXplWNrOO2B/idTvI9cVBLpjTuZEmWY+vU/l2/GhJFD7m9SziKKwmbj5Ijlcf73rWROtzfuski+QvYAlz+Zraht1KFWCgLxjjk1YW3PmJHMUSMckBsk0Nt7DSSMiy01ImKqC0nQk84+tb0eh3Bj8x0Hl47HGfwqWE75B5UcaAcfN1/Kur0nSri+K7smP8AiHQEVnbmdkEpcmrOf0XRbu5uPkjZo1PVen513Nj4fhsiskzRo2RlZH5zXTW+krbRLGbiS3eMAuqBQo9Mf/XqO6mtbG6k8u4tkZXwzyjdIPofSuujQ5dWefVxTm7IUXsdtGIzOjhDk7IyCTjsfT2FPV5bpQ8EbkY+diu3aO2aoyTJcyLFpa3F1Mx3Euir83XIJ/OobgXocz6veQwwgbSWwefw5/HFdBz8t9TREzwESy7D5anCvIF49h1xXL3Opme+2xPPAIW+VE3y/N9egFP1XXNGjt9my4ugAQXiAGT2OT2zUTazeSWLRyWz2kDpgPNHgj2A4x+VRJ9DenBrVosW0c0xKhJ41JyxQjDepqWWwihQtJPISThMsAo/3q4zUfFM1pGYYZ1fZ93bxiuTvfEd9dSHz7hyM8DdgflWDrRgdcMPOeux6de+JrPSZAolhWQAqyxP98HsSK5698UR6iksSWYcPjbJI7bYR1OEHBJ9Sa5CPULphJm10yREZQ5eJcDg4HXkHHOKs2V0XnRhe2loQ2Vjs7V2JI6YBGOfc4rJ1pS2OiOHjBXe5q6jJqd08MqRGO3RSY3ggEKhc8nIH6nNUru41a2kEgaefB8vm88zJweMKQema0jKCrfbl8TX8jrhU2LtyevCnjJHpXLBIpNXiMNnMsrSgBIHZZGA/hBXkH3xmk211KXvaLod14d1x3i8nUNAsGUKEW4EoiKjH/LRSTknjmur020tdS0+WxtI5o0jkJaAEMyZHUYHIz79+leX2zaVc3LRS3mpxGRz5SSHzgAeuSSCT/Ouut7W40/ZcaVfvNcKMo0KuJScjgoRuPOOma6KdXuctSmk9HqZureD20m++0aLqjT37P5axSSNbRqcZ/eE8HPIABByB64rnbzXLkGTT77ZpuZPnEhWW2gboTjble2RtOcda7XU/El/r2BqbWsscTFXgaPGD6MDhh09eKyH8Pa1Fb28kepXws2zNDHMxKEgEfKec9SK7IVImfvP4jO03VmsdNjs7G+tI5M+Z51/L+4lRDtPlfLlznnCkHHbNSan9qlknuYdZ0yaaONcx2HmqFOfSRctx6H0rGh0+ybz21S8aG6g5hVIQQT6njHc+/FXLDWbLT7wx6Pqccs0oaKeWUNGm1vZhwR7etKVmzeF4O6Z1PhvX7CRGlmsI0vETBc8o5GAWbuM12Eb3l9aRi2sjHau4GVmEkDjPJVx/I153rEMELWz3NtHb28oRTNpsytH6bmVs4JPPUfSvT/CF3Jp1nbxxm1aN1IEVvkFgDwWTpk+orlqwW5NWVlzI6GODzLZ7eSQxlVyny8g4/l9M1yfiCwWOWGS9l2xkbfOQZTd6HuK69JbW6mCBPIuVGTDKxTBz1U9vxqrfiMlkuQjfN8ryZ2/j2I68iotpZnLSqOMjz+bwx5zGRG2Kv8ACMnI9R3rkPEekzWtxnzQy4yskRyPp/8AWNe6S6WYESSONWh2glUbeEHqPasbVdMiCsJoYpIJlwJVBOfcjt9amVJfZOiOK5nZnz3JbFDJhnj3LgMq5DH3BpsGpXVpFJCRmFgNyEZU49D2rufEfh65tcmVA0akkMpzx71xt9GfLZGjYwrk7sHdmpXmbWT2JYJnnUSWoMc68kHnI9x6VPYXBtCo2t6tjjn+tZtvJA37xWMM6cKyscN+HY1oQ6haT3SC73BgNr7emexqHG1rFxl0ZZa3WYSNGEeItyCeVz6Vi39kksNwjqBMo/djOQw9q1rqAJdia1n8xDgbhxgdsioogshMKvbSHtnnPfr+lFrg09zn/C96YZY7ORpDEJd+wHjP/wCuvUP7Xj/55v8A98n/ABrynUbdLC9W9iXIQnzI+ymtb+2x7fnT5tNTJx1OnuoIrd5We5kmklBVeTkA9sdR+NVpZ5YbZLdLiOJEHMcYGW92x3p02nXDz/6dcJbxMfuxnGff1NatpolvCVBiLbx+7lmBQD3x6U7jtpdnKl7q4lVLW2K848xwQWP9a0l0i7kCNcO29eSvQVenWK3nAmBb5vux8sav/aZGRobK0mi3Y+WRdzkfh0H1qHduw07aj9HsbeOTzJNpII616BY20nkrMZntrfbxIif1bA/EZrn/AAzpuqxy7rdoIEXne4yVP4g8/QV0jabZX+17/UJ78g/NuQlSR6Af/WrqoQUVc4cRUu7XG+RYSbWPlzynggOZ3PPTk4z9OKXzJVHmaXp1vBtPyy3ahmXHbavGfc1RuTqKSta6LpZguwpZPNcLuQHGUXvj0Jquunavqqf8ToXciROY3SOIA5x05+X61vc51C+psSWPl6WJbjV7cPLtYrFsDk/3cZJC54JqldQaY0bTeazTuVCxuhcA98nPTvRJpPh3TsTTJEsk6bVWF0JTA649T6Vy2r3y29u6wLLnJKynKkD/ABok1FamtKm5vQs6vN9l+fUpZVtQCESwRANx7FnHI+nSuX1rV4mt5pWjPUgLcx3MxzjgGUMF/ADvWRfajNqLTzX95E80a/Ib1XkZh6IegP1xVd7+a+jNudbmuLKEK4e9tHEUMmDxtUkAHkZPX0rklPn2PRjQcVqZWpatNcsqLp9taLnK7d42k9cbskj61Tlkkc4fCKwwxUbuPaqr3EstwC8quM4BBOB9BV0xtFFG7qzMrfLnp6lSD1rmbvud0KdloJbRTuvlJbSyjcFSQW/zqx/hGD0PpWvZ3N1FK9lp0Gsm5m2JtVyr7xnI2IMnnoO3elBlis1khmgikkyPs8ZZXT/aIxjB+tbHhvTr61MOq6odStdKikAeeMbHc/3Yy2Nze3pmheRMtrsZHN4gtrSe7/tW6BgxHKVvSHUtnCEZznrxjj2rI0/U5NMvI7ua1tr5MMvlzkgYPU5Ug5969K/sXVvGD3Wq3NpbzQBG+zIrQ28hGPlMpHJ4GeM5Oa841uweC8kge1MEkICyITk59fx9qclJE0+WV09y5MsEsgnexgFtMiRItpdB2jYnJOC3LdsHgGtDRL+a2ncRQ3OqCDhbWWV0nhUA4eJ1bgqewH6VzEfmJy3EiABeBSzS3GpNc3Ursbm2VZd+ApyWxnIwcjI6c0RqWYp0ejPVtWWb7NbazpGo/wBtW7ruWcKEuoSBhlfby205zuHOeahg1EyFbuS3a3khj+/bgeW2D1Kn7rfTg46VwvhrWI9N1O1l1W2nuLAEr88hjaF2AywdeSB1256V6paJpikwDR3jtXOI5EuiyzD++rPg5GQMYx610qd3dHFUhyK0lfzOI8TaZZQ2st1bNPdXbyBxNaDzogM87hwynnuAKdFevcXGnC6tLARQRtJBcrYIksueMPkYfGOD7Vr+JtHTQt9xAJJlckNDvK7PQ8fyrklu7qYwQiGZIgCYWnlVUH97B9M+ldNOaLiueBt6q1rew3KZgdkVEFsn7gjHAbaOJDzzTvDvii88ORSW8i6hDaLJsScrvWJ/Qgj+orjrjavmpd3CW13uyskR85G9sjpW1p9032GOHU4IfJMilplkO917gjOOh6kVdSN03EpRSXLPVHrcmpPdW6S6pBBqFqwDiZc+Yn4jkfStLS74zQMmlM0wxzZXeAf+AkjB/Q1xVqt3ZXMieGtZhtLmCBZXUzBjIjchR/Ce1Zc2u32q3kNrqWp7LyCX5YRF5RcE8k9x0HSuN3g/fRzexU/gPV7W+GnHCxMsXG+3dCPrg9v5VauGRk8+2k3Qsc7eBg+hHY/zrzuLxjIZUstUglu7cnaJPM/fJ+H+c1v22pRx2qzaeyXFqMoylwzIOysD1qozUtjnlRlB6oqeK9Pe/wBNeWJmIVsuh6g/TrivItWEto7G1ZVDcSxsM857V73M0F3ZRXNqGglYlVZGztIHf9eK838S6LPNfyXItSVZsbUX5c+o9PWs6ia1R2YaakrM83vLdlt1kaJCPVR1+tVJLUqPNA+VgMgeldNdQGNCiOjhiV25wFPofSsieGUXKxsdqD5mhZuvsD2+lZ37nVYbaSiSBo4m2yjG5TxuqbVbqBlTyI9nO0nPJb19qzNQjSciW3R4nRdrIT+vFVbdpF3RTbFjbjc3zD8PelsCL1+RIFVl3RNhPMOOvb61U/sr/pov51px2ClIIZZRJHkuAflBGOoJrQ8ix/56SfkKcoXMpPXQ6vU9Whe8dtKtUmUHbvcb8ew7U0W+pXd1GLizYMw3L5rFR9SB1FdFdSJ55Tybe2d1/dyNIGK7T1AHQ+x9KzBpsmo3G/7TNJk4YMxX8RjkCnK5MbW1Ens3uLqKG8uRJPAD8g2+UoPZVUdfrXbaBoKWdsJGRlLqCG2DJH05I+nFN0WA6VbRq6YIGfuhWIPuea6YSAWayFHVCeQpC/mTXRCHVnDXrNrljsZ1ymnaciyXEciqxI2qfmf0+Uc5rPl1W/uYlh0PQJVt+d8t4RGv1HIJ/OpL3XINMJD3CxSyfN5QQSA+hyCeayzeatek3KIHiRSBE0LnfxkHIGB+JrZHLGLe5PLDq0cYF5rmn6bDvyptYU3Htncctj61kyWsFzPMsmqz3zA7EkuLtlD88EAcfgarXekeKb/SbqcXWn2lsvLGd0+UDn5SAT27GvPdR1PWrm3khfXbie3iwCi/u1z2wp5NZSrKJ30MK6mzRqeKdTTQr6bTrf7AzrIQ7RqTJEf7pJAH5Cqt74gsrmaK3udW220VsT5sFoWPmYyIyDjvxurlrTTre4t7uWe4ZbiLaY4NhLTknnnoMDnJq/OfD9tp8iW+hancakRgy3N0Eij9giDLfiaw53LXoejKnGCUepgedcXGoqLUPcDJd41YDcq/M3XjoDWnNFcNqsFymjaNp0F/E8US6o7PAcjPmA54Pofu5PFcnqNpdxSgSxbPMwVj2/Mc9MDrXR6lpvirVba3v9btb0W6RLa27Tw+XGsaDARBxwBWMGlds1mnK0TEjmiu9ZM0FpFDCg8ySG2IRQF+9t3E/wAzV9NTiE7SohcsDtGTkH6iqdrogd1aTBYtgIOea63T/Cj26rJer5YbB+8CIxnA3/3azcnJ6G6jyrUyG1G8nEavNJshB8oMSdmfQ1MNU1C5Gye6uriMNv2zTMyhsYzgnGcd6sawbC0EaxTrI7DLBVwF9vc/pVB1ujaJPbwr5DMUXc3ORjJx17jrTjzPRCfLo7HSN4jvp7aKF7+6kVcBUNwwCYGBjnjirtrFHrdlBFbzWi6sXclrq4aIuuPlXLDYT6c54Apvwu8LP4l8Qx2F7JIkdyjhnVVO0AZ6N/TmqnibTP7Pvbi0Vg3kyNHu2/ewccj8K6Iwk1qYSUVPkjvuZ9/BNYTGK7iaN+54IJ9mHBqvqOnwraJdC+sZQ2NkIf8AfDjk7ccY6ZzRa+I57WJbC6ZmtIpPNW3k+aAvjGdp6ccVpS2GmXwmuNIR1BU4tpphuTgfMrDG/nPy/wA6x5bGj5tmZMF3DdWLW9xfXylUaX7OkIlXzF+71YYUrnJ6jHeu4+F/iDXraSOOy0+31SGQ+Usd04O0rydjFv3fB69D9a4tbO4eH5Zhut2LJC0W7n06c59DxxVjTECTSXU2nxXSYWOJ7GdbcK46sytk5x9OeaqErNMwq004uLPoO7tL3W9Pnims7e2IGzZkNt46B1+8fevJjodwMiWDz1t2JiVnJWPk5ATPOT+tdr4J1qT+yIXubXxDaYXieREngZsnpjBA+uc1H4glhur+9NjLp8CmNWkMkjRvITnLRBujdiPyrtp2ep5kZSptwOS1ex8NTSOIdQiLCMOPPcW7AhRuVgy5Lbs4ANcNqCzy6nHZaWZ7iQEBUkjBZm/iCheq5zjPOK9R1S1gurSZ0ttSv768XZLMNszZ7cEZHTnHJrjLWyfT9lrpviWwhmnInVZsq6uQV2hmXKvgnIB24712tcy0NKNXk31K2tJPfNaNdWhREKxxhJVHlnHO4Y3ZLDPXA6Vtzare6P8AZbDWLWRlb94tyT5rAbs7k3YOOvAwKjv9D8TaTsvIr29mtXGZr6ztMFVZecrgZUAdvc55rl9Pu5tM1y3ml238MIwZPJJABP3ZFbp6duKVWF9GXQkpbHqmmXS2l2L3UrHzrCdS1nLAoYt3I3DqfbqDXUaZpek6rCt3pIcS4OUkyp/A9yPSuT8E6l9re5t7WaLw99qO4WxTfayD+8obJXPqpxXW6Rod3ol0ZL2GdopMfvbeTeE/2gP6GvOlHknawq707MguJbnRpE+2kR2LMEW5jG5FbHAkHb6npWoSL6MIWzcqcZQ4IXGc5HX6960rx5HV2klS5imHlvcGPIZT/DIh6/XrXM6lpVzossMujPLcWZJ/cM2PLXuUPcf7J6VaV9zijL7zn9e8K3PmytFAXWXLLPEoYepOM/nXG6hpNzaybJLeMZA3IclZB9f8K9u0nVxq1uqXSOUfcr4UKzZ6Hb2I9utYWu6BDcNMVXzFTO1lc5P1GOD7jr3rKVK2qO2lib+7I8b1GGOSJniRoJU+VIxhgR7nrWQiQSWJWVY9w7k7SPbB613uoaSUMtwUuYZFU8Mmeen4j3rLWeJrSKC602CUbdqyKoBJz3I6/Q1jc7YpNaHPPbW6Wccou08xDxGM5A/lVnzh/wA/Sf8AfFSTW1pZ3itLnyZMgxhclfTg1f8A3P8Az7v/AN81akRKJ0niG7lhWaGwVFjdsZiUAfj1P5mtrwlus7FZJLhZ7hyCVUcqPTNX9L0NAoa4jV1JzsLYA9KvJp8Mdx80oHYKin9KqCd+Y5p1E48hPNqEsLNI8ltAeGzK3myD6HoKr6pqtj5Jkmju9VkPRZG8qMe49abdwoJAn2dwByGXAX8yc1W+xo8v+kfZeuAs91ufr19K6OZo5FCL3K48SXgyum2VpZxcBhEi7/8AvrBNWdNufE2qYC2TXJI3CW4DuFHqAxCkfhXa2U1rDZ7n1W3tlUYHlwk59skAflXD+KNXvLufyrDXjAIzxmQjcPTAHSlra9xwSnLlijUuvCOtanAw1PV47e1YlmgMyop74AXp9KwrvwZ4f0kxveTTXgYH9xaLtY/WQk1cs7eaTYdS1SOcIoysW7n06gVfuWs0RD9qEwH3gPlIHocURgp7milOm7J/ccOZ1s9X3aHpkWnqAQQW844IwcluKyfEVvqF5fR3VtYy3DpEsRMNqXXKjHOBjOO9d++n2DKZha6lOqYOQ6Ihye5Pb8a0f7E1TDT6Frq2EuWjNuJGZCQOd55UHHt+NFSlpY6lXjGz6+Z5nYajrdrayLFHo2nSD5VX7MrzZHdnI+X8T+Fc34t1O/kKpquqNezEbtgnEoB/AYB9hVzxTbXT3zpPcpdSBjvMR3Ln1Fc1PaeU4yrH2rhlN2sj0aVCN1JiWN28cTPbW6sxXG9+x74qtcSXzIyiVo0PVU4zW1cNdX0xnun3SkD5toXgDHRQB0ArOunKOFPLfWs1psdihdXZUsraNplLruOR8zcmujIVbcKQAq55Ucn3NYdu6RKS1aNkba8mEcl7FaIU3Frgklj/AHVVQSSf/wBda05crbMqsUdn8Pr8WfiTSm+1LbQpP5klxgkLGFJbOPy/GsDWr/7Zf3UjSGQO7OHJ5bJPNaFpq76do09jpVl5NzcqY7i9E7EyxddmzGFH05rItdIluYJJQJnmRsugi+UL6hs/pitvaaWRlCkudzenQyJLRbrIAxngnvXRaijy2toLbTNL0t4VBJsYijTEgYL5J547Y6mq+mQJ5siBgzLkY71f1TVp9R1C2e6u7eZ1t0iISDyvL2ggKQPvH375qeZNBOm3NWMc63CkSQX9gguY33C7RirsvdW7H2NXL2HRtc2vbNLbXXEUaN8yBFXqzHnJx2qhrMUcmTw3HNYVs720wCltmeB3FY83QHSvqj0rwXqPiXRcXFjI7wSDDGeHejAcYyfTHauhlv7OO5u5dY0ZJ5JvnjkikaJozjBXIJwvU9DzW58K9a0+7toLS8J+1NhYywypIH6HH4H61vePdMsGtUnjTY8h5DRlAQe+eRwa64ppI8atOPtXFqxwcXiEL5CadZ70SPG2+PmmPrkjbtDYzkE81nTeHdK1CSJtRcRm4babp1Gwt9ByMfStw+FbmKS1W5htWhmB8po7oKJOCfvHkH8MEU3SooUuJrGWzvxPGox5bhyDnru4wMdDzXZQlrqY1OVK8Gc9f+F7G1jB07VX1TychoYWeNo+Dx34qCXXLpks18ReTNYspja9tiBclQMBWYHDjOM7q2L++1VNcgtm0+ytrohfJu0PluccA7hwxPfNXNSj0K/jlXUIH0nVFOJJlTfDO3QttUYXntxXofEl1MItxkuYy/CWlahc3LNZTWep2yxEoLBkMtu3bKyAFV9Qtep6HeX6JHYXsH+kqwP3htYDoAfutx2zXndvoV/pGo6XPoc9vbXc5ZI7rZhHGM4bP3fT8a7TRtc1a2/c+K9HgtogdrSIRskb1KqTg+4rhxFNN6HTUbqK+/5mzKiiQSrHvt5fnwDg47/lTZbEywE2o8yI8mPONp/p9amggt4xuthH9nf5kiaT5gD/AHc8Gq88LoEu7J2IQ/NFK3UZ6DH9fwrmUbaHI1qcXqqXttfw6hp0klpCy4m2+vpgev8AnFbGm6nNe6cl2sBklbCbVGC/OCD6ECthRb6ijssex2++vKjP+e9czeR3Wi3jSs++3c43MeFPQFvf/aov0ZpF82nU2ta0w39mwVVPO3y5VOOnY9RXmmuaCbCUPAwe3PLK/AQ++P5/yr0mPUikCQagZFkkOFdFzH+Ddvxrn9et5Y7k+bKChGQxGD9M1hWVjrw03ezPJrq3jvEIQuXVtvXOPep/7Puv+fk/l/8AXrW1m1KTuyxumRgvC23cPQjBBqD7Kf7stc6PRb7HqWh3jT2rLLJmT+8zAn6VpXHnw2wlW0umUdZCDsUeuRXlyeIp7WeURrhmbnjaB+PpV621i51AZeZY9/GJt0n4AZAxW9GomkmcFXDyT5kdbJq1nEFjudQtYUIB3CYsoPTDBVyD+NTs1gwX7KYpZGORtWb957DccVz2hyanueRP7PXGFy9pv49Tkkce9S61B4jaxkkkis0Ac4k3rhu+QMHH5e1buWlzBU7ytcbqd1qbzmCGz1S1hEn7s+W6AY6gZbrV3RgY233hmiJ+YGWbk/ka57SXv55mbVdV02QSAH97LK6KOmcADB/Kruow3kbNdRaposxZQgEER+UDvknj3rOMubU6HC3u7HWSGO+tcPdIyrwFMxJP51iTzyWglgeTejEYVcYYDpzzXMW3iGaR1t5XtgQSMRADJz16dDXQ2ULXG15EcAdCB1NaRqX2E6Lp/FsWr26mbTInvpXMTfIQQSUUn7wPAB9K3PDr2V3aXkepX10tnEoHlnYsbnHOdh+Ynjmq1/bl7ARiMhGYIXZ/lYdht9qzhPbR20zSSRM4ZhlEMatjuFPr/Srm2Qkpxsjh9SSGKeY28JKhjtPoPSudu5A0g8wDjsBXTaxrUMYYKu7vx3rlZXkv7jy7YpucZyf4fauBx10Papt21KFzeMmSBjHasS6mM0m5Ysk8delbupR2lkuLiUSzHjAPOayoTLcSlYoyiHv0rOVkdEW2tCtHbMgV3myx/hGeKsxwbXV1wpH51r6ZpSs+JSAo6k1uLZ2kKbkQY7u9Tysbj3M+xvHjtwJEdm9cdKnk1docNHHMnZ+ev4ZptxeWSZDSfP0woz/KlttT0y1uo57zTmvbYAgxOCFfIIGT7HB/CtIClZdCY3mn38hnv2c7us8CgSKfccZrO1fRtQsEt79gJ7CYnybuI5jkx1Unsw9DzSx2MM6rJanaT2zUsN1f6ZC9uTJNYSuHltdxCSEd8f3sd6XWzBxlHWBRLiWD5chsVTWNDMCcbq1vsKXzvLoW+T1tGbMy9/ujlh7iswQ7pDuV0ccEEYwfQ1LWoXTOr8Hu6XYWJmXkYYdRXtltGt7oiQPP5ZDfIS25M9wcnK/yryTwtIE8QCO+ZrhZnRDKnBBIHIzjkDjnivU7Sa1Es1rbQKcggC5AIk6/ip9s130E3HU8PMNZKxS1azt7i409oIrrznj2RC/nDxOig45B3KODjtSS6hHpNrBmKOC+UBPMLeYxB6lWAwUH908iqd7DK+sefdRPavIBsUR7QAOhXtj8a2NPjWW7MEmjW1zG+AbiGTYVOP4hz+ldMdDilHRXM3XEstQ+y3I1W3W7hPmEXKgRyeyhfu/Wr2pWl151tc2UkEC7VV51ZZIWcfNtLdD9ODjitLXvDsN7pjtBasrxYdMgFivcZ7/jXN6Tq0mmaRHaW9oTHdXEqmLyS+Bn/ZGAwB7Zrqp+8vdObzRgJqMkOrGK8uLeXy2DRizl/dShuM7GOUbJxgHqOldrHp+kXE/y3EtxPMm5riN8so7KwIxwOoHpXk/jLS/7P1ONNRinWOZ8280ilEaP6Ebgc9+9bvh7xHLb20GnatPd3FjBuiWdCFa3j5wy8fOPryKUnd2Z6fsuaClBneaaZbGZoIJnubckLucDAP17flVttReR5YwE8+I7SCMOPr6iuSGq/a9U2W1zaX8irk3FqxYOp+7kf3h0Oav2WoOk8EN8YQSx2OpwxJ+v8q5Kto6kSoOSuzaa9MifPbmJ84LDofwpLuMXsG2Qb1xjp1/Crckcrosm4Eeox+tZ8V8onMSFfN+6o9fxrC/MtTmSs9DCt7ltDldGEstgflKq3MY749R7V0ENvDdQ7rdI7/Tx822GQOYR9M5xx0zxWVqN7Y2gdrsYYZKhecmuNt/Edxp17LJp6hYZj+8jAxn6Hsaj2iWkzqVCU/egdh4i8Mw6lCLmwk2xgZ2nt7Vz/wDwjMv/AD2H51saW8GvWjSW13LbTkndnkg+hFH/AAjuo/8APwP1rOpTSd0XTquK5ZS2OYsfDSS200rq7ujZyrhTj/azWbGiQXBMjxgMSMS5f8hXRyPEsgSSAsN2T0J/DJ5rD1GQS6ihgVUA6q2T+OFoSjGNzW8pOzOt0XVrXTLP/j4lUOpDBLdgD+G3pWVf61pGtskdzb6lJcx7laYzFYIkzwccDPsa2tPS7ktCjr9p/d87bUqFz3JJyfxrkJ7p9Hurxba7WzMsZxvkiCTDPcMDjH51o5WSMKUFKT7lS/Yqu9LCH7E6Axi72ln91Ab24BrMsZzFFL5UDB5ARtdgoX8AOa3prq91GxRbnxLbvCMlYrcvIU9sItUYJorQtDNMQc8FrU7jj1zgisXvc747NMz7F1iufNnjRSD0/rXZ2Xib5doZfLHQYzXI3kIu7gSANFvGQT3+mKcUWBG8xN2V6HOKqDcdi6kI1F7x6Bd+JLe604KrgXMJDKd2OB2x3Peuc8R+JfsunvF5ijziWOUyxJPOMjj8K4u+15LGIGONWkUY+b1rkNU1WW6uTNdO0sj/AID8BWlStaFnuYU8NaWmxr3uo+fjzG4U8AcfnWdLfMoby1bj0rLQtNJkts9gKlliZjxI2PSuF1GenCCLNlPLcSAynaPXua6K1VmA2J16sRzWZo9pEoVuC3fNdHLi2aIAlcjJoTNV5E8cJhEZckjr16VDqlwG2qTwOnpT8iWNmd+QKx72QvKir0zWnQFqTiNST3J9K0L5IRp8UYBJ6nNVYV59cVfvmzBBEQMcZxSRMldopWltIjB4XKH9K0BcmYBLhcMOhFEZSOMqGwQODio7RSXyT948Gkax7lPUtPLEXFm7QzoQVljYqQeo5HNXdM1VdanNv4nZhdkYW9UcsR03Y6n361YuoxErNGuH6EdjWJexrKDJCdrjqtPm5RSpqav+J6LodvqXh/XYJ4Qqvw8byqCGGOCQfY8GvRrorq/l/wBoLBHLINpgZxCA3qrYx+deEeC/E80V3Hp94yyWxYL+9JIjBPJB7V65Yy3Nnp+6eKWbT3OwMu14055yMHGfwNd9GcZrQ8DG0pRld7lS5im80xxajPdNHgLaSMWdB03KfusPYflVjRWOozbkjt4plGCXYpn8uKSy0tdS1ho4jpTlv+WSSvFO69eAOMYz0pbrSp9PdWs7R2V8ExXDmTAzw24DK10x3OaTi1y9TTFx4ht7+2S4MM1szkHyWJIXBwcHggetc7DZbfGti2myJcXs037xrdz+6j4y7g8K2R1PXNampT6xFbSfZ4FgcKdm079v1U157oWstp+uG11RYY1eQySSSQHzM4ztJBBKHA45xnIropS5WYKk5JtI6v4l6pFfeIrW11SaCKOCVWkuD8+QpC4G0cY+YkVd0Sy0bVLG7ktrKCFUlZY4vshZ1QKCGV26v3x6Vzmv6bpupXdrcaSbm/DsJZbVRtZwrF32j0ONoHXrUUnim/ttctINQNvG8shu2SRVkjJxhSQh5GzAx1yM10uMfZpROaCqKVkzZu7WLS7qOSDT49jEeVdBAsm4dR6jqKtNf20y29pdALfnLHfCG3jsVIzj6mmy/Z3tFvL79zDcvtBhnMih+zc/MAfTtU9vbxb45rhUkmRCYnhbJP19/Y142IlaVmexTlzRuzoNGvJZLTDQ/MMqdw5BFZGu23lMLmMAuDk44xWrp+oiSIyudwxtLrzyOxFZ2s3sTwFSydd3JwTWHS5ypNVNEcffXUV9PHHdRhcn7+ev1qDUdKntV3RBHgPCYNPZHuZJJAQFjyRgVTW9kkbyCxOGxsPQ/jXHe+56cHZWRIusyWUJmt38m8i43BAyuO6sDwasf8LCn/54w/8Afla5/wAQbbcKiNneQCBzTf7Mk/uGt4VJpWRFSjSm+aRbvZXOoxR24U/N8znJxWrYMPtokuJdueAI8Ln8aZLbPHq1s6xHazclhwRVq4L29/HsiUDg4HAPsaq2hE2nojV164/4k5aBU8qNhvaS4Zn2k9Cq84PqKwNtld2E8ks+k6XFOBt8u1aQSDocM5JWneIdRcXBju77aWHKFWYJ+QOB7Vh3txDeXEt7HqOmJ5jZFnBHOQhHcDZhc4ziqlLWxNGFkdBfajNFp3+haqqPsCoLeMQwoo4AXLFsnqayobq5nlE91fW0r7uHCqWz1yVAwfqaraVMrSPdzSqqRnlkkO3d2JwBWgskc/kQrbW0O0nmFMGQHuxJ5qLcx2Riok32GS5XeCN2dx2rj/8AUKh1GVtPtZJTZxzJEu7Ej49+BWlaQTI8gRbkj7oaJGYD2yK4L4kartMVlCXEgJaTJ7dhitopJczIb5nyo5XUp5L25kuX+UOxbaOdvtWDKWlY+Xkop4zWgLl3jaFT8pHzn+lJZ+V5mHVhHggFRxmuGcnJ3Z1RjZFWGGUENIcrWtEoC/Lg571UmLeaqLlh6CtKFHELNIAo/Os0jZbE9guDy2Wz+lXLmcySjGc9OelRRRiOKLyyGkPXNSvGqzKJAV2jOPerN4PuX4c7Bk9qztSIQqwOemK0oVHkl2PzVi37NLKBgEbttadDKUtTdsYi0auQcY5xS6tckyxMAcgYrpI7T7Fp8RkUbigOK4zVbhZ78Ih+YHmhGMal2E1y5dcfdH6Vt6AGkmO7JXqM+tYVsqmXBB611mmQeUSwIGAMUWvqdLmuUfevFg/KQewI71hsiSuxwAfU8VsXsgeX5DjPaqrwi4tdpAWQE5I6mlN6ji7ROQu0a0vEfbtyeCO9e4+B7ifVdDBhZC+Ak0QkMTumODk/Iw/WvINVhDr5M4KvjKntXX/C/wARx2zHT74ncSNnQrn3B4I+taYaVp2POzCDlT5o7o7S7sfPvrYpZ3E10Wbyo7aURMCBnJznBGDkZ5rTj1DWTCkTsZQUG2WVSHCZycE9TxkCuc8QXmo+H9as7u9jlFvFyrIAjFTzywPUg8Guuk8RK2wzPN9hkhUKkaghVOCAzj2/GvUi76I8aV2k7XHrNbtdfaPtE8jsNzrJGUABHI56n6Vg+JtL0rWE8pJYrVgMQtOMKT3Hmfwj06/SuvsIY7y2eTT1Ajil2wrIpZVyM856jr1rmPEEU9nf+akSR3DOJE+6YzgYI6Y79Kq/cwjJxl7uh5xf6DrmkWyXCR3QtznZdwS8HtkMpyB9aisLrV9RsZLaeH7bbfLK8kYjaVQpALK2NwOABnp616FcapfaXcw+deSaeNoObVPNhcnrvQHA+g/KquoWNkxa+u9OtsyDMd5pMwUEn1TkA/TBpe1lFbnRGSm/fWvc5CPUF0+S4guLG5+zyHbC7uAc543evHpjmuz8LNIIHQRLM8p3hnbDIO2KwpdNguo/3N/Ib1TuEN7GSMf72SOvaoNI+1Qaq8c8q5X5WVGzsP8As+1edVm27npRip07JnpFv5TGaJSVOfn4GQ3euf1zTygUs2WPT0Namk2WpQuzN9jksm5UgESg+/OKfrthdSRrPGoIQZx1AqZyvA41aM9zkZVxbmOAkEjDDHBNczrkBstrRSsJGGSCMYrultfMRmx8zcrx3rm/FVjJFAZrli0hP3cdfpXNFN9Dqi1c5Pw+JL/UGebLJCQeRkbq7nyvr+VZem2YsbVFIxK3zP8AU1t+c3rXbTVo2OerNyldDvEV3cG4xFEVhVwxI6iqNyyCVZJFZycHJNX9MvIZ7KRZmYysMEP2qKaKCS3RowHZfvDHBpO8o8xTSi+U53xfqcltKkhnaFQowElYE5+gx+dUtKns7p1DXpWNhuKrIWBPofWuqutOOpJtt3EDCMqVEe8fT5q4G9RbKUQtp0e5c/MsBUsO5yP8Kzle/Ma0WrcvU9A8EaHDqlxNEL6aFTKsIhiQfvAec88Y/GtnW/BsGnyPb3NwkN0eYlZsAkdMdsVw/ge4v47lpbO5a2tgQzRGfBcjpxXqvh+5u9ZGofbGjma3wRFM65Unjg/TNdVBxa1M8RKdOd09Dyi71ifR4pXeSfaoI2RylRu6bsV5XcXK3sl7eTzKrL8yqeshJ6CvT/jlNaQ3FrFpkcyRXCs4EmMk5wenPXNeOX4VfIiTrjL/AFNYYn3XyI3pTUo89ty3atuUQ5++cknpVm9nCYgiLPHHwCOnNWNNsoZ0XdOoXoc9qpsYkZ0jkJ5zg9K5GnY7EyWwYCUs3Xuc1qiUM4zGdvXrWNbh2YlcDHXFbdnllBEZAA+Zu5FQbpF9SjWzN58ceFJwR19vrVO2LyTqcbgeQc0jRPI7AfcPb2rQ023ywwCSPetEjVaamjJD5NuznHTvXNoDLqUEKhiDIM45710eruwtwrkAjtWV4QQTeJbY/uwd+F8yQIM46ksQB+NW0ccno2zvdWIjktIpjJukG3GORXnN+i23iG4j3FsHIz6V2/iLVfM1u2uWjZUSPYG6kn14rgdbkb/hIvOfG2QY56mqlGyuY027m5ZRgzKwOS3WuphC+UxAJUDmuV0qRTOgJ5PeusCtFFu3KRj8qmJ0N7GdO6CRAnBHpTJp/LUDG7nnHaq7uDOxHUmi/YgL5XQ9vWlM6UtCXUbVLuyLoRvUcCuNkd7eVZVchlPDDt9a6i7doP8AVhkDc59KwLhCsjuVBDjn0rNuxzs9i8B6jH4x0UaLqcr/AGvZiB2b5SR2P9Km8P3Fx4RurjStR2RQGTMPmLhSc4KlvXuO1eReEdbk0TxBbXMLZVWHytz/AJFfRmoRW3iHw7De2YGXGTE+H8thzxntXp4etzq73PCxVP2E7fZY61aaSL5IfKBz5jRkNuGeCoBHaqoeJZfMkZxIMowcbsL16E9ahj1WzuY/Lm0yJZIW/fKpO3ceBk4yP5Ve8izIzbSpb7QRiCZGzzxlXwD+GK7L9ThktdTGfykQNbyRqGJ3ELgD2IrgfFWsRW07eVA9mc8y2zfIx9SnrXdeKLprazKu6SOgxkKA344ryq+1BrqfypACoPpiuKvU5XY78JS5veZJa+PtYhk+z29zY6nalScmAK23vnODx6c+1X/DtymrXvntdp9rRSY42DYbA4Ge341ND4Etbmza5m2QzOMowU5TjqBU2h+EJNHlEst0t0O7rldorOo/dO+E6aTtudx4R8V2GpxQ2MpmjvgCJIWjOOOvPSuwvJlW1Axt45rA8OfY3KtCMvGPm45NdDdYmjOASpHBrOOx51bl59Eea+Ir64W4CxFcKTjnGKpWuoXGq3cdrK5NvCPMkGOpHTn+lauuacP3plTJLHBqv4SsjFY3ErrgzSkD/dHH+NZ0E3Ox01JRjSujOuEE9zsHXPNaH2Yeq/rVrUdPKSrcRL9VqTd/0zrrlo7HPF3V0VtJt454p3Oxl3EbXOWqrcWws3YwSbomPIHIrHu7qRW3HBwSVeEYb8eeal0/U5DGzbIzKOGX7rsfTYeD+FZxa2N5xl8RtpYnycxIWeTpGW6n/ZNcRriXB10W0izwF8h0lzE34k5Br0fw/rVjck2Vy6AkY2MoyPpmtTxFZyQ+G5oyj38DKXikMeZIm7c+lWoXVjnVZxlqjy/RIrfQ9atrzVrC5mskzhy+dnpjFem6DZ6bp9/f+J7xlstOvFaSPgOJAexXHX6etebRaxaahbS2l1FIrKBtTBznoRkDj8cV2Om6dpXiDTE0pbdz5MRNvO1wUMcgHTPT8CKujbYvENtXfp8jw74j39td+MJ7izklaxUgxBzhgvXHt3rlLaL+0b8so2gtwP8A69ei/EDwdJBerNbvJIGXZIsqgOj9xgdR6GuQbQ7q3jYGGRPdlK/zrnxMZOo2zroOLiuVkN/CsX7sEll44P8AWqNtBvcluB65qSdpUYiQ5YDGSc0y13Bg5zgGuV6s7Ea1sojQICADxx1NaySCKIBsj0FY9uX81STkN6dq3fJ/dAspIH50JG6egkJee4MkvTvWiLl98cUAAwcHAqijKgIyM4JxTtNYi6UYbcTmqTsXurkurMGjQbwCzfMeuOab4StluL2VyAypwMj8zVbWn2LJxjFaWhumn6ZEpA82X52PU1TdzBI6HVJbSa6gjumkWJFbmMAncB8o+mcZNcl4vtBshni4CnqK1Jd9yDOchF4zV69hW90V4vk34BXPUmtWrxsSo21OZ0Fi8gySGHNdddTkWSlCCvTOa47T/PstQeC5heOSNirK3XI4rdurhVsCo4UnOKyWm5VryRFbyYkYMS5JyQefyrRChhzgA+orK05PMbO7kDOMcitXYyJHwSSMc+tSbydtCO6KtHtkIJPT1rElRUO1wNoPetadPm3t8uOg9axdZLY3K5xn8qTXUxe9iu0KyT7VQFT0Ne7/AAieJ9Me1vhMhTA3quSPSvDbQLOwaN9pHGa9s+Fs1zaWbW155JtJCWWRxghv97pz6VthtJnn5guaiaGs6b5Xim3MUhSO7jaInoCRyM/rV0aEY4B9raKVVI5lX7vvyCDR4x/dx20tu4E0UyOu05PXB/nWozvBGokmklKjJjaMgDnrn0r1IPSyPGk3ypmZqOl2V5bvHje8mBGQOGHQ4I44rzhvBKTawq7pgm49CFB/E16Nqcqx28rO8cUABYIinGawrea2MS3AlklZhhVfC7D7c81hWhFvU3w9WUE7FmLRpoLdY8+YCPlJPQemKzb8KsYgU5mbocHbW/a3VveMV2PHMQMNups1lB5wMjszk9Aelc0432NITs/eK+h3EcRRXkbzBhX+XiurklDImwFlxwRVO0061+y7cfeHOODVpPs9qoVXyFHU9acY8u5nUmpu6OQ8Wztbq6rGWc5wBzV/w5bRx2Nok+VAjBOeOTzWV49vYvsshVm3sCAR1q27bBFExYbVUEfQCijZTbNK13SSNvVLIBU8pcg81Q+xt/zzP5Vt6dMHswknJA4Oam2j/Z/KtZas54VHFWPF76SFcixuJYpXJJS7AIc/7J6ce9O062iaVG1KFhGTy0rbgT6ZHSprNgtnKsAZTLkSxOgkQ89gen1FZVsXhumgLtaEnKmVsxH/AArF6K56V7po61vDFpqCMlpMNi8qN33Pof8AA01dS8VeG4mt5klv9KAwWXDbR2yOv4iq/hzWbKyMg+0y2d2Ww5ADwyj3Hauss9VN1G+9o5Qedy8itoNNHHVUk9ro82udWivdWWcyJGdwJ3AKTg+tdn9oW9/eWbJbMQCQuACazfE/hm31KJp4VWO467o8c/UVycdxd6bIYb0iOMZ2ykHb9DgUk3TZTaqJeR2Guaqb2za01ZpvOQZRuHHHvjOPxrk7sLdRGNyDKB829c8exPSrUOvvcL5cyoccqVIbH0NZuqbppTJAjqx6MKuVVSQ6cHE5LV9Pt43YorYzycViTEfdVDt9cV1FxPPE2y+QhCcbgODWPebC58s8Z4wa4ZxXQ9OnJ2syvYR/vFyMCtp5h5ZQAjHOfWsuPOzbG3PuKnEvG3b161ntodcdSS1j3zZlycdhVpS/21QvBA/GqDM0R3IfzqXT2aW6Dkhv8KL9DotoRa2x85Yyc7iM1o2en3AthM5bL48tACWYHpgdaz7yUJqXmmPzQjA4PANd5revJ4/1eK+Ei2KxQpBFBCxPkqo7HjvzWkGlqzllzcyilp3ERUTwqwcMDn5m28KecAnseD+VZulapNpl5b3McjQ3MbB0LAgr6H8R/Otu6vNMsnu7vxDfNquqSqqRMxC7MDG4hQATwBgjvXn2t3guWupVmWAKm9BIT8+P4R7+g6cVd09hq/K+ZGjrOpPq/im9vZNitPIZCqkkLnsM84qS8fzLRowQGHQiue0mViFlfo/etJnZwWUEjpisZO5UY2ska+ipsRG5ZyMHHetaFnlkxIQRmsXTSEQM7dgQK0N4MqsrYJ5z2NNbGk0S6oxkU+SOnJPWuemdWAUDnPNbt04MZKtsZhjFZDWio6SO4bcOijp9aGmzArw20c8w25jfdgY716n4P0rxBp0Al+2wyacrDfbPMV3D+9s7kV5vJbJtSVcoQeAK9I8D3AtNKna6lupfP+WOPyxsCj+PcRnrxgcVdJJS1OTEt8mh1OuXH2pLNY0dA8ilmQZIUHrV64a8kmmIm8yAJtcIQrbfQf8A66ztGSW4n82VZvswO3Ma7sA+xIFX9TaKASyXT+W7IIwxxlUHQY7HivTpuyuzxJrXlRwHjrWWs7RIYJHDsMbMdvrXC2Go3k93Gm52IPIHTFb/AI1vrC4wfPaSUE4Ax0qLwtpmoyD7XaW9rMrD5BJcxq312E5/SuGrJznoelT5aVPY6rTrmYwodrsvfjH611mmXkEjI+wrMvPzPk/yrk0sdYZcE2sUa8lfOwPyFXtOlcnraxv28iMvkj1LHmpu0zCSTR3BlLAsjqdy8gnis9vkYlpFOOorGa9IOZGmc90wFUn8Ky9W1aNX5RoSeRmTIqJ1LEwpu9iTxLbRXgkmZ8BFJ6+lahIuPImQ5SVQQfqK801/VJJkdYJFVCpDgNwwruvBEzXnhizDHc8CKp/AVVFpt2LrwairnU6fu3hDnb2rd8pvSqOnRB4g46jrWtuPqK61ocEmfP6SpJkIxhZfvIGPH/1qtXMUi6WsltNbXCnKmGY8oPbHI/lWXNHvkMltIJHXJwV+97GnwyreRxxxxhJR98HqvsK5k7nrNWMyASpM6uPLz1QnIP0rb0a7Szy008kCnoYzx+XeqN/blI88MU4yDzWc8pX93MzE47rjFTsN+8ehaf4ijJKXAWcDoy8H61u2s2l30eH8t1PBRsZH4V5HbyGF1LOVz0IH3q6nR43vriP7PuaXptXqfwqoVHfUxqUE1dE+v+DoWl8/S5TaN/dHKsfp/hVGKLWtKUNNYfaocfMYxuP1wea7IteWsQ8+38+NOvYir1lrNrKgRv3XOCGHStEk3qYOUktNTzl7zTNSidchJuhjYYYfhXn+rWL217KLdMqPTpXufiLQtL1GEma3R2P/AC1X5SPfIry/xD4Y1DTCZtOuDcwHrFN94D2NTUpto6cNVszlLECTPO1+4PBqUhkBwMg96YssbTAXEbW046qwxn/GtOBUkXhhx61ytHqwnYouQR0PTp60+ybySDwDnB/KnX8RjTOMZ5HtWWZGWUHOBntUnVHXY04rb7Rq6oWyvt9Kz7q3aw194Q7xIfmJQleK1PD583VlPByO9dDdaT/aHjHSpor3TrMllzJey7I9y/MAeDwduOnU1UdXYznLk957I5m8tzExe2k8+M/ebJII/Gs+4AuZIoFUgueRntXaazdyXl5d3upLAhmkY+bAuIWw2CVwBkD2FYGm2STazNLDMlxBvIjkQFdy9jtPIz6GnKNmbRmpRSE1uE21tBtRUUAAAcYFR28p+yrtJyT+lSeLbpWlWBeo4NQ6bEUtMvkk8ioejsJJWNqIBYwQw5wCKt+VuJKofRT2FRaYgbY7Ywoz71qOoDjaOSegpkyfQyHh3XKGRjtyMn2rWjtROwVFA2+lXbG2Z7pdsLTM3RFQsT9AOTW/dWF3aSLNPpvkORuEcpRM/wDAc7v0remro5KtRRsjPg0C0iR3ubeR2DA+SfMjbHpkDH+eKtWhtot5neSGJBhUD/oSe1Pu4b/Umja+eDT4kXC+WgUke4HU+55qMLp9mFEUQnccGa6bIz6gVppF6HDOXMtWbVtqt7LEW0izeaKMDErAIi++TTr3RLnUNPee+aWWWUELIJxFDGfqw3SH2GBTPDniGJcRxYvnB5IhMoi9MKvU/U4roZdYXWvML2U5mQbPMdHC8dQVjHH4mt1eaPNqTcJWSOBi8OadDMPNQPJ0YxOqg+x4JFbcGj28UTGO5h2j7sSZJq5Ba3aybk06yvrjP+rWPzhF6DCttH4k1cuLcgo+pTW6M2CbaAohHttXisuXoW6r7mdEkJi2yCJcnG0jJb8KlYpENkETqx+6BGQP5cVqoYE5s9KEJPKEgH9Sf6VRvZ7l3ZpJliToFBJP+FZ8tiVO70My4t5Ywd6liRjnA/Lms660NriISTyqVIwUBLE+3FaDRymYNbB7puzEjP6Vd8q7lQeciq45K5yB9fSs/ZpvU3U3HY4K6hsbNJI7q2fYPuMF5/HJroPhhdQTLfi0Y+Ssu0r3XIB6VkeL9O86Bmku1dgPupwq1znwv1BtH8WTWjuNl2MKCeCw7flTg+WVjSceem31PobSnwxjByG71r+VJ/zzNY+lrFdRNsk2yjlV9fxrT+y3fq3/AH0K67nmytc8CZI1mY3CKQeEKHGKopbfZL95BIxWUZDDjDDtTLK7jJZLkmRBnPqKkuHjuV2MMJ0R0PQ1xXPX3J2u2uS6yptc/ISV/nUVzYQTRjaGSZDhs9Pw9RT7JGZirlWZOrDv7mm3QCuGO9Af7pyCfWmmHoZrqLCROsiA5K44/Cuu0W/tbVorm3lDAr8y9HUdDmuaeEyn5kHpn1+taENnZqDJvdGUdFGf1rSDsyZrSx6TP4gVLaOWFkljYbWRWG4geo7VS8Q2un/ZE1C2DQXXG63LbvMH07da87OrqLhPN2RHIUyqMLj/AGhV+bXbmaWQRmLaOrQ5Af0ODmujmTRjHDtSVi9ceJp4xjy1SPPERz8o9N3vUP8Aa8dxG2/5QeWBGQKi0fUdPurW6OoJcvqDMBG6soRcfe3L1PtipJrCKSPEYPzelc/tJJnW6UVpY53XNOtL2FiQHB9q5KSCbSpMx5eEdVJ5ArvLjSrqGJnQBo8+tczfRus+ZF3A88dqUoqSujSno7FZp47qAsAMY9ayZ1KDaBx71O0D2twZYRvT+Jc8VUvLhS4KFsdge1YSR3UpW0Lvh9xb6vAGYc8V2ur3l1oOoaXrlnFBJJbNnE8QkQggg5U+x69q85052OpQd2LgcV69dwx3ek/Zbrl9nBPI6VKdmVUSlo+pyHifXG1oyT3NhzfhjFLEDFEhDDcVUcH0x6nPJqGznTRrEsRh2U4z2qgmlPptzIbli0aNtU7weMZwBms2+vGu5witkD3q6j1uy6MVGHKgty17etLJ1Y/lW88ISLAJH0FUrCzEZXBII5wK014baxLE881nyt6s0ukP0+Z4cbecdfpWxEbiZi4RVz05wK5+5vorVN24DHXnrWZJ4ku5m8izHlljgFVy7fQVcdNzmq1EtUdyl8bUq0+oPApX5lhcoxHpkc1Ja+ILW2cf2bbmFzwZpR19/Wub0bw7q0w+0SwhXboZ2Jb647V0Nn8OtUviXn+0zq/O2ONsAfgOK6Ixm17qPLr4mnfVkF94stVlAmnD3GcfM/8AIdqjttVmu5CINMku5CeS8JYHnjg8CvSvDfwysdItFnuNAlMpYATNMFY+oIPAH4Vpta6fLIYobdbeCEgMtnIVU89Wl+vpWsaVtZM8+WKTdoo5HR/+EruI1gTztMsB1QzLaRgc+nJ79jW/Eulm58u1kFzKSOVhnvST3PzFE/St15LZZtkMSq6rtUwRtPIR3+dvlH61qWVnfyQCMAWUR5O35pHAHfHArddjllK+rMmW1uFUC4uXS2KgBbuURqD7RRcfgc1LpllPZM72dpbRJKf+PiaIKD/uKeR+VXprrSdIkMktxGZdvJUB5CffstcdrnxClWRorCIIScBnbcT+Pb8Kyk4w1bHCM56RR1GpQoMy3eoPMAPmEQEf5ZGa5DWNZsnnextwJZv4ShznPqfWsHXdTv7izJuTNKX52Kev1HTH1rl7XUtT02ZnjmEMrdFjUDaPqRXPOpd2sdVKg7as259a1nQ45FeKJYmOPmBJHtkViNq808m54js3bmxmqV/dSX1yZNS82R26Yfcv4+lXrrUbaTTo7W0UQyqwPnBCzdOnpisea52Rp+RavdRtHt1FvaEPtwXkO4/4VyOoQCOVZ4mZJY2Dq4/hPbFakUUgm+e7kkB7uoHNXJLPy49+BJ7A1N23c1iuU9E+HPjKHU7ZEuWEd5HhXB4yfUV6Z9sj/wCeo/OvmNLMRXK3NsWt7lenoR6Guk/t3Wv+ett+R/xrphV01OOrhVJ3icZaalb3IO18MCQcDv71o29/aq5jf5WJ5OeT9K5jWNHVdauJbdjASSwCnvmorbU1imWDUcLIv3GKEq/+FZuVzeLsd7bTxBsR7154JbmnSAuSjsQDxnHINYMLQXUK7ZwHJ6A8/hWn+/R40kkWeJMEEHDL9amxe463nLwFFlIZefm9fSruizm8mVGAz025/SqrwGOfz4nATGWDd6iso/Jl8yJjlmOMHkUXsNnaN4e0+4ZkdmjfaT26/wCFcbq+i3Nl5hR2jxyPQ1v2V7/pSeYzF2wM10V3bpeWx3BpMHBycFR2612RamtDBSlTd7nllq7W5Y7tzscHnHP0rp7DVRbwZnyPXnp+NT3sMVrH9nFpG6tz5j8MB9fWqX9m3lq8UsEC3dqU3MqMvmKPcZ/WodLU61XU1qbsmoxXNmRHwCMBuMH6VnRaKZreXLKyHkBl5x9abDaW0kX2mxukbDAmELyPwrQt72aOXEaxrngEA4/AdqjkcWK6a9046TSQksseNuPu54zXPaxowkXzIGw46YHX616Lq8czu0rGPaOTtBPPpmmDTIr9VWxZxLtAOV4z6AU3FS0ZoqjjuePW8ktrfRGVCjqwOD3r1u31SN40ZipcLjj6VBqPg2VYVGpWqSBhuV435XB5yDyK5280C9sU82xlkOeFSTn9az9i4msa6m9yDXktpzPI85W5jdBHEo4dSDuJPbGBx33ViWsKLKS3OOymny6Vr01w2+wdnPHysK19I8G67fPtEQjIGSgUuyj1OOB+JpShKdkkawrRhdyZFHPHHFuY4FVkubu9k26fA80meCOg+p6V6Rp3wu8iwN7q6s5VhiOV9o/3sdMfnXW2Oj6Hp7vELWW98s8CIbIGB9W7dua6IYWT+I462YQSfJqeSaV4LutSuEN2zyysf9TbDc2frXq3hXwbomjxsNXnhs2ZCVWJTJKW7BsDj6ZrQuNY1ie2aLw9GLaFOWXTYRtAxjl+/TrmnWF3r9lC51TVHWLIGwMkjdOpHOK2jSjHU8utWqVdGy/bWlj9p8xlItQQfkgKcdxyc/5Nbg1O3ZHGjQTtIw2sxlJjH0Gea4nVdZtZrRomjvrm8wR++lAQHsxAGSPxq/pOtWlvbxSqI4mH+vKYVEX2Gcmj3r6GDoNq73Ort7V5AJNTl89hyBN/q0/4COv41FjTRc7vOhu2U4wAEhX+mfrmuZuPHkFwz2uk2Et7cE4STaAg/mW+mKqW1s+oymXxBcMJx9yygtxnr6dvqaESqLiry0Oxk8QxkhLO2QDpxyp+p7/gKo6tqF2kZa6n8qA8rH0B+g6n8aopKqvImnR21vEPvENuYY9T0J9hXHeLpPNTcJ5mbOAS3BPsKVSXKrodOkpSsP8AEWrRg4SQlSuABiuTku1lYlFywPIHQVlXXmCcebIX5754qWIgRMI1HPXLdB9K4pT5ndnoRp8q0FuNYuJX2xAYUcE5qvM5nXzJrgBz/Cq8n6CrHledb/JswDg4+8PciobWzKTEqxZWPLdDUM1jFEcDGQ+VmbB+8Wi2gfjViSDy2KqBkj+EVa1CCWNN9sFVB1YNnn6d/rUDzB0j/eHdtz9KmxrzLcakgOwSYJHpVzy3eL5dhfsucfnWbe3iJbEyxgRtzuzg59PWsw6zPLA0Wl2SxRDhpnyefx5p20JczoJb3yGHmRbwB8zu3yL+NXP7Ysf+e1t/31XJW+l3d7byz3jtKeAFPQ/QdBV7+xk/55D8qL2J3LGoxiLU3V0AXcQCvcVVvtLhvIHUrvKn5G7iui1KzE4O0hmbhSO1ZEMzqdrjlflPrU81ncm11ocTd6TdWs5e1dwyHJUnrWnpWtkSG2vI3SZvl+bpn61rX9rcQyebHMxDHAVgDkH+lWk0RL2MeesW7GVkX+RrSNmxNuK1JImcL5bcpj72f0qQCK1KGVyAT2BJrnpzewXJthGBDHwC5+bj0FbemXavZrG53XCHB3e9NrUtS0udDpFzDOMBG8xWyrFcA+1aN/eytIJoZSjDgr1rHja7iU/ZPnC/NtVSc+9dJJp7X/h5dTgSLKAZT+I59RWtJu1kZyavdmcbtbtdrBd4OCD1PvWffSzW2vtM7sPKVdjxjAyem4VKIWV45CoilBKsjd+9V23LeKsyiUT/AHh1x9feteZjSSGy6gYU8i7slQs5k8yEBGI9iOo+tTLdwLGs0F3NFGxwdyBsVJPCJJAsqv5CNnkYyPSqd/a7pDFb7l2jK5H6U9wUjVmki8tH81Jo+m8gg5/GrkRtEWJoJdsg4LLwB/jWCLYyWgSaaQSqRhcZGPXPaoZbO4mbbbSFnUc44zUOm2XGSejZ1U0k32qKWKXc69+zfU1b1M295G8YcmdQD+8OcH0BFcvZrqlowEVxIo64YBvw5p2rNr+oFZCbWQQrgkLsbH0HWtIJ2sxuK5lZmtbvF5HkysizIDudur856np/9atvSvEunWtgkASKCXcWl2hpGYZ/i7E49K8tjvr2N2imcIe5Axmrti08zME2vgH7xrSEmtiqtBNe8z0O/wDFUF3cqyRttVdqbnL5/A/0qP8AtC7uhEkaJbWznG7gr9dv+Nc/p8U0yRoCioDgttHH9at300NrbiPdNLIfRgq/TOK282cEoRWkTU1aGKS1ZXvLyeKFDsjZ1TA64yBz7YrmEl0+LR7xbeNgZI2YAkqqtn+934zxU8F/qLW/l2yiSWQMq56KvTvXP39pcywJb3eqyT26HCwooWNfx71HMkrm1Om72H2nizVbi3ay0pYba0aMRSOse4lRztBPPWtXTdPvZlR5po2RRu2uMD8FH3j9araNbLAgaJMxr3PQV1Gkzm6k2LIqAjLOSFA+rdhWDqOTNp2gvdRq2lsdOtlht7aGylZQWlil33Emfp/qwf0p8MEenqZbhjIzjc0O44PpvbO4/nT2NvZxOlm+4MMtIeS/qcnoK5/UNTgljK2rF9/bHDH1x6VUpJHClKYatqjl3eOVIecEIMDHoB6VzN7PcandJFFIu+Q7RJKwjX8zwPxqnqM91b3flyrtP3umePeqE2oSFCAx8skcdM1xTnfc6oU+VaGpDpZhkIuG+cZGA+4fnVZvKjUOrKpJPy55NIkUnlxgS7XcZGT2qQrb+azyuoULtJYcg+uKzvc02IYbaSVi6hvmGQCcjFVp1ljkaOG4jMSffdmwoNU9RubhICtpc+TaM21pGwX/AC9KwE0ybVZggu52twQZNxwMZ7CmloS31N668QWyoYPPFxMo4EPzKPfNZcdy97DCbaWW3lLP5qlcBVyNpU9yeSavR6BZ2sphtEJKjAOc7iasRWHkvtkQLxzzRewJXI7CyjYu08jSvjglyRVy1sCylI0YL1z2NW7SKNLc7U+YnjIq7AkjKVjGOOahsq1h+m2ZcBHbap59M1q/2fH/AHjRYwPHgSDC4zk1obB/eP5VDdibmHbNlXiHTOfXkVkXuYrgBcc9Tjrmtqc51S5+zgpArHBIwaztaRgY3QhlH3h/WiS3QQZWMXmQDcckD5aZFM6AAOAVq3GokEQXGAfvUx4o4pplkxx0qo7FEV3dRzussgYyA5ZhVZLRbedpSS0UnzKR1z3qZMOksaou7qM9ajs5GuUe3dVXap2MTjmtFK+5na2x1WialbzQFYJ1iuP9WrOemR61HHqN5pCRww23mx7gxEuQpAPDD1FcfpZUSSQXEZJY8ENg1rSxuBuLTB1AA+fG38K1jUsrBya6nQac0mp6lJ9ueNBEDIcfKWyRgAmtJbNTc7kfeQSVGPSuK0u7mju5Ip5HkV/uZ7V2GkXc9lM0ojEsRTaN4+761vGSloyZxcdRt66RjG3LsQDnoPWq1xKn2lZUVcDjaBnrSavKL13nhPlJbx/MGHBJJ/yKwI7+5a6MIijDELjJwaNmKOps39rJIDKfk3Dj39qbpIRDuIIZTyRxU8N1JLI6SMjRxDAzxn3qldN9kLGI7geSR0xWytuTe+jOlubqzFgX2Dzc8ZrkX1+5N35BJaI8AVYt3N55SAkSc5z0xWrJ4bsVksYheCCS4cCS4lxthRsZIHc9apqU9UaRcKd1I5W7RGmO5PmJ5XjirGmw254aSSM5BDL+u4d/wr0Z/Buj2mnaiPtbXCRr+4mYj9647j29q811UrFP5G7DgbRgc5q+XkVxwrqqnFF2S7nhl8q3lc7m+U4x+Jq7Kst5cxWsJMjscuVBOB3qldxRW6wz23nM0o2gOMfiK3dNEml6ULsblubg4V8ehPArHd2Y20oqSKyiGON13BITlG353N+VUXsVlhDBi8YP3MYVB61au7u9u7ZYEijUBi/mCPDEnqC3p7Vo6Boklxse5n/cqpJQNgLgd6Gm9AUuRXuTeHtNSSyRZRlG5CdOPc1T1GROLW2VQhYhQoHPqasRak0dqlupVUX5Qccn1P09q5i+vHl1mMY2IE25XjA9eO9YVJJKwkpOV2at3cXTSR2Ku0qSAknoFA5qSVo9NgW5icyyKNm0nBOfT0p9h9gGns5lnaTd8qKc/KPUnmsK/W4mDTRsQitgdsVjJ8qv1Ba6Ed/cLKrggL5nJGc4rJVJWTzQpEaHbvK8elaMUEc0YlmcBeiheKdZwLJMVxugAJA6ZIrG92aJ2MefTJ0u4hZzM2/kZU7SB3x1Ap0dtJIVkuy7TPyAe3tWy8ryEmNChjyF7gCqK3Cs6g44PJ75pXQO5C+jrJOs0rjOMEY4amybY5cQKir0wOOKsS3qPP8AuQAinqT1PpVby5Ziz7P3e7JPpS5gUe5saTZm4VpCvyg4NS3MKeYx2E8YHFWLKILbL5ZK9yKv21tFcKAqkHHJY8VPMNaamVDbqEAZ1j3HkkcLVmGF1ESnad5PzD0FCxCS82FkJB6etaytEkoUJyOOmKTnfUUmTXKrJGoVgoUZ6c5qDavq35mr9xbRrbq+Sx64puU/55fpU8zJjsZt223XZ24DHkisu9CXRuFd2R+oO3Oa2Y4PtmpvKxXdyozwMCs7VAItQDpnCjBHY1cnrcmK2RmxottCGK/L1B70hxLMHfa+QMf/AF60BC08j7wNrfMSRxWQAYpmQqQjHgrQnpoaWuQyllvWc4PJBx0Ap1lHCjSbgCW5ye1OumMso8pSpVec8E060hM6lBy4+Ziaq4dClGka3EjIvzjpmtnS5ITODJvxj51Pf1IqpJEkUocYGO+OlLfOuUZAAM8le1UnbUT1NZ9Phimju42WWIygLnoF9K38xTQSmJ40WIEgZ4b/AGR71ylteTFIosEwB1ckgYHNdDKI2uJPJCCOM544H1rqpzvqYzT0TK1/arcWgvGhkjtwwBZSdpYdj+P8qyNKje7ubm62Kdh24I7ev1q5qFznR0mtQSzysZIyeNuetM0FFjtpGic5mJfgda0umwSaTJJlSGOYo4YMQPL+o6/0qi8RW0MXIY5dyT0qW+AFjcmJSXLL5bZwODzn1pl3IwjYk/vJPlcY6VrF6akozbNphcErk7OefSvZvhXpsVxourazdWi30pBtYImAPlrtyTz3YkfgK8wshGZY4mcrHLIokz2UHr+Wa7zw9fQ6cmp2sLnbJ8qBWxuGeCPft+NXCLtuRiJc0bIoSX8Ed1MlqlxZafY2zZink3bpiNpPf16e1ecQI2oX8ty2Spf5feul8bE2liyxSIxnfHpz3NT6LZwR6dbkAqyr+vrRVevKbYePKuZEdvbXWoXUbyv82QgZuwrqG0tNLurFrxRIrSBMMSqDK5z+VW9BsilvJPtAWLDE+nvXnepahc3viZ7e2upp4DKSiFtw3dzz+NFlBeYWdWTitEjs7+4gsf8AUqqwtwoV+W/4D/WrqgWlm17ujWAJu8vgq7Dt9BXNWxzI+9jI0WAXbtj0qpq2rC5iitNxWONv3hznb1IX/Pes6lSwKnsR3e+RLdojmeXPBGBGp9D+NVhara7knQb3O7zckkqB0I6dapC+mmvfOL/KhwQBwTVu7vUuXVULlyoGc1xuaZpZrQdDbg2AljdhJIxGxcAg9RVSG5K/uW3bB94P2/D0pLp5tNnjm3up2EJxn8f1qK0tJ5nhumQeSvBJ/PpWcnd6B6iX0cMV0ChLRAduhPtVgIsemGfLK7kgL7U11kku1QbljDZA7n3p2pBj8oJ2oMncMGsm+pRlXLuA3kSNgDc69BipdO03zoGupQUGcLXQ+GND+3SvJMQsSYYccNU+sWi20p8nvyI/ehuyuK93Y5uSzCyjIGCO3atNLbMSK+VGBnPGagSOZmdpk2E9CeatyQ3JHK/PwMsf51nzGli1HbrBFhWPHPHSrcNzAIZI1VizdCO1UGaQW4Zm3MuQcD+lXrOB3tllKDeOM55/EVF3cGkJYWgjuxKVBGMdOa0lhRZ081AAfXrn1rOE7xzMkp2DOc+orWjUzJG+Sy5BwaLtkSWpo36IQDjA2gjipcJ/dX8qPL8xA2QAeBjt7VL9jf8Av/pWm7MTkdO3pfuJAGRicjHSm31us92zBN0angip75zZ3CCM8SHlu1XrIeWjyAEKRnNU+xW2qOfiADkEHaM4BqghaKc7hlgeBjtWrNERbvPnPJIArPt4mnXLKyspzn/GkjQp38MhuTI67QRkVFbmWMHaAGPQ+tXbgtI+AN2OCD3pZUQxIY8owGDVXuBmy713Bz9OP1pkgxZAvneTwQe3pTp91xMSu75eMGonZ02gDGTgZ6CmmBLYTiKWNSo2+g7npXSxBho2oHqzR4b1HzDpXOSbCisvEq4PpzWpY6gvkOkvLPg8nvW1J2ZE9UMm82CwkEi7o0UxjB4BqXT5pW+zWFshM7L8uOxAJP04ya0p7YT2dlGoAeQEMAPc88VnxRLb+I3fTpJfIiIWN2OSOMHP610pWsQndMS/RvKRVYqyH5h7UL9nkIKyfvAjFlfoTxjHvzVmOJ9Sut2NxL7VHTcByajuLeGSedY4hG0eXk7YUdh+Fbx1V0ZN20GR3ItbuxmhLRnyywbjgkdea2dYulsb24vraNRvPk7ew6Zx+IrI163e3htpsK8a242sp4HAOPwzTPF85g8K6EQ4aS7LSNtOc4OP6VequSrO3mVtTmGsa1a26E+XEoU+me5/GuvstPAnihwcEhQMda5HwhEDcvK4Idmyx9K9b0Cz33C3JySQY0+XJAPU/lWCk5zudUpKlCxifEPUIvD+ibbWFCmP3j7+rFfugegrgPAEWZoryVNzSn92o4wM/wD666D4wT276LDbQOfORhn03MeQPoOKpeDzBZ6aks4LCBFK7eSuemf1rRu8wh7uH82zd12ApLczACPayljjAJPPQVyN75c0Yigj34VjK5XAZyd3NdFrGprfW02RKiyN5uCpHA6c1z8jyJZS2SsNjsr8Dndnrn05rnqy1CCaiYdsXgt5ov8AWktgcchcZz70+FXimEi7iH7mr2o2zW8kG1gjgbWx785px8uO0kLoclsbvX1rkZaZWnka8kBZ8lR8o/nUttDOtswCu/ykgD+H3qOVxFbptQIW4JHXArQ025C2YCcsRtJH6ipbsKwzTIyJy0pb5fmGOoFVdSYTTnCtljxk5J961Y3MFvPIpOCmzgZwDWBJKzSqEOWBxzUJ3NIq7Ou066Ww0hfKaTL8MHHA+lVAZL+4LFHPcY6D8azQ02wi4cZjIAwOORWtphd3hRFKnb8z7uCameonHl1LaWRkhAfk55FEiIVKxAnaMMSamtJjE7gYkHK4H86inglMkrr8gGAwNY3uHqQoUcoqRBgT8zEYJ+lbOnI0hZQEGeoIqpawoIF53NnOB2rZ02EEtJt289CO9UtWRN6GfeWHO9gGRTiri2bbIjG7Fdv3cVeEKTr5UwIKtnNWLqNrTy2QEqB6UdCHPoNtVkJVJEVUXpzk1pfZfemwoGhWcrhjyPerPnP6fpWu25i229DzfXLSWSJfkIVORinwOz2ChyQxG3Aooolobx1Q+4iQaaMZDhtpwKzfspUnDFR7UUUmO5RvbGaE7tpOfSo9jfZxlGyTwKKKrqNO6JWsFRUkRTlh8wINUb+3KQKxjO4dhRRVdQuUXj86PAVi+cDAPNQxpKs7RlCGBOW9PaiirWw+p09tcTJai6BdfIjI4HUnHNQWPmWFrHPdBminfLBByQeuKKK6k9LmXWxr6IqRQiXBXZu2EnGMnP8ATrWOGnS4kuPLLDjcCOgzgUUV0wdzCXU2dZs5Doccske3duyqjoeSf1GK5HWrn+0LPw/aCBla3WRD8p5G4Y/r+dFFXW0ZnRd9X0Zv+HIvJiEhB+ZyF4/hBxXtGlwrZRwB2yxh3c9iRwKKKwpfEzTFN8sUeKfFm2RNbhs7dpHjWQMpJ3YGP/r1etII7PTlaLPmMAG/ulcd/eiilN2bZun7kUZyXE9vkC3eaBz0C8geoqtiOW5Zxu2kHqpAGB/jRRXLLc1uQtctJcRRMGeNW5wOTS3g32oiVD5jfd9uetFFZNgV7y3n8xQ4OFwOmavpmG1EbLuC5IKjBz6UUVnIL3sF7M8Vsu1Cd/8ACV71l6dbTzXAAG3JzlhgUUU4I2hojcGnmCQl0zuXIz3rQsbOQ2oCI2H5IGeKKKipuEnoW2tHhRCkbAjqQKvRwzJbkyZaRzhuM8UUVl5mLZYjtNhMcY4PJB7mpt0qRErG+fT1ooo3JuGgyTzSubmNkLHINdWIvMTLcjHAoorW1tDGv8QeTlVVd3rgdql+yj+6aKKpGDbTP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    45-year-old woman with purpura from scratching plus loss of labia minora. The white areas of LS show a cellophane-like shiny surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: F William Danby, MD, FRCPC, FAAD&nbsp;and Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31299=[""].join("\n");
var outline_f30_36_31299=null;
var title_f30_36_31300="Albendazole: Patient drug information";
var content_f30_36_31300=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Albendazole: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     see \"Albendazole: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/1/10261?source=see_link\">",
"     see \"Albendazole: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Albenza&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat infections caused by worms.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701449",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to albendazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697732",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for 1 month after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a high-fat meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2946539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may crush the tablet and mix it with 2 tablespoons (30 mL) of water if you are not able to swallow it whole.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11029 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-C9F66847B9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31300=[""].join("\n");
var outline_f30_36_31300=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130833\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026729\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026728\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026733\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026734\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026736\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026731\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026732\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026737\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026738\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=related_link\">",
"      Albendazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?10/1/10261?source=related_link\">",
"      Albendazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_36_31301="Antibody mediated rejection in RT biopsy";
var content_f30_36_31301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F81994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F81994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light microscopy showing antibody mediated rejection in renal transplant biopsy, ATN and polymorphonuclear leukocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous interstitial polymorphonuclear leukocytes (PMNs) and extensive acute tubular necrosis are evident in this renal transplant biopsy. Histologic findings in antibody mediated rejection may include PMN infiltration. This specimen also demonstrated positive C4d staining on immunofluorescence.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Helen Liapis, Washington University School of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31301=[""].join("\n");
var outline_f30_36_31301=null;
var title_f30_36_31302="Dual chamber pacing system malfunction: Evaluation and management";
var content_f30_36_31302=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dual chamber pacing system malfunction: Evaluation and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31302/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31302/contributors\">",
"     David L Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31302/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31302/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31302/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31302/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/36/31302/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic evaluations are required to maintain optimal pacemaker programming as well as to identify any system problems. A review of the common pacing system problems of dual chamber pacemakers and the methods of evaluation and therapy are reviewed here. The malfunctions presented will be limited to those that are manifest on the electrocardiogram. Other complications, such as infections, venous thrombosis and emboli, pacemaker syndrome, and tricuspid regurgitation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=see_link&amp;anchor=H11#H11\">",
"     \"Implantable cardioverter-defibrillators: Complications\", section on 'Tricuspid regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A more general review of the evaluation and management of single and dual chamber pacemakers and of the modes of cardiac pacing and indications for pacemaker therapy are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=see_link\">",
"     \"Pacing system malfunction: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PACING SYSTEM COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pacing system is comprised of the pulse generator, also called the pacemaker, and the lead or leads that connect the pulse generator to the heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31302/abstract/1\">",
"     1",
"    </a>",
"    ]. Either component may be the source of a clinical malfunction.",
"   </p>",
"   <p>",
"    The phrase \"pacing system malfunction\" includes problems that might arise from any of the components of the system. Inappropriately programmed pacemaker parameters, although not representing abnormal pacing system function, may yield suboptimal results for the patient. The normal characteristics and unique timing systems and algorithms of a given pacemaker should be examined, as they may be interpreted as malfunction by a clinician who is unfamiliar with the specific pulse generator. Recording system artifacts must always be considered in the differential diagnosis of a pacing system malfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DUAL CHAMBER PACING MODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pacemaker programmed to the DDD mode is capable of pacing and sensing in both the right atrium and right ventricle. Virtually all of the dual-chamber rate-modulated pacing systems can also be programmed to any of the available modes, including DDI, DVI, VDD, and all of the single-chamber modes (",
"    <a class=\"graphic graphic_table graphicRef79459 \" href=\"mobipreview.htm?27/27/28091\">",
"     table 1",
"    </a>",
"    ). A review of the normal pacing modes is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LIMITING THE MAXIMAL PACED RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In dual chamber pacing systems that are capable of tracking P waves, there is a programmable limit placed upon the maximum paced ventricular rate that can occur in response to sensed atrial activity. This is essential because, if there was no limit, the pacemaker could potentially track atrial flutter at the rate of the flutter waves or track atrial fibrillation resulting in a rapid ventricular response. In addition, there may be clinical and physiologic reasons to limit the fastest rate of the pacing system, such as active ischemic heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Total atrial refractory period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total atrial refractory period (TARP) is comprised of the AV interval, during which the atrial sensing circuit is refractory and the post ventricular atrial refractory period (PVARP). The PVARP is a second refractory period that is initiated on the atrial channel by a sensed or paced ventricular event. With early generation dual-chamber unipolar pacing systems, far-field oversensing was relatively common. To prevent this, paced events in one chamber initiated periods of refractoriness in the opposite channel of the pacemaker. In addition, a ventricular depolarization could potentially be sensed in the atrium and, thus, when an R wave is sensed in the ventricle, the PVARP is initiated.",
"   </p>",
"   <p>",
"    When the interval between successive native atrial complexes is shorter than the TARP, some P waves will not be sensed. Since the pacemaker can only track those atrial depolarizations that are sensed, as the intrinsic atrial rate increases, eventually the device will only track every other P wave (a fixed 2:1 block response). The occurrence of abrupt 2:1 upper rate behavior may sometimes result in symptoms of presyncope or sudden fatigue in those patients who can exercise to a sufficient degree to achieve atrial rates in excess of the 2:1 block point.",
"   </p>",
"   <p>",
"    Contemporary pacemakers are capable of recognizing rapid atrial rates for the purpose of reverting from a tracking to a nontracking mode when the rapid rate is felt to be secondary to a pathologic atrial rhythm. The change in mode is called mode switching. Mode switching requires that the pacemaker be able to detect atrial events occurring within the PVARP even though it does not track these complexes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link&amp;anchor=H10#H10\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Mode switching'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the sensed atrial rate exceeds the trigger rate, there is an automatic change in pacing mode from an atrial tracking mode to a mode incapable of atrial tracking, for example from DDD to VVI or DDI, or DDDR to VVIR or DDIR.",
"   </p>",
"   <p>",
"    To prevent the pacemaker from detecting a paced or sensed ventricular signal on the atrial channel (called a far field R wave), there is a separate timing interval within the PVARP called the post ventricular atrial blanking (PVAB) period during which the atrial sensing circuit is disabled. It is initiated by the ventricular output or ventricular sensed event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maximum tracking rate timer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to modulate the upper rate behavior the maximum tracking rate timer is initiated by a paced or sensed ventricular event and must be completed before another ventricular output pulse can be released. Thus, even when a P wave occurs and the AV interval, which was initiated by that sensed atrial event, times out, the release of the ventricular output pulse is delayed until the maximum tracking rate timing period ends.",
"   </p>",
"   <p>",
"    While this limits the maximum tracking rate, it also effectively lengthens the interval from the sensed P wave to the ventricular output pulse (PV interval). If the atrial rate is stable, the next sensed P wave occurs closer to the preceding ventricular paced complex; if sensed, the same series of timers is initiated, and another ventricular paced beat occurs at an even longer PV interval. Eventually, a P wave will coincide with the PVARP, not be sensed, and, hence, not be tracked, resulting in a relative pause. The net effect is group beating at a fixed ventricular rate with a progressively increasing PV interval. The group beating and increasing PV interval are similar to AV nodal Wenckebach second degree AV block. As a result, this form of pacing system function is called pseudo",
"    <strong>",
"     -",
"    </strong>",
"    Wenckebach upper rate behavior [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31302/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other techniques are used to modulate the upper rate behavior of the pacemaker, including rate smoothing and fallback [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31302/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RATE MODULATED (RESPONSIVE) PACEMAKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of rate-modulation capabilities to DDD function has resulted in a number of interesting rhythms since the pacing rate will be controlled by either the sensed P wave or the sensor-input to the pacemaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31302/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Rate modulated pacing is of particular value to patients with chronotropic incompetence due to either concomitant pharmacologic therapy or an intrinsic disease process; these patients will not increase their native heart rate in response to a physiologic stress.",
"   </p>",
"   <p>",
"    With regard to upper rate behavior, there are now three definitions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The upper rate limit (URL) is the maximum paced ventricular rate that can occur in any setting.",
"     </li>",
"     <li>",
"      The maximum tracking rate (MTR) is the maximum paced ventricular rate that can occur in response to sensed atrial activity, defined by the total atrial refractory period (TARP).",
"     </li>",
"     <li>",
"      The maximum sensor rate (MSR) is the maximum paced ventricular rate that can occur in response to the sensor input to the pacing system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both the MTR and MSR are subsets of the URL. While these two timers are often programmed to identical rates, many pacemakers allow them to be programmed independently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TRUE DUAL CHAMBER SYSTEM MALFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;True pacemaker system malfunctions occur when there is loss of capture at a time when the myocardium is capable of being depolarized, loss of sensing when an appropriate signal occurs during an alert period, or oversensing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/996?source=see_link&amp;anchor=H6#H6\">",
"     \"ECG tutorial: Pacemakers\", section on 'Pacer malfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Loss of atrial capture",
"    </span>",
"    &nbsp;&mdash;&nbsp;True loss of atrial capture in a dual-chamber pacemaker results in effective ventricular pacing only. With complete loss of atrial capture, the patient may experience symptoms of pacemaker syndrome. If an atrial stimulus fails to depolarize the atrium and following the subsequent ventricular if retrograde conduction is intact, this may lead to sustained retrograde conduction or even induction of an endless loop tachycardia (ELT). If there is retrograde block, the lack of atrial capture will allow the native atrial rhythm to occur, which will be intermittently tracked, typically appearing as if there were an atrial premature beat simply by juxtaposition of the native atrial rate with the paced rhythm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Loss of atrial sensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG manifestation of a loss of atrial sensing depends on the status of AV nodal conduction and the intrinsic atrial rate.",
"   </p>",
"   <p>",
"    In the presence of complete heart block, loss of atrial sensing will result in AV sequential pacing at the programmed base rate of the pacemaker. P waves will march through the tracing, occasionally being reset when there is atrial capture; at other times, they will render the atrial stimulus ineffective due to functional noncapture resulting in the appearance of fixed AV sequential pacing.",
"   </p>",
"   <p>",
"    In the absence of complete heart block, the intrinsic atrial rate will determine the presentation. If P waves were able to be sensed normally then the ECG would demonstrate intrinsic P wave to V-paced intervals (so called PV or P synchronous pacing). A lack of PV pacing would therefore suggest loss of atrial sensing. If the PR interval is normal, however, the loss of atrial sensing may not be readily apparent from the surface ECG since the pacemaker will be appropriately inhibited by the sensed ventricular events.",
"   </p>",
"   <p>",
"    Safety pacing, in dual-chamber pacemakers, is the delivery of a ventricular output pulse at an abbreviated AV interval, following atrial pacing, if a signal is sensed by the ventricular channel during the early portion of the AV interval, ie, the cross-talk sensing window. It is used to ensure that ventricular depolarization occurs if the sensed event was something other than an intrinsic ventricular depolarization. The abbreviated AV interval is usually in the range of 100 to 110 ms. If the sensed event was indeed an intrinsic ventricular event, the abbreviated AV interval delivers the pacing artifact early enough to prevent the pacing artifact from being delivered in the vulnerable portion of the cardiac cycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Loss of ventricular capture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of ventricular capture is obvious in the presence of high-grade AV block. Loss of ventricular capture is not as apparent when AV conduction is intact, because the ventricular stimulus may coincide with the onset of the conducted QRS. If the QRS is narrow, it will probably be interpreted as a fusion beat. If the QRS is wide, as with a bundle branch block, one may easily be misled into believing that capture is intact. In either case, if the pacing artifact coincides with the native depolarization but does not contribute to the activation of that chamber these events would be designated pseudofusion beats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Loss of ventricular sensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Undersensing on the ventricular channel may not be obvious when high-grade AV block is present, as each P wave is tracked and triggers a ventricular output. Even when AV conduction is intact, undersensing may not be recognized unless the ventricular stimulus occurs well after each native QRS. If the AV interval allows the ventricular stimulus to coincide with the conducted R wave, which may be normal depending upon where sensing actually occurs within the QRS, loss of ventricular sensing cannot readily be identified from the surface ECG. In addition, the small diminutive bipolar pacing artifacts may not be easily identified on the usual ECG recording, further complicating the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ventricular oversensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oversensing on the ventricular channel will result in inappropriate pacemaker inhibition and rates that are below the programmed base rate. Depending upon where the oversensing occurs, the sensed ventricular event will also initiate both a ventricular refractory period as well as a PVARP. This may result in functional atrial and ventricular undersensing with failure to recognize intrinsic P waves and R waves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Atrial oversensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the DDD mode, oversensing on the atrial channel will be interpreted by the pacemaker as the occurrence of multiple P waves. This may result in periods of more rapidly paced ventricular rhythms as the pacemaker attempts to track what it believes are atrial depolarizations. Symptoms include palpitations from the loss of AV synchrony and salvos of rapid paced ventricular rates or pacemaker syndrome as a result of the effective ventricular pacing. It may also be the initiating trigger for an ELT.",
"   </p>",
"   <p>",
"    Far field R wave sensing (ventricular paced or sensed events) may result in the pacing system to label a normal rhythm as a pathological atrial rhythm, and it may initiate the mode switching algorithm with loss of atrial tracking. Examination of the markers and atrial electrogram will help to identify the presence of far field R waves. When these are present, the PVAB should be reprogrammed to be sufficiently long to prevent detection of these events. Inappropriate mode switching in the patient with high grade AV block may result in symptoms of pacemaker syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link&amp;anchor=H28#H28\">",
"     \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Pacemaker syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     BIVENTRICULAR PACEMAKERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with significant dyssynchrony due to intrinsic conduction disease, cardiac resynchronization therapy (CRT) with biventricular (BiV) pacing can improve intraventricular synchrony. This is accomplished with an additional pacemaker lead usually implanted via the coronary sinus to stimulate the left ventricle (LV), most commonly its lateral or posterolateral surface. Simultaneous (or sequential) stimulation of the LV and RV pacing leads provides more synchronous activation of the heart than RV pacing alone, which may actually cause dyssynchronous contraction. Among patients with heart failure who are in sinus rhythm, restoration of ventricular synchrony improves cardiac performance, symptoms, and overall survival. The efficacy of CRT in patients with heart failure and chronic AF is less well established, although available evidence suggests a benefit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/983?source=see_link\">",
"     \"Cardiac resynchronization therapy in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biventricular pacemakers are prone to the same problems as dual chamber pacing systems. However, the specific features of device malfunction are in some respects distinct, and therefore merit separate discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pacing system components and pacing mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components of a BiV pacing system typically include an atrial lead in the right atrium, a right ventricular lead in the right ventricle, and a left ventricular lead that is most often placed in a cardiac vein by way of the coronary sinus (",
"    <a class=\"graphic graphic_figure graphicRef79450 \" href=\"mobipreview.htm?15/35/15925\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Biventricular pacemakers are usually programmed in DDD or DDDR mode if the patient is in normal sinus rhythm. Atrial events that are sensed or paced trigger an AV interval that is intended to be long enough to optimize the atrial contribution to ventricular filling but short enough to ensure ventricular pacing for the vast majority of the time and ideally near 100 percent. Pacing is necessary if resynchronization is to be achieved. Proper timing of the AV delay may require Doppler echocardiography to maximize the left ventricular outflow tract velocity time integral and left ventricular filling and ejection times.",
"   </p>",
"   <p>",
"    CRT often results in a QRS complex that is narrower than the native QRS complex because of fusion between the two paced signals. However, QRS duration does not always normalize, and some studies have shown a poor correlation between the width of the paced QRS complex and the clinical benefit of BiV pacing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     CRT malfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biventricular pacing systems are prone to the same system malfunctions seen with other types of pacemakers (see",
"    <a class=\"local\" href=\"#H15\">",
"     'True dual chamber system malfunction'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In addition, there are other system problems that are specific to the CRT setting. Since many patients with BiV pacemakers do not require pacing for the standard indications, pacemaker malfunction will not be associated clinically with syncope or \"pacemaker syndrome.\" Instead, loss of ventricular synchrony may result in exacerbation of heart failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Loss of capture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left ventricular lead of a BiV pacing system is separated from the myocardium by the full thickness of the vein wall and by any epicardial fat that may be encasing the vein. The capture threshold of the left ventricular lead may be higher than that of the right ventricular lead. In most contemporary CRT devices, the right and left ventricular leads can be assessed independently if loss of capture is suspect.",
"   </p>",
"   <p>",
"    Loss of capture may be manifested by widening of the QRS complex or by a more subtle change in QRS morphology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31302/abstract/10\">",
"     10",
"    </a>",
"    ]. It is not always possible to recognize loss of capture based upon the surface ECG alone (",
"    <a class=\"graphic graphic_waveform graphicRef71566 \" href=\"mobipreview.htm?27/37/28243\">",
"     waveform 1",
"    </a>",
"    ). An intracardiac electrogram obtained by interrogating the pacemaker will commonly demonstrate an obvious change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Oversensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oversensing is the detection of an inappropriate physiologic or nonphysiologic electrical signal. Skeletal muscle potentials generated by isometric contraction of the muscles in close proximity to the pulse generator are the most common etiology of oversensing, although inappropriate sensing of electrical activity in another cardiac chamber is also a potential problem.",
"   </p>",
"   <p>",
"    In a BiV pacing system, oversensing of atrial activity on the ventricular channel results in ventricular inhibition and loss of resynchronization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31302/abstract/11\">",
"     11",
"    </a>",
"    ]. This can be a result of malposition of the left ventricular lead too close to the AV valve ring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Mechanical lead failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;All major electrical malfunctions, including loss of capture, undersensing, and oversensing, can be associated with a breach in lead insulation or in conductor failure. In standard single lead pacing systems, a breach in lead insulation causes a marked drop in the measured stimulation impedance, while a conductor coil fracture causes a marked increase in impedance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PACING SYSTEM EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the system involves a single chamber or dual chamber pacemaker, the process for evaluating the pacing system is similar. A detailed discussion of pacing system evaluation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=see_link&amp;anchor=H46#H46\">",
"     \"Pacing system malfunction: Evaluation and management\", section on 'Pacing system evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PACEMAKER DIAGNOSTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to interrogation of programmed and measured data, which is absolutely essential, most systems can provide telemeter event markers and endocardial electrograms. When these are available, the clinician should take advantage of them, since they will greatly facilitate the evaluation. A detailed discussion of pacemaker diagnostics is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=see_link&amp;anchor=H50#H50\">",
"     \"Pacing system malfunction: Evaluation and management\", section on 'Pacemaker diagnostics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phrase \"pacing system malfunction\" includes problems that might arise from any of the components of the system, including the pulse generator, also called the pacemaker, and the lead or leads that connect the pulse generator to the heart. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pacing system components'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    True pacemaker system malfunctions occur when there is loss of capture at a time when the myocardium is capable of being depolarized, loss of sensing when an appropriate signal occurs during an alert period, or oversensing. The pacemaker cannot unpredictably alter its manner of function unless there is a component malfunction. Given the overall reliability of the pulse generators, if a bizarre behavior is encountered, one should consider a device eccentricity, a lead problem, or a recording artifact before entertaining the diagnosis of a pulse generator failure. In these more unusual circumstances, if a definitive diagnosis is not reached, it is always helpful to contact the manufacturer's 'help-line' prior to invasive troubleshooting. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'True dual chamber system malfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Biventricular pacemakers are prone to the same problems as dual chamber pacing systems. However, since many patients with biventricular pacemakers do not require pacing for the standard indications, pacemaker malfunction will not be associated clinically with syncope or \"pacemaker syndrome\". Instead, loss of ventricular synchrony may result in exacerbation of heart failure. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Biventricular pacemakers'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ellenbogen A, Wilkoff BL, Kay GN, Lau CP. Pacemaker troubleshooting and follow-up. In: Clinical Cardiac Pacing, Defibrillation and Resynchronization Therapy, 3rd ed, Saunders, Philadelphia 2007. p.1005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/2\">",
"      Barold SS. Upper rate of DDD pacemakers. The view from the atrial side. Pacing Clin Electrophysiol 1988; 11:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/3\">",
"      . Use of rate smoothing to treat pacemaker-mediated tachycardias and symptoms due to upper rate response of a DDD pacemaker. Clin Prog Pacing Electrophysiol 1984; 2:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/4\">",
"      van Mechelen R, Ruiter J, de Boer H, Hagemeijer F. Pacemaker electrocardiography of rate smoothing during DDD pacing. Pacing Clin Electrophysiol 1985; 8:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/5\">",
"      Higano ST, Hayes DL. P wave tracking above the maximum tracking rate in a DDDR pacemaker. Pacing Clin Electrophysiol 1989; 12:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/6\">",
"      Higano ST, Hayes DL, Eisinger G. Sensor-driven rate smoothing in a DDDR pacemaker. Pacing Clin Electrophysiol 1989; 12:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/7\">",
"      Higano ST, Hayes DL, Eisinger G. Advantage of discrepant upper rate limits in a DDDR pacemaker. Mayo Clin Proc 1989; 64:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/8\">",
"      Hayes DL, Higano ST, Eisinger G. Electrocardiographic manifestations of a dual-chamber, rate-modulated (DDDR) pacemaker. Pacing Clin Electrophysiol 1989; 12:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/9\">",
"      Pitney MR, May CD, Davis MJ. Undesirable mode switching with a dual chamber rate responsive pacemaker. Pacing Clin Electrophysiol 1993; 16:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/10\">",
"      Yong P, Duby C. A new and reliable method of individual ventricular capture identification during biventricular pacing threshold testing. Pacing Clin Electrophysiol 2000; 23:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31302/abstract/11\">",
"      Lipchenca I, Garrigue S, Glikson M, et al. Inhibition of biventricular pacemakers by oversensing of far-field atrial depolarization. Pacing Clin Electrophysiol 2002; 25:365.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1018 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-58B3102C39-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31302=[""].join("\n");
var outline_f30_36_31302=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PACING SYSTEM COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DUAL CHAMBER PACING MODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LIMITING THE MAXIMAL PACED RATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Total atrial refractory period",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maximum tracking rate timer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RATE MODULATED (RESPONSIVE) PACEMAKERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TRUE DUAL CHAMBER SYSTEM MALFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Loss of atrial capture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Loss of atrial sensing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Loss of ventricular capture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Loss of ventricular sensing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ventricular oversensing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Atrial oversensing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      BIVENTRICULAR PACEMAKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pacing system components and pacing mode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CRT malfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Loss of capture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Oversensing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Mechanical lead failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PACING SYSTEM EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PACEMAKER DIAGNOSTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1018\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1018|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/35/15925\" title=\"figure 1\">",
"      Cardiac resynchronization leads",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1018|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/27/28091\" title=\"table 1\">",
"      Ventricular and atrial pacers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1018|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?27/37/28243\" title=\"waveform 1\">",
"      Loss of capture BiV pacing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/983?source=related_link\">",
"      Cardiac resynchronization therapy in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/62/996?source=related_link\">",
"      ECG tutorial: Pacemakers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/14/21737?source=related_link\">",
"      Pacing system malfunction: Evaluation and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_36_31303="Definition and mechanisms of leukocytosis and neutrophilia";
var content_f30_36_31303=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Definition and mechanisms of leukocytosis and neutrophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31303/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31303/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31303/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31303/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31303/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31303/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/36/31303/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the mechanisms causing an increased total white blood cell count due to an increased number of circulating neutrophils (ie, neutrophilic leukocytosis). The causes of leukocytosis (ie, neutrophilic, lymphocytic, monocytic, eosinophilic, and basophilic) and an approach to the patient with neutrophilia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35705?source=see_link\">",
"     \"Causes of neutrophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link\">",
"     \"Approach to the patient with neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal total white blood cell (WBC) count in adults varies from 4400 to 11,000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    the majority of normal leukocytes (approximately 60 percent) are mature neutrophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Leukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis is defined as a total white blood cell (WBC) count more than two standard deviations above the mean, or a value greater than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    in adults. Leukocytosis to values in excess of",
"    <span class=\"nowrap\">",
"     50,000/microL,",
"    </span>",
"    when due to causes other than leukemia, has been called a leukemoid reaction. However, this term conveys no useful information concerning etiology, and is mainly of historic interest. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Leukemoid reaction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since the limits of normal include two standard deviations above the mean, 2.5 percent of the normal population will have a total WBC count above",
"    <span class=\"nowrap\">",
"     11,000/microL.",
"    </span>",
"    This becomes important when an otherwise normal patient with a modest increase in WBC count is being evaluated.",
"   </p>",
"   <p>",
"    While leukocytosis is most commonly due to an increase in the absolute number of mature neutrophils (neutrophilia), it can also reflect a marked increase in the absolute numbers of lymphocytes, eosinophils, monocytes, or, more rarely, basophils. Granulocytosis is generally used interchangeably with neutrophilia, although they are somewhat different. Granulocytosis can also reflect leukocytosis due to increased numbers of eosinophils or basophils.",
"   </p>",
"   <p>",
"    On the other hand, some patients have an absolute increase in one of the above WBC elements without an elevation in the total WBC count (eg, neutrophilia in a patient with lymphopenia due to AIDS). Thus, in order to avoid confusion, it is reasonable to employ specific terms which describe the actual state of affairs in a given patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Left shift",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard definition of a left shift is a band form count greater than",
"    <span class=\"nowrap\">",
"     700/microL,",
"    </span>",
"    a condition often called \"bandemia.\" (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link&amp;anchor=H19#H19\">",
"     \"Approach to the patient with neutrophilia\", section on 'Left shift in the WBC differential'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Leukemoid reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis exceeding",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    is referred to as a leukemoid reaction and is often characterized by a significant increase in early neutrophil precursors in the peripheral blood (eg, myelocytes, metamyelocytes) along with increased numbers of band forms. Even less mature neutrophil precursors (eg, promyelocytes, myeloblasts) may be observed in severe leukemoid reactions. Proliferation of all the normal myeloid elements is observed in the bone marrow in leukemoid reactions, in contrast to acute leukemia, in which the most immature elements (eg, promyelocytes, myeloblasts) predominate.",
"   </p>",
"   <p>",
"    As noted above, the term \"leukemoid reaction\" conveys no useful information concerning etiology, and is mainly of historic interest. The most important hematologic disease to rule out when evaluating a patient with a leukemoid reaction is chronic myeloid leukemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35705?source=see_link\">",
"     \"Causes of neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neutrophilic leukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophilic leukocytosis is defined as a total WBC above",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    along with an absolute neutrophil count (ANC) more than two standard deviations above the mean (greater than",
"    <span class=\"nowrap\">",
"     7700/microL",
"    </span>",
"    in adults). The ANC (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) is equal to the product of the white blood cell count (WBC) and the percentage of polymorphonuclear cells (PMNs) and band forms noted on the differential analysis:",
"   </p>",
"   <p>",
"    &nbsp;ANC &nbsp;= &nbsp;WBC",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    &nbsp;x &nbsp;percent (PMNs &nbsp;+ &nbsp;bands) &nbsp;&divide; &nbsp;100",
"   </p>",
"   <p>",
"    An elevated ANC greater than",
"    <span class=\"nowrap\">",
"     7700/microL",
"    </span>",
"    in the presence of a total WBC count less than",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    is called neutrophilia.",
"   </p>",
"   <p>",
"    Neutrophilic leukocytosis is commonly seen in infection, stress, smoking, pregnancy, and following exercise. It can also occur in the chronic myeloproliferative disorders, such as polycythemia vera (PV) and chronic myeloid leukemia (",
"    <a class=\"graphic graphic_table graphicRef80503 \" href=\"mobipreview.htm?29/51/30524\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35705?source=see_link\">",
"     \"Causes of neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lymphocytic leukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytic leukocytosis is defined as a total WBC in excess of",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    primarily due to an absolute lymphocyte count in excess of",
"    <span class=\"nowrap\">",
"     4800/microL.",
"    </span>",
"    An elevated absolute lymphocyte count in the presence of a normal total WBC count is called lymphocytosis.",
"   </p>",
"   <p>",
"    Lymphocytic leukocytosis can be seen following infections such as infectious mononucleosis and pertussis or in lymphoproliferative disorders such as the acute and chronic lymphocytic leukemias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=see_link\">",
"     \"Approach to the patient with lymphocytosis or lymphocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Monocytic leukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monocytic leukocytosis is defined as a total WBC above",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    primarily due to an absolute monocyte count above",
"    <span class=\"nowrap\">",
"     800/microL.",
"    </span>",
"    An elevated absolute monocyte count in the presence of a normal total WBC count is called monocytosis.",
"   </p>",
"   <p>",
"    Monocytic leukocytosis can be seen in the acute and chronic monocytic variants of leukemia and can occur in acute bacterial infection or tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Eosinophilic and basophilic leukocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;These disorders are defined as a total WBC above",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    due primarily to an absolute eosinophil or basophil count exceeding",
"    <span class=\"nowrap\">",
"     450/microL",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     200/microL,",
"    </span>",
"    respectively. Increases in the absolute eosinophil or basophil count in the absence of a WBC count above",
"    <span class=\"nowrap\">",
"     11,000/microL",
"    </span>",
"    are called eosinophilia and basophilia, respectively.",
"   </p>",
"   <p>",
"    Eosinophilic leukocytosis can be seen in variant forms of chronic leukemia, solid tumors, infection with helminthic parasites, allergic reactions, and following treatment with Interleukin-2 (",
"    <a class=\"graphic graphic_picture graphicRef53980 \" href=\"mobipreview.htm?8/1/8213\">",
"     picture 1",
"    </a>",
"    ). The causes of eosinophilia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common causes of basophilia include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any of the classic myeloproliferative neoplasms (ie, chronic myeloid leukemia, primary myelofibrosis, polycythemia vera, essential thrombocytosis)",
"     </li>",
"     <li>",
"      Other hematologic malignancies (eg, basophilic leukemia, mastocytosis, hypereosinophilic syndrome, atypical acute and chronic leukemias, myelodysplastic syndrome)",
"     </li>",
"     <li>",
"      Allergic or inflammatory reactions, including hypersensitivity reactions, ulcerative colitis, rheumatoid arthritis",
"     </li>",
"     <li>",
"      Endocrinopathy, including hypothyroidism (myxedema), administration of estrogens",
"     </li>",
"     <li>",
"      Infections, including viral infections, tuberculosis, helminth infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Basophilic leukocytosis is a distinctly unusual condition, and is most often associated with basophilic or mast cell variants of acute or chronic leukemia (",
"    <a class=\"graphic graphic_picture graphicRef51971 \" href=\"mobipreview.htm?22/41/23185\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60902 \" href=\"mobipreview.htm?21/53/22364\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     REGULATION OF NEUTROPHIL COUNTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral neutrophil count reflects the equilibrium of several compartments. The bone marrow contains a mitotic pool, a maturation pool, and a storage pool (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"mobipreview.htm?30/58/31651\">",
"     figure 1",
"    </a>",
"    ). Outside the marrow, there is a circulating pool, a marginated pool of neutrophils adherent to vascular endothelium, and a tissue pool. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical assay for the number of neutrophils, the white blood cell (WBC) count and differential, measures only neutrophils in the circulating pool during their brief three to six hour period of transit from the bone marrow to tissue. A complex interplay of factors regulates production of granulocytes and their movement from one pool to another, but the movement is always from marrow to blood to tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6185?source=see_link\">",
"     \"Normal neutrophil development and kinetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutrophils are derived from a common progenitor that also gives rise to erythrocytes, megakaryocytes, eosinophils, basophils, and monocytes (",
"    <a class=\"graphic graphic_figure graphicRef60964 \" href=\"mobipreview.htm?19/4/19523\">",
"     figure 2",
"    </a>",
"    ). Proliferation of the common progenitor is stimulated by interleukin (IL)-3 and granulocyte-macrophage colony stimulating factor (GM-CSF), while later differentiation is regulated by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experimental evidence supports a feedback inhibition loop in the regulation of neutrophil production. Lactoferrin, which is contained in specific granules in neutrophils (",
"    <a class=\"graphic graphic_table graphicRef57400 \" href=\"mobipreview.htm?41/7/42109\">",
"     table 3",
"    </a>",
"    ), suppresses the production of CSFs by monocytes, resulting in a decrease in neutrophil production when granulocyte counts rise. Acidic isoferritins may also participate in this downregulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     CXC chemokine receptor 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important information about the regulation of neutrophil counts derives from research on myelokathexis, a rare syndrome associated with neutropenia and characterized by a cellular marrow with retained mature neutrophils (kathexis = retained) and abnormal nuclear morphology of the myeloid series. While associated with neutropenia rather than neutrophilia, this syndrome suggests that there is movement of neutrophils from the periphery to the marrow as well as from the marrow into the periphery and implies an important mechanism by which neutrophils are released from the marrow. Retention and release from the marrow seems to be related to the presence of the CXC chemokine receptor 4 (CXCR4) on neutrophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     WHIM syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the initial descriptions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/6,7\">",
"     6,7",
"    </a>",
"    ] several patients with the constellation of Warts, Hypogammaglobulinemia, Infections and Myelokathexis have been described, leading to the acronym WHIM syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/8\">",
"     8",
"    </a>",
"    ]. The inheritance appears to be dominant and considerable heterogeneity in clinical characteristics exists among these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Neutrophil counts are in the 100 to",
"    <span class=\"nowrap\">",
"     450/microL",
"    </span>",
"    range, and bone marrow cellularity is usually increased. Myelokathexis is associated with an increased rate of apoptosis and decreased expression of bcl-x in myeloid precursors, which explains in part the abnormal nuclear morphology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/13-15\">",
"     13-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the cases of WHIM syndrome have been linked to autosomal dominant mutations in the CXC chemokine receptor 4 (CXCR4), all of which cause mutations in the carboxy-terminus of CXCR4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/11,16-18\">",
"     11,16-18",
"    </a>",
"    ]. Stromal cell-derived factor-1",
"    <span class=\"nowrap\">",
"     (SDF-1/CXCL12)",
"    </span>",
"    is the ligand for CXCR4, and is important in regulation of B-cell lymphopoiesis and in myelopoiesis during embryonic life. It also controls CD34+ cell and lymphocyte trafficking postnatally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/11\">",
"     11",
"    </a>",
"    ] as well as release of neutrophils from the bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations of CXCR4 in WHIM cause failure of receptor downregulation and internalization, resulting in prolonged activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Activation of CXCR4 leads to increased retention and homing of neutrophils to bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/11,19\">",
"     11,19",
"    </a>",
"    ]. However, activation of mutant CXCR4 causes increased retention and apoptosis of neutrophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/22\">",
"     22",
"    </a>",
"    ] likely explaining the neutropenia, hypercellular marrow and apoptosis seen in patients with myelokathexis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/13,23,24\">",
"     13,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the WHIM syndrome is extremely rare, significant new understanding about the regulation and trafficking of myeloid cells has come from study of patients with the WHIM syndrome as well as from animal models. These studies suggest that the",
"    <span class=\"nowrap\">",
"     CXCR4/SDF-1",
"    </span>",
"    axis is very important in maintenance of neutrophil homeostasis and cellular mobilization in both health and disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/25\">",
"     25",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An inhibitor of the interaction between",
"      <span class=\"nowrap\">",
"       SDF-1/CXCL12",
"      </span>",
"      and CXCR4 has been developed and termed AMD3100. The combination of G-CSF plus AMD3100 has been shown to improve mobilization of CD34+ cells in subjects who had previously failed mobilization with chemotherapy or cytokine-only mobilization. AMD3100 has also been shown to be a potent and rapid mobilizer of endothelial progenitor and angiogenic cells. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=see_link&amp;anchor=H13#H13\">",
"       \"Sources of hematopoietic stem cells\", section on 'Plerixafor (AMD3100, Mozobil)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment with glucocorticoids markedly decreases circulating levels of eosinophils. This is mediated in part by sequestration of eosinophils in extravascular tissues, an effect that may be due to the preferential upregulation of the CXC chemokine receptor 4 (CXCR4). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=see_link&amp;anchor=H9#H9\">",
"       \"Glucocorticoid effects on the immune system\", section on 'Eosinophils'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retention of CXCR4+, CXCR5+, CD27+ memory B cells in inflamed glands seems to contribute to diminished peripheral CD27+ memory B cells in primary Sjogren's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25162?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathogenesis of Sj&ouml;gren's syndrome\", section on 'Overview of pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The bone marrow is important in the release of neutrophils that have reached maturity and accelerated release of less mature cells in response to inflammation. However, it also plays an important role in regulating circulating neutrophils. In animal models at least, infused peripheral blood neutrophils redistribute equally between the marrow and the liver, neutrophils derived from exudates home to the liver, and marrow-derived neutrophils return primarily to the marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This suggests that the marrow recaptures circulating neutrophils and can re-release them. Retention of neutrophils in the marrow is increased by activation of the CXCR4 while blocking neutrophil CXCR4 reduces neutrophil retention and mobilizes neutrophils from the marrow into circulation in animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/19\">",
"     19",
"    </a>",
"    ] as well as humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Inflammatory mediators cause much higher release of neutrophils in the presence of CXCR4 blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/19\">",
"     19",
"    </a>",
"    ]. Furthermore, surface expression of CXCR4 on neutrophils decreases with maturation and with activation. This would favor retention of younger cells in the marrow and cause mature and stimulated neutrophils to remain in the circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glucocorticoids and other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms controlling the release of neutrophils from the bone marrow are only partially understood. A variety of compounds induce neutrophil movement into the circulation including endotoxin, glucocorticoids, a leukocyte-mobilizing factor derived from the third component of complement (C3e), chemoattractants such as C5a, cytokines such as tumor necrosis factor (TNF)-alpha, and certain androgens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. To successfully emerge into the circulation, neutrophils must deform and migrate to the luminal side of the endothelial sinusoidal surface. Endotoxin affects the relationship between marrow sinus endothelial cells and the stromal macrophages covering nonluminal sinusoidal surfaces; it induces retraction of macrophages away from the endothelium which facilitates contact between neutrophils and endothelial cells and allows neutrophil egress from the bone marrow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35705?source=see_link&amp;anchor=H26#H26\">",
"     \"Causes of neutrophilia\", section on 'Glucocorticoids and other drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Release of neutrophils from the marrow storage pool can result in a two- to threefold increase in the neutrophil count within four to five hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/30,36\">",
"     30,36",
"    </a>",
"    ]. At any given time, more than one-half of the neutrophils in the peripheral circulation are attached to the vascular endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/37\">",
"     37",
"    </a>",
"    ]. These \"marginated\" neutrophils can be released almost immediately (ie, \"demarginated\" within minutes) at times of stress, an effect that is mediated in part by epinephrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutrophil margination is mediated by specific receptor interactions. L-selectin is constitutively expressed on the neutrophil surface and tethers the cell to the vessel, probably by binding to sulfated glycoconjugates on the endothelium. E-selectin and P-selectin may also be involved in this process (",
"    <a class=\"graphic graphic_figure graphicRef60528 \" href=\"mobipreview.htm?42/23/43376\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The production of neutrophils can be increased in the presence of an inflammatory stimulus. These cells spend about nine days in marrow, three to six hours in blood, and one to four days in the tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, the total neutrophil count, as measured from peripheral blood, represents a population that comprises only 5 percent of the total pool sampled during a fleeting 2 percent of its total transit time.",
"   </p>",
"   <p>",
"    In assessing neutrophilia, one must consider the movement of neutrophils from one compartment to another, as well as changes in production. Thus, neutrophilia can be due to increased production as in infection or myeloproliferative disorders or inhibition of egress from the blood as in certain chemotactic disorders or steroid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35705?source=see_link\">",
"     \"Causes of neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Practically, however, evaluation of these processes is limited to an examination of the peripheral blood and bone marrow. Existing radiotracer techniques, albeit sophisticated, are not of much clinical use. Similarly, clinical tests such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) challenge or epinephrine stimulation, which reflect the presence of a releasable marrow storage pool or marginated pool, respectively, have limited differential diagnostic power. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link\">",
"     \"Approach to the patient with neutrophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Flow cytometry studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early release of neutrophils from the marrow storage pool under conditions of",
"    <span class=\"nowrap\">",
"     stress/inflammation",
"    </span>",
"    may be reflected in the appearance of",
"    <span class=\"nowrap\">",
"     CD10-negative/CD16-low",
"    </span>",
"    neutrophils in the circulation, as measured by flow cytometry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/38\">",
"     38",
"    </a>",
"    ]. CD16a and CD16b are components of the low affinity Fc receptor on neutrophils, and may have short term implications in host defense. If this observation is confirmed in the appropriate clinical settings, such flow cytometric studies might help to quantify this release phenomenon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31303/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10322069\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal total white blood cell (WBC) count in adults varies from 4400 to 11,000",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      with the majority (approximately 60 percent) being mature neutrophils.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neutrophilia is defined as an absolute neutrophil count (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) greater than",
"      <span class=\"nowrap\">",
"       7700/microL.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35705?source=see_link\">",
"       \"Causes of neutrophilia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The standard definition of a &ldquo;left shift&rdquo; is a neutrophilic band form count greater than",
"      <span class=\"nowrap\">",
"       700/microL,",
"      </span>",
"      a condition often called \"bandemia.\" (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link&amp;anchor=H19#H19\">",
"       \"Approach to the patient with neutrophilia\", section on 'Left shift in the WBC differential'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphocytosis is defined as an absolute lymphocyte count greater than",
"      <span class=\"nowrap\">",
"       4800/microL.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=see_link\">",
"       \"Approach to the patient with lymphocytosis or lymphocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monocytosis is defined as an absolute monocyte count greater than",
"      <span class=\"nowrap\">",
"       800/microL.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=see_link&amp;anchor=H20#H20\">",
"       \"Approach to the patient with neutrophilia\", section on 'Monocytosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eosinophilia and basophilia are defined as absolute eosinophil or absolute basophil counts greater than 450 and",
"      <span class=\"nowrap\">",
"       200/microL,",
"      </span>",
"      respectively. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Eosinophilic and basophilic leukocytosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=see_link\">",
"       \"Approach to the patient with eosinophilia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of compounds induce neutrophil movement from the bone marrow into the circulation including endotoxin, glucocorticoids, a leukocyte-mobilizing factor derived from the third component of complement (C3e), chemoattractants such as C5a, cytokines such as tumor necrosis factor (TNF)-alpha, and certain androgens. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Regulation of neutrophil counts'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35705?source=see_link\">",
"       \"Causes of neutrophilia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/1\">",
"      Hollowell JG, van Assendelft OW, Gunter EW, et al. Hematological and iron-related analytes--reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat 11 2005; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/2\">",
"      Dinarello CA, Mier JW. Lymphokines. N Engl J Med 1987; 317:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/3\">",
"      Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/4\">",
"      Broxmeyer HE, Gentile P, Cooper S, et al. Functional activities of acidic isoferritins and lactoferrin in vitro and in vivo. Blood Cells 1984; 10:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/5\">",
"      Broxmeyer HE, Lu L, Bognacki J. Transferrin, derived from an OKT8-positive subpopulation of T lymphocytes, suppresses the production of granulocyte-macrophage colony-stimulatory factors from mitogen-activated T lymphocytes. Blood 1983; 62:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/6\">",
"      ZUELZER WW. \"MYELOKATHEXIS\"--A NEW FORM OF CHRONIC GRANULOCYTOPENIA. REPORT OF A CASE. N Engl J Med 1964; 270:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/7\">",
"      KRILL CE Jr, SMITH HD, MAUER AM. CHRONIC IDIOPATHIC GRANULOCYTOPENIA. N Engl J Med 1964; 270:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/8\">",
"      Hord JD, Whitlock JA, Gay JC, Lukens JN. Clinical features of myelokathexis and treatment with hematopoietic cytokines: a case report of two patients and review of the literature. J Pediatr Hematol Oncol 1997; 19:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/9\">",
"      O'Regan S, Newman AJ, Graham RC. 'Myelokathexis'. Neutropenia with marrow hyperplasia. Am J Dis Child 1977; 131:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/10\">",
"      Mamlok RJ, Juneja HS, Elder FF, et al. Neutropenia and defective chemotaxis associated with binuclear, tetraploid myeloid-monocytic leukocytes. J Pediatr 1987; 111:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/11\">",
"      Balabanian K, Lagane B, Pablos JL, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 2005; 105:2449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/12\">",
"      Gulino AV. WHIM syndrome: a genetic disorder of leukocyte trafficking. Curr Opin Allergy Clin Immunol 2003; 3:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/13\">",
"      Aprikyan AA, Liles WC, Park JR, et al. Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression of bcl-x in neutrophil precursors. Blood 2000; 95:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/14\">",
"      Mackey MC, Aprikyan AA, Dale DC. The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans. Cell Prolif 2003; 36:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/15\">",
"      Latger-Cannard V, Bensoussan D, Bordigoni P. The WHIM syndrome shows a peculiar dysgranulopoiesis: myelokathexis. Br J Haematol 2006; 132:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/16\">",
"      Diaz GA, Gulino AV. WHIM syndrome: a defect in CXCR4 signaling. Curr Allergy Asthma Rep 2005; 5:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/17\">",
"      Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003; 34:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/18\">",
"      Christ MJ, Dillon CA. Myelokathexis in a mother and infant: a second case suggesting dominant inheritance. Mil Med 1997; 162:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/19\">",
"      Suratt BT, Petty JM, Young SK, et al. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. Blood 2004; 104:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/20\">",
"      Kawai T, Choi U, Cardwell L, et al. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. Blood 2007; 109:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/21\">",
"      Kawai T, Choi U, Whiting-Theobald NL, et al. Enhanced function with decreased internalization of carboxy-terminus truncated CXCR4 responsible for WHIM syndrome. Exp Hematol 2005; 33:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/22\">",
"      Boxer LA, Allen JM, Baehner RL. Diminished polymorphonuclear leukocyte adherence. Function dependent on release of cyclic AMP by endothelial cells after stimulation of beta-receptors by epinephrine. J Clin Invest 1980; 66:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/23\">",
"      Papadaki HA, Eliopoulos GD. The role of apoptosis in the pathophysiology of chronic neutropenias associated with bone marrow failure. Cell Cycle 2003; 2:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/24\">",
"      Gorlin RJ, Gelb B, Diaz GA, et al. WHIM syndrome, an autosomal dominant disorder: clinical, hematological, and molecular studies. Am J Med Genet 2000; 91:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/25\">",
"      Eash KJ, Means JM, White DW, Link DC. CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. Blood 2009; 113:4711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/26\">",
"      Suratt BT, Young SK, Lieber J, et al. Neutrophil maturation and activation determine anatomic site of clearance from circulation. Am J Physiol Lung Cell Mol Physiol 2001; 281:L913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/27\">",
"      Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/28\">",
"      Hendrix CW, Flexner C, MacFarland RT, et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000; 44:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/29\">",
"      Deinard AS, Page AR. A study of steroid-induced granulocytosis in a patient with chronic benign neutropenia of childhood. Br J Haematol 1974; 28:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/30\">",
"      Ghebrehiwet B, M&uuml;ller-Eberhard HJ. C3e: an acidic fragment of human C3 with leukocytosis-inducing activity. J Immunol 1979; 123:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/31\">",
"      Mitchell RH, McClelland RM, Kampschmidt RF. Comparison of neutrophilia induced by leukocytic endogenous mediator and by cobra venom factor. Proc Soc Exp Biol Med 1982; 169:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/32\">",
"      Jagels MA, Chambers JD, Arfors KE, Hugli TE. C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood 1995; 85:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/33\">",
"      Vogel JM, Yankee RA, Kimball HR, et al. The effect of etiocholanolone on granulocyte kinetics. Blood 1967; 30:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/34\">",
"      Lichtman MA, Weed RI. Alteration of the cell periphery during granulocyte maturation: relationship to cell function. Blood 1972; 39:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/35\">",
"      Hirahata T, Bjorkman D, Chamberlain JK. Endotoxin: a twofold effect on bone marrow ultrastructure. Scanning Microsc 1987; 1:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/36\">",
"      Dale DC, Fauci AS, Guerry D IV, Wolff SM. Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest 1975; 56:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/37\">",
"      Ho-Yen DO, Martin KW. The relationship between atypical lymphocytosis and serological tests in infectious mononucleosis. J Infect 1981; 3:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/38\">",
"      Orr Y, Taylor JM, Bannon PG, et al. Circulating CD10-/CD16low neutrophils provide a quantitative index of active bone marrow neutrophil release. Br J Haematol 2005; 131:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31303/abstract/39\">",
"      Ribeiro D, Veldwijk MR, Benner A, et al. Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion 2007; 47:969.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8379 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31303=[""].join("\n");
var outline_f30_36_31303=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10322069\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Leukocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Left shift",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Leukemoid reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neutrophilic leukocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lymphocytic leukocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Monocytic leukocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Eosinophilic and basophilic leukocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      REGULATION OF NEUTROPHIL COUNTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CXC chemokine receptor 4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - WHIM syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glucocorticoids and other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Flow cytometry studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10322069\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8379\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8379|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/58/31651\" title=\"figure 1\">",
"      PMN development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?19/4/19523\" title=\"figure 2\">",
"      Overview of hematopoiesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/23/43376\" title=\"figure 3\">",
"      Extravasation of circulating leukocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8379|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/1/8213\" title=\"picture 1\">",
"      Eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/41/23185\" title=\"picture 2\">",
"      Basophils in CML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8379|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/51/30524\" title=\"table 1\">",
"      Classification of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/53/22364\" title=\"table 2\">",
"      Accel phase CML criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/7/42109\" title=\"table 3\">",
"      PMN granule contents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/12/3274?source=related_link\">",
"      Approach to the patient with lymphocytosis or lymphocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/52/29511?source=related_link\">",
"      Approach to the patient with neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/55/35705?source=related_link\">",
"      Causes of neutrophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6185?source=related_link\">",
"      Normal neutrophil development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/36/25162?source=related_link\">",
"      Pathogenesis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38682?source=related_link\">",
"      Sources of hematopoietic stem cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_36_31304="ACR relative radiation 2";
var content_f30_36_31304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F50652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F50652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    ACR relative radiation information (Part 2 of 2)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 669px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Royal College of Radiologists. Making the best use of a department of clinical radiology: guidelines for doctors. 5th ed. London: The Royal College of Radiologists; 2003.",
"       </li>",
"       <li>",
"        Martin CJ. Effective dose: how should it be applied to medical exposures? Br J Radiol 2007; 80(956):639-647.",
"       </li>",
"       <li>",
"        International Commission on Radiological Protection, 1990 Recommendations of the International Commission on Radiological Protection, ICRP Publication 60. Ann ICRP 1991; 21:1-3.",
"       </li>",
"       <li>",
"        Bor D, Sancak T, Olgar T, et al. Comparison of effective doses obtained from dose-area product and air kerma measurements in interventional radiology. Br J Radiol 2004; 77(916):315-322.",
"       </li>",
"       <li>",
"        National Council on Radiation Protection and Measurements. Exposure of the US population from diagnostic medical radiation, NCRP Report No. 100. Bethesda, MD; 1989.",
"       </li>",
"       <li>",
"        Conference of Radiation Control Program Directors. Nationwide Evaluation of X-Ray Trends (NEXT) - Tabulation and Graphical Summary of 2000 Survey of Computed Tomography: file://www.fda.gov/cdrh/ct/2000survey.html; 2007: In publication: CRCPD publication no. E-07-02.",
"       </li>",
"       <li>",
"        United States Pharmacopeia Drug Information: Drug Information for the Health Care Professional. 27th ed. Greenwood Village, CO: Thomson Micromedex; 2007.",
"       </li>",
"       <li>",
"        ICRP Publication 80: Radiation Dose to Patients from Radiopharmaceuticals. Rev ed: Elsevier; September 1, 1999.",
"       </li>",
"       <li>",
"        Mettler FA, Jr., Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 2008; 248(1):254-263.",
"       </li>",
"       <li>",
"        Wall BF, Hart D. Revised radiation doses for typical X-ray examinations. Report on a recent review of doses to patients from medical X-ray examinations in the UK by NRPB. National Radiological Protection Board. Br J Radiol 1997; 70(833):437-439.",
"       </li>",
"       <li>",
"        Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: The National Academies Press; 2006.",
"       </li>",
"       <li>",
"        National Council on Radiation Protection and Measurements. Ionizing radiation exposure of the population of the United States., NCRP Report No. 93. Bethesda, MD; 1987.",
"       </li>",
"       <li>",
"        Amis ES, Jr., Butler PF, Applegate KE, et al. American College of Radiology white paper on radiation dose in medicine. J Am Coll Radiol 2007; 4(5):272-284.",
"       </li>",
"       <li>",
"        National Cancer Institute. Radiation Risks and Pediatric Computed Tomography (CT): A Guide for Health Care Providers. file://www.cancer.gov/cancertopics/causes/radiation-risks-pediatric-CT. Accessed August 2009.",
"       </li>",
"       <li>",
"        ACR practice guideline for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. In: Practice Guidelines and Technical Standards. Reston, Va: American College of Radiology; 2008:23-37.",
"       </li>",
"      </ol>",
"      American College of Radiology Appropriateness Criteria.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31304=[""].join("\n");
var outline_f30_36_31304=null;
var title_f30_36_31305="Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment";
var content_f30_36_31305=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31305/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31305/contributors\">",
"     Sandra J Hong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31305/contributors\">",
"     Sachiko T Cochran, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31305/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31305/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31305/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31305/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/36/31305/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 70 million diagnostic radiographic examinations using radiocontrast media (RCM) are performed worldwide each year, with at least 10 million in the United States alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/1\">",
"     1",
"    </a>",
"    ]. Procedures using RCM include myelography, angiography (including cerebral arteriography), venography, urography, endoscopic retrograde cholangiopancreatography (ERCP), arthrography, and computed tomography (CT). Adverse reactions occur predominantly in association with",
"    <strong>",
"     intravenous",
"    </strong>",
"    administration of RCM.",
"   </p>",
"   <p>",
"    This topic review discusses immediate hypersensitivity reactions to RCM, including their clinical presentation, epidemiology and risk factors, diagnosis, and management. The different types of RCM currently in use are also reviewed. Strategies to prevent repeat hypersensitivity reactions to RCM in patients who have previously experienced reactions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;RCM can cause a variety of adverse reactions and the pathophysiology of most of these is poorly understood. As a result, various systems of classifying these reactions exist, based upon severity, timing, signs and symptoms, or presumed pathophysiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/2\">",
"     2",
"    </a>",
"    ]. In this review, adverse reactions to RCM are divided into two broad categories: chemotoxic reactions and hypersensitivity reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chemotoxic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotoxic, or physiologic, reactions are related to the chemical properties of radiocontrast agents and are",
"    <strong>",
"     dependent",
"    </strong>",
"    upon dose and infusion rate. These include vasovagal reactions, seizures, arrhythmias, and organ (especially renal) toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vasovagal reactions",
"      </strong>",
"      are considered to be a form of chemotoxic reaction because they may be related to rate of infusion and concentration. These relatively common reactions present with warmth, flushing, nausea, or emesis and are usually transient and self-limited. Severe reactions can involve hypotension or bradycardia. Vasovagal reactions are attributed to fluid shifts caused by the infusion of a hypertonic solution, although the precise mechanism is unknown. These reactions do not preclude further administration of the causative RCM, and slowing the rate of infusion is often sufficient to avoid further symptoms.",
"     </li>",
"     <li>",
"      <strong>",
"       Renal toxicity",
"      </strong>",
"      is presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"       \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hyperthyroidism",
"      </strong>",
"      is discussed separately (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=see_link&amp;anchor=H7754869#H7754869\">",
"       \"Iodine-induced thyroid dysfunction\", section on 'Sources of iodine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chemotoxic reactions are not discussed further in this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypersensitivity reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity reactions to radiocontrast are idiosyncratic and largely",
"    <strong>",
"     independent",
"    </strong>",
"    of dose and infusion rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/6\">",
"     6",
"    </a>",
"    ]. They can occur in response to minute amounts of contrast agent. These reactions can be further subdivided into immediate and delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Immediate hypersensitivity reactions",
"      </strong>",
"      (IHRs) develop within one hour of administration. IHRs are the focus of this topic review.",
"     </li>",
"     <li>",
"      <strong>",
"       Delayed hypersensitivity reactions",
"      </strong>",
"      develop from one hour to several days after administration. This category includes mild to moderate cutaneous eruptions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/8\">",
"       8",
"      </a>",
"      ],",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      and various uncommon reactions, including erythema multiforme minor, fixed drug eruption, Stevens-Johnson syndrome, flexural exanthema, and vasculitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/9\">",
"       9",
"      </a>",
"      ]. Delayed reactions are not discussed further in this review.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate hypersensitivity reactions to RCM develop within one hour, and usually within five minutes of RCM administration. Signs and symptoms include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flushing",
"     </li>",
"     <li>",
"      Pruritus",
"     </li>",
"     <li>",
"      Urticaria",
"     </li>",
"     <li>",
"      Angioedema",
"     </li>",
"     <li>",
"      Bronchospasm and wheezing",
"     </li>",
"     <li>",
"      Laryngeal edema and stridor",
"     </li>",
"     <li>",
"      Hypotension and rarely shock",
"     </li>",
"     <li>",
"      Loss of consciousness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Coronary artery spasm may complicate severe IHRs during coronary angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Immediate hypersensitivity reactions to RCM can be clinically identical to IgE-mediated anaphylaxis and equally severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of most IHRs is believed to be non IgE-mediated. The following mechanisms have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct mast cell activation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Activation of the coagulation, kinin,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complement cascades [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/15,17-20\">",
"       15,17-20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inhibition of platelet aggregation with increased serotonin release [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inhibition of enzymes such as cholinesterase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence for the above mechanisms largely consists of case reports and in vitro studies of small numbers of patients. The pathophysiology remains controversial because the in vitro findings suggesting specific mechanisms can usually be demonstrated not only in",
"    <span class=\"nowrap\">",
"     cells/serum",
"    </span>",
"    from patients who experienced IHRs, but also from normal controls who tolerated RCM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Thus, these mechanisms may reflect pharmacologic properties of RCMs under specific laboratory conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, evidence for IgE directed against RCM agents (true immunologic anaphylaxis) has been demonstrated in a small but growing number of cases, so a small percentage of these reactions may be IgE-mediated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/23,26-30\">",
"     23,26-30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3065708\">",
"     'Skin testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;IHRs to RCM are seen most often in patients between 20 and 50 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/29\">",
"     29",
"    </a>",
"    ]. Reactions in children are unusual, but then studies using RCM are performed less frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elderly people have a significantly higher mortality rate from complications from RCM in general. An Australian review of mortality associated with the use of RCM over 3.5 years found that mortality was age related, with a death rate of 35 per million injections in those over 65 years, compared to 4.5 per million in those under 65 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for immediate reactions include a previous IHR to RCM, asthma, a history of atopic disorders, and possibly the use of certain medications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Previous immediate hypersensitivity reaction to RCM",
"      </strong>",
"      &mdash; Patients who have experienced a previous IHR to RCM are at increased risk for another reaction, compared to patients who have tolerated RCM without difficulty [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/10,34-38\">",
"       10,34-38",
"      </a>",
"      ]. Prevention of recurrent reactions in patients who have experienced previous reactions is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=see_link\">",
"       \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Asthma",
"      </strong>",
"      &mdash; The presence of asthma may increase the risk of IHR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/10\">",
"       10",
"      </a>",
"      ], although not all studies have found this. In one series, treated asthmatics were not at higher risk compared to the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/39\">",
"       39",
"      </a>",
"      ]. Until the impact of treatment is better understood, all patients with asthma should be considered at increased risk.",
"     </li>",
"     <li>",
"      <strong>",
"       History of allergic disease",
"      </strong>",
"      &mdash; Atopic individuals (ie, those with asthma, allergic rhinitis, atopic dermatitis or food allergies) are three times more likely than nonatopic individuals to have a severe adverse reaction to intravenous iodinated contrast media [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/10\">",
"       10",
"      </a>",
"      ]. However, much of this risk may be borne by the subgroup with asthma since few studies have evaluated those with atopic disease, but without asthma.",
"      <br/>",
"      <br/>",
"      Seafood or shellfish allergy is",
"      <strong>",
"       NOT",
"      </strong>",
"      an independent risk factor for IHRs to RCM, although this is a common misconception. Patients allergic to seafood are not at increased risk beyond that of any atopic individual or patients with other food allergies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/10,40,41\">",
"       10,40,41",
"      </a>",
"      ]. The epidemiological association between seafood allergy and RCM reactions has been attributed to a common iodine allergy since there is a high iodine content in seafood. However, iodine and iodide are small molecules that do not cause anaphylactic reactions and are structurally unrelated to shellfish allergens (which are tropomyosin proteins) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. The likely explanation for the association is that seafood is a common cause of food allergy, and individuals with any atopic condition in general are at higher risk for RCM reactions.",
"      <br/>",
"      <br/>",
"      Another source of confusion is the patient with contact dermatitis in response to the skin disinfectant povidone-iodine. Patients with this history also do",
"      <strong>",
"       not",
"      </strong>",
"      appear to be at higher risk for RCM reactions and vice versa.",
"     </li>",
"     <li>",
"      <strong>",
"       Possible risk factors",
"      </strong>",
"      &mdash; Treatment with certain medications have been proposed to increase the risk or severity of adverse reactions to RCM, although there is no consensus regarding these effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/44\">",
"       44",
"      </a>",
"      ]. These include beta-adrenergic blocking agents (beta-blockers), as well as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and other nonsteroidal antiinflammatory drugs (NSAIDs) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/34,45-48\">",
"       34,45-48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TYPES OF RADIOCONTRAST MEDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RCM agents currently in use are based upon fully substituted benzoic acid molecules with three atoms of iodine replacing the hydrogen atoms at positions 2, 4, and 6 of the benzene ring. The different agents can be classified based upon three properties (",
"    <a class=\"graphic graphic_algorithm graphicRef66974 \" href=\"mobipreview.htm?4/56/5006\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83944 \" href=\"mobipreview.htm?28/61/29662\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/22,49\">",
"     22,49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The charge of the iodinated molecule (ionic or nonionic)",
"     </li>",
"     <li>",
"      The molecular structure (monomeric or dimeric)",
"     </li>",
"     <li>",
"      The osmolality of the injected preparation (hyperosmolal, low osmolal, or iso-osmolal relative to normal serum osmolality [275 to 290",
"      <span class=\"nowrap\">",
"       mosm/kg])",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Categories of agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The various types of RCM are most commonly categorized by osmolality. High osmolal contrast material (HOCM) agents have osmolalities &ge;1400",
"    <span class=\"nowrap\">",
"     mosm/kg",
"    </span>",
"    and low osmolal contrast material (LOCM) agents have osmolalities between 500 and 900",
"    <span class=\"nowrap\">",
"     mosm/kg.",
"    </span>",
"    There are also iso-osmolal agents, which are isotonic relative to serum (approximately 290",
"    <span class=\"nowrap\">",
"     mosmol/kg).",
"    </span>",
"    Thus, iso-osmolal agents have a lower osmolality than \"low osmolal\" agents.",
"   </p>",
"   <p>",
"    Four categories can be distinguished if the agents are further subdivided based upon the charge of the iodinated molecule and the molecular structure (",
"    <a class=\"graphic graphic_algorithm graphicRef66974 \" href=\"mobipreview.htm?4/56/5006\">",
"     algorithm 1",
"    </a>",
"    ). Most agents belong to just two groups: ionic HOCM agents or nonionic LOCM agents (",
"    <a class=\"graphic graphic_table graphicRef83944 \" href=\"mobipreview.htm?28/61/29662\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ionic monomers &mdash; The first generation ionic monomers are salts that consist of a negatively charged (anionic) triiodinated benzene ring paired with either a sodium or meglumine cation. This class of RCM has the highest osmolality (&gt;1400",
"      <span class=\"nowrap\">",
"       mosm/kg",
"      </span>",
"      of H2O) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/22,50\">",
"       22,50",
"      </a>",
"      ]. Ionic monomers are less expensive than the other RCM agents. The use of these agents is now largely limited to extravascular procedures, such as cystograms.",
"     </li>",
"     <li>",
"      Ionic dimer &mdash; Ioxaglate is the only ionic dimer commercially available in the United States. It is a LOCM RCM (600",
"      <span class=\"nowrap\">",
"       mosm/kg",
"      </span>",
"      H2O) and is composed of a monoacidic double benzene ring with iodine atoms at 2, 4, and 6 positions on each benzene ring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonionic monomers &mdash; The nonionic monomers are triiodinated compounds with many hydrophilic hydroxyl groups. These agents are referred to as second generation agents and have low osmolality (500 to 850",
"      <span class=\"nowrap\">",
"       mosm/kg",
"      </span>",
"      H20).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"       Iohexol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/45/36565?source=see_link\">",
"       iopamidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34709?source=see_link\">",
"       ioversol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/46/17126?source=see_link\">",
"       iopromide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/41/31380?source=see_link\">",
"       ioxilan",
"      </a>",
"      are commonly used RCMs in this group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/22,50\">",
"       22,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonionic dimer &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"       Iodixanol",
"      </a>",
"      is the first such preparation in this class. It has two nonionic triiodinated benzene rings and is iso-osmolal relative to serum (approximately 290",
"      <span class=\"nowrap\">",
"       mosmol/kg).",
"      </span>",
"      Thus, iso-osmolal agents have a lower osmolality than \"low osmolal\" agents. Although iodixanol is more costly than the other RCMs, it is associated with a lower rate of immediate adverse reactions than other commercially available contrast agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/22,51,52\">",
"       22,51,52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Incidence of reactions by type of RCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The osmolality of the agent is the factor most strongly associated with IHRs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild to moderate IHRs occur with 5 to 13 percent of procedures using ionic HOCM agents and 0.2 to 3 percent of those using nonionic LOCM agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/10,14,31,39,53-64\">",
"       10,14,31,39,53-64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Life-threatening immediate reactions, which are usually hypersensitivity reactions, occur in 0.04 to 0.22 percent of ionic HOCM infusions and in 0.004 to 0.04 percent of nonionic LOCM administrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/10,65\">",
"       10,65",
"      </a>",
"      ]. However, there does not appear to be a difference in overall mortality between lower or higher osmolality RCM.",
"     </li>",
"     <li>",
"      The iso-osmolal agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/63/13301?source=see_link\">",
"       iodixanol",
"      </a>",
"      may be associated with similar or even fewer IHRs than the nonionic LOCM agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/57,58,66\">",
"       57,58,66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION OF IHRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggestions for preventing initial IHRs are presented here, although primary prevention has not been systematically studied. In contrast, prevention of recurrent IHRs in patients with past reactions has been studied and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Choice of RCM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric use of LOCM agents for all intravascular procedures has become a widespread practice, and this has largely obviated the need for premedication of patients at potentially higher risk for an initial IHR. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In settings where the use of LOCMs for intravascular procedures is NOT routine, we suggest that nonionic LOCMs or iso-osmolal agents be chosen for the following individuals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with asthma",
"     </li>",
"     <li>",
"      Patients taking beta-blockers, interleukin-2, or NSAIDS",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the ACR Practice guidelines suggest that use of a nonionic LOCM agent be considered in the following groups of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with previous serious allergic reactions to materials other than RCM",
"     </li>",
"     <li>",
"      Patients receiving contrast by power injector",
"     </li>",
"     <li>",
"      Any other circumstances in which the responsible clinician believes there is an indication, such as patients whose risk factors cannot be well-established, patients specifically requesting a LOCM, and individuals who are very anxious about a possible RCM reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Need for premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Provided that a nonionic LOCM agent will be used, empiric premedication of patients who have not experienced problems with RCM in the past is",
"    <strong>",
"     not",
"    </strong>",
"    supported by the available evidence. In addition, premedication imposes additional inconvenience on outpatients, since they should be advised not to drive or perform any activities requiring alertness if a sedating agent has been given [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/19\">",
"     19",
"    </a>",
"    ]. However, there may be cases in which premedication is administered, based on the clinician's judgment.",
"   </p>",
"   <p>",
"    Patients who are receiving HOCM agents for",
"    <strong>",
"     extravascular",
"    </strong>",
"    procedures, such as cystograms, also do",
"    <strong>",
"     not",
"    </strong>",
"    need to be premedicated routinely, because the rate of IHRs is much lower with these procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Attention to asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with asthma, in addition to the use of nonionic LOCM or iso-osmolal agents, efforts should be made to optimize asthma control prior to the procedure whenever possible. If such patients experience symptoms of an IHR using this general approach, then they should also receive premedication before any future studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of immediate hypersensitivity reactions to radiocontrast media is based entirely upon the recognition of characteristic signs and symptoms. Testing is not required for the diagnosis. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Signs and symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotoxic reactions can sometimes present similarly to IHRs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasovagal reactions and IHRs may both begin with flushing and a sense of warmth. However, a few clinical features allow the clinician to distinguish the two [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/2\">",
"       2",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bradycardia is characteristic of",
"      <span class=\"nowrap\">",
"       vasomotor/vagal",
"      </span>",
"      reactions, whereas tachycardia is more often seen with IHRs",
"     </li>",
"     <li>",
"      Nausea and emesis are typical of",
"      <span class=\"nowrap\">",
"       vasomotor/vagal",
"      </span>",
"      reactions",
"     </li>",
"     <li>",
"      Pruritus, urticaria, angioedema, laryngospasm (hoarse voice), and wheezing are specific to hypersensitivity reactions",
"      <br/>",
"      <br/>",
"      Vasovagal reactions are treated with fluid resuscitation, elevation of the lower extremities, and sometimes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe chemotoxic reactions can be confused with anaphylaxis. In patients with cardiac disease, the infusion of RCM can cause intravascular volume expansion and precipitate acute cardiogenic pulmonary edema, which may mimic anaphylaxis. Adult respiratory distress syndrome can also resemble anaphylaxis. Urticaria or angioedema, which are specific to IHRs, are helpful if present [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Investigational tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing is not routinely performed in the diagnosis of IHRs. However, certain laboratory findings can demonstrate the involvement of mast cells and basophils and suggest the diagnosis of an IHR. This can be helpful if distinguishing between a cardiac event and a severe IHR, for example.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5020871\">",
"    <span class=\"h3\">",
"     Tests performed immediately after reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In severe or fatal immediate hypersensitivity reactions, serum or urine tests obtained as soon as possible after the reaction may show elevations of tryptase or histamine; these are chemical mediators that are normally found within mast cell and basophil granules and are specific to these cell types. Their presence in the serum indicates massive activation and degranulation of these cells and can help distinguish anaphylaxis from other acute, severe events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/23,67-69\">",
"     23,67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tryptase (a mast cell proteinase) has a half-life of 90 minutes and may be detectable for several hours after an acute event. Elevations are best detected between 30 minutes and 3 hours from the onset of symptoms. Several groups have reported elevated serum tryptase levels following severe or fatal immediate reactions to RCM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/16,23,68,70,71\">",
"       16,23,68,70,71",
"      </a>",
"      ]. Milder reactions do not usually result in elevations of these markers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/23\">",
"       23",
"      </a>",
"      ]. An elevation in serum tryptase is consistent with either an anaphylactic reaction or the rare condition mastocytosis. However, normal serum tryptase levels do not exclude anaphylaxis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link\">",
"       \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Histamine has a more rapid metabolism and appears only transiently in the plasma. However, histamine or its metabolite n-methylhistamine, is sometimes detectable in urine for longer periods of time and is measured with a 24 hour urine sample, collected as soon as possible after the reaction.",
"      <br/>",
"      <br/>",
"      The diagnostic and prognostic utility of these tests has not been studied in IHRs to RCM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/7\">",
"       7",
"      </a>",
"      ]. Specifically, it is not known if elevations in tryptase or histamine help distinguish among the pathophysiologic mechanisms causing IHRs, or provide information about likely recurrence upon reexposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3065708\">",
"    <span class=\"h3\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be a subset of individuals who have experienced severe IHRs in whom RCM-specific IgE can be demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/23,26-28,30\">",
"     23,26-28,30",
"    </a>",
"    ]. This was previously thought to be rare, although more recent studies suggest that such reactions may have been underrecognized. Skin test results may also help guide the choice of RCM for future radiological studies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=see_link\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An allergy evaluation may be considered in patients with IHRs that were severe or had clinical features of IgE-mediated reactions (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Signs and symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <br/>",
"    Skin testing should be performed by an allergy specialist, preferably within two to six months of the reaction, as the incidence of positive skin tests appears to decline prior to and after this time period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/72\">",
"     72",
"    </a>",
"    ]. Based on the relatively limited information currently available, the authors and editors would suggest limited skin testing to patients with reactions within the past year, who also require future radiologic studies in the near future. Skin testing techniques are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=see_link&amp;anchor=H2#H2\">",
"     \"Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions\", section on 'Preventative measures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infusion of RCM should be stopped immediately upon recognition of an immediate hypersensitivity reaction. Subsequent treatment depends upon the severity of the reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2063187\">",
"    <span class=\"h2\">",
"     Acute cardiopulmonary collapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening IHRs may present as acute cardiopulmonary collapse and patients with this presentation should be treated according to the American Heart Association 2010 ACLS guidelines (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20746?source=see_link\">",
"     \"Guidelines for pediatric advanced life support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Moderate and severe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate and severe IHRs may be identified by the presence of bronchospasm and wheezing, laryngospasm and stridor, hypotension, and loss of consciousness. In this setting, the infusion of RCM is stopped and immediate treatment is administered. The approach is identical to that of anaphylaxis, and includes oxygen, intravenous fluids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , and antihistamines.",
"   </p>",
"   <p>",
"    A rapid overview of anaphylaxis management, including correct dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , is provided for adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 2",
"    </a>",
"    ) and for children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids administered during emergency management are not believed to impact acute symptoms. They may be beneficial in preventing or reducing the severity of delayed symptoms, although this has never been conclusively demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intubation may be required and supportive medications may be necessary for up to 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients receiving beta-blockers may require more extensive or prolonged treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H29#H29\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Glucagon for patients taking beta-blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4553345\">",
"    <span class=\"h3\">",
"     Treatment errors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    in the treatment of anaphylaxis is different from that used in advanced cardiac life support protocols and multiple studies have shown that this continues to confuse clinicians in emergency settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Correct dosing is shown in the tables for adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 2",
"    </a>",
"    ) and for children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One study reviewed the treatment of 545 radiocontrast reactions occurring over six years at a large university hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/75\">",
"     75",
"    </a>",
"    ]. Fifteen reactions required the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , and of these, the dose or route of administration was deemed inappropriate in six reactions, most often resulting in epinephrine overdosing. It has been suggested that hospitals pre-prepare reaction kits for treatment of RCM reactions, and that these kits contain clearly labeled pre-loaded syringes for intramuscular injection of epinephrine, and separate preparations for intravenous administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31305/abstract/44,74,75\">",
"     44,74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Mild",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient's symptoms are transient and very mild (eg, mild flushing or pruritus, a few urticaria), then treatment may not be necessary (although it may be given) beyond immediately stopping the infusion and close observation. Mild symptoms that begin five minutes of more after completion of the infusion of the RCM agent are often self-limited, typically resolving fully in an hour or two.",
"   </p>",
"   <p>",
"    However, symptoms that begin during or immediately after RCM infusion should always be treated, regardless of severity, as these reactions tend to persist or worsen. We generally give",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg intravenously) for very mild symptoms. The patient should be observed carefully for improvement or progression of symptoms.",
"   </p>",
"   <p>",
"    The infusion should not be restarted if an IHR is suspected, even if the symptoms rapidly resolved, due to the high risk of recurrent and progressive symptoms. Outpatients who have been given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    for a reaction should not drive themselves home, due to sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Reactions during critical procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are circumstances in which a procedure cannot be safely interrupted, such as a diagnostic and therapeutic cardiac catheterization performed on a patient in shock. In such situations, it may be reasonable to treat aggressively per ACLS guidelines, try to stabilize the patient, and complete the procedure. Each case must be considered separately depending upon the clinical necessity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypersensitivity reactions to RCM are idiosyncratic and NOT related to dose or infusion rate. In contrast, chemotoxic reactions (eg, vasovagal reactions, nephrotoxicity) are related to dose and rate of infusion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate hypersensitivity reactions (IHRs) to radiocontrast media (RCM) present with pruritus, urticaria, angioedema, laryngospasm, bronchospasm, hypotension,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of consciousness. Most are mild, but a small number are life-threatening. These reactions typically develop within five minutes to one hour after administration. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hypersensitivity reactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Higher osmolality agents (HOCM) cause more IHRs (up to 13 percent of doses) compared to lower osmolality agents (LOCM) or iso-osmolal agents (up to 3 percent of doses) (",
"      <a class=\"graphic graphic_algorithm graphicRef66974 \" href=\"mobipreview.htm?4/56/5006\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef83944 \" href=\"mobipreview.htm?28/61/29662\">",
"       table 1",
"      </a>",
"      ). Many institutions now administer nonionic LOCM agents routinely for any intravascular procedures. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Incidence of reactions by type of RCM'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Primary prevention of IHRs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most significant risk factor for an IHR is a previous IHR. Other risk factors are asthma, other atopic diseases, and possibly the use of beta-blockers or nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Provided a nonionic LOCM agent is to be used, it is not necessary to premedicate all patients with one or more risk factors for an IHR. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Need for premedication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of an IHR is based upon the recognition of characteristic signs and symptoms. Laboratory testing is not required. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The infusion of RCM should be stopped immediately as soon as a hypersensitivity reaction is recognized. Subsequent treatment depends upon the severity of the reaction. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The treatment of moderate and severe IHRs is identical to that of anaphylaxis, and includes",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , intravenous fluids, and oxygen (",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"       table 2",
"      </a>",
"      ). Intubation may be required. Patients with cardiopulmonary collapse should be managed according to ACLS guidelines. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Moderate and severe'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild reactions (flushing, pruritus, urticaria) that begin during or immediately after RCM administration (ie, within first minute or two) should be treated because these reactions tend to persist or worsen.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       Diphenhydramine",
"      </a>",
"      , 50 mg intravenously, is commonly used. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Mild'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild symptoms that appear later than five minutes after the conclusion of RCM administration are more often self limited, although treatment may be given. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Mild'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/1\">",
"      Christiansen C. X-ray contrast media--an overview. Toxicology 2005; 209:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/2\">",
"      Cochran ST. Anaphylactoid reactions to radiocontrast media. Curr Allergy Asthma Rep 2005; 5:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/3\">",
"      Havemann BD, Goodgame R. Grand rounds in gastroenterology from Baylor College of Medicine. A pustular skin rash in a woman with 2 weeks of diarrhea. MedGenMed 2005; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/4\">",
"      Sandow BA, Donnal JF. Myelography complications and current practice patterns. AJR Am J Roentgenol 2005; 185:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/5\">",
"      Borish L, Matloff SM, Findlay SR. Radiographic contrast media-induced noncardiogenic pulmonary edema: case report and review of the literature. J Allergy Clin Immunol 1984; 74:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/6\">",
"      Federle MP, Willis LL, Swanson DP. Ionic versus nonionic contrast media: a prospective study of the effect of rapid bolus injection on nausea and anaphylactoid reactions. J Comput Assist Tomogr 1998; 22:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/7\">",
"      Brockow K, Christiansen C, Kanny G, et al. Management of hypersensitivity reactions to iodinated contrast media. Allergy 2005; 60:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/8\">",
"      Hasdenteufel F, Waton J, Cordebar V, et al. Delayed hypersensitivity reactions caused by iodixanol: an assessment of cross-reactivity in 22 patients. J Allergy Clin Immunol 2011; 128:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/9\">",
"      Brockow K. Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism? Immunol Allergy Clin North Am 2009; 29:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/10\">",
"      Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 1990; 175:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/11\">",
"      Wang CC, Chang SH, Chen CC, et al. Severe coronary artery spasm with anaphylactoid shock caused by contrast medium--case reports. Angiology 2006; 57:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/12\">",
"      Doyama K, Hirose K, Kosuga K, et al. Coronary artery spasm induced by anaphylactoid reaction to a new low osmolar contrast medium. Am Heart J 1990; 120:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/13\">",
"      Druck MN, Johnstone DE, Staniloff H, McLaughlin PR. Coronary artery spasm as a manifestation of anaphylactoid reaction to iodinated contrast material. Can Med Assoc J 1981; 125:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/14\">",
"      Hagan JB. Anaphylactoid and adverse reactions to radiocontrast agents. Immunol Allergy Clin North Am 2004; 24:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/15\">",
"      Simon RA, Schatz M, Stevenson DD, et al. Radiographic contrast media infusions. Measurement of histamine, complement, and fibrin split products and correlation with clinical parameters. J Allergy Clin Immunol 1979; 63:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/16\">",
"      Ring J, Simon RA, Arroyave CM. Increased in vitro histamine release by radiographic contrast media in patients with history of incompatibility. Clin Exp Immunol 1978; 34:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/17\">",
"      Lasser EC, Lang JH, Lyon SG, et al. Prekallikrein-Kallikrein conversion rate as a predictor of contrast material catastrophies. Radiology 1981; 140:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/18\">",
"      Lang JH, Lasser EC, Kolb WP. Activation of serum complement by contrast media. Invest Radiol 1976; 11:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/19\">",
"      Szebeni J. Hypersensitivity reactions to radiocontrast media: the role of complement activation. Curr Allergy Asthma Rep 2004; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/20\">",
"      Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005; 216:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/21\">",
"      Zir LM, Carvalho AC, Hawthorne JW, et al. Effect of contrast agents on platelet aggregation and 14C-serotonin release. N Engl J Med 1974; 291:134.",
"     </a>",
"    </li>",
"    <li>",
"     Grainger R. Intravascular radiological iodinated contrast media. In: Diagnostic radiology: A textbook of medical imaging, 4th ed, Grainger R, Allison DJ, Adam A, Dixon AK (Eds), Churchill Livingston, Oxford 2001. p.27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/23\">",
"      Laroche D, Aimone-Gastin I, Dubois F, et al. Mechanisms of severe, immediate reactions to iodinated contrast material. Radiology 1998; 209:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/24\">",
"      Amon EU, Ennis M, Schnabel M, et al. Radiographic contrast media-induced histamine release: a comparative study with mast cells from different species. Agents Actions 1989; 27:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/25\">",
"      Stellato C, de Crescenzo G, Patella V, et al. Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator release. J Allergy Clin Immunol 1996; 97:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/26\">",
"      Mita H, Tadokoro K, Akiyama K. Detection of IgE antibody to a radiocontrast medium. Allergy 1998; 53:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/27\">",
"      Wakkers-Garritsen BG, Houwerziji J, Nater JP, Wakkers PJ. IgE-mediated adverse reactivity to a radiographic contrast medium. Ann Allergy 1976; 36:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/28\">",
"      Kanny G, Maria Y, Mentre B, Moneret-Vautrin DA. Case report: recurrent anaphylactic shock to radiographic contrast media. Evidence supporting an exceptional IgE-mediated reaction. Allerg Immunol (Paris) 1993; 25:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/29\">",
"      Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol 2005; 115:S483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/30\">",
"      Trcka J, Schmidt C, Seitz CS, et al. Anaphylaxis to iodinated contrast material: nonallergic hypersensitivity or IgE-mediated allergy? AJR Am J Roentgenol 2008; 190:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/31\">",
"      Lieberman PL, Seigle RL. Reactions to radiocontrast material. Anaphylactoid events in radiology. Clin Rev Allergy Immunol 1999; 17:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/32\">",
"      Callahan MJ, Poznauskis L, Zurakowski D, Taylor GA. Nonionic iodinated intravenous contrast material-related reactions: incidence in large urban children's hospital--retrospective analysis of data in 12,494 patients. Radiology 2009; 250:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/33\">",
"      Cashman JD, McCredie J, Henry DA. Intravenous contrast media: use and associated mortality. Med J Aust 1991; 155:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/34\">",
"      Greenberger PA, Patterson R, Tapio CM. Prophylaxis against repeated radiocontrast media reactions in 857 cases. Adverse experience with cimetidine and safety of beta-adrenergic antagonists. Arch Intern Med 1985; 145:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/35\">",
"      Witten DM, Hirsch FD, Hartman GW. Acute reactions to urographic contrast medium: incidence, clinical characteristics and relationship to history of hypersensitivity states. Am J Roentgenol Radium Ther Nucl Med 1973; 119:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/36\">",
"      Fischer HW, Doust VL. An evaluation of pretesting in the problem of serious and fatal reactions to excretory urography. Radiology 1972; 103:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/37\">",
"      Shehadi WH. Contrast media adverse reactions: occurrence, recurrence, and distribution patterns. Radiology 1982; 143:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/38\">",
"      Greenberger PA. Contrast media reactions. J Allergy Clin Immunol 1984; 74:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/39\">",
"      Bettmann MA, Heeren T, Greenfield A, Goudey C. Adverse events with radiographic contrast agents: results of the SCVIR Contrast Agent Registry. Radiology 1997; 203:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/40\">",
"      Huang SW. Seafood and iodine: an analysis of a medical myth. Allergy Asthma Proc 2005; 26:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/41\">",
"      Beaty AD, Lieberman PL, Slavin RG. Seafood allergy and radiocontrast media: are physicians propagating a myth? Am J Med 2008; 121:158.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/42\">",
"      Sicherer SH. Risk of severe allergic reactions from the use of potassium iodide for radiation emergencies. J Allergy Clin Immunol 2004; 114:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/43\">",
"      Scherer K, Harr T, Bach S, Bircher AJ. The role of iodine in hypersensitivity reactions to radio contrast media. Clin Exp Allergy 2010; 40:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/44\">",
"      Morcos SK, Thomsen HS, Webb JA, Contrast Media Safety Committee of the European Society of Urogenital Radiology. Prevention of generalized reactions to contrast media: a consensus report and guidelines. Eur Radiol 2001; 11:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/45\">",
"      Lang DM, Alpern MB, Visintainer PF, Smith ST. Elevated risk of anaphylactoid reaction from radiographic contrast media is associated with both beta-blocker exposure and cardiovascular disorders. Arch Intern Med 1993; 153:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/46\">",
"      Greenberger PA, Meyers SN, Kramer BL, Kramer BL. Effects of beta-adrenergic and calcium antagonists on the development of anaphylactoid reactions from radiographic contrast media during cardiac angiography. J Allergy Clin Immunol 1987; 80:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/47\">",
"      Miller MM, Miller MM. Beta-blockers and anaphylaxis: are the risks overstated? J Allergy Clin Immunol 2005; 116:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/48\">",
"      Morcos SK, Thomsen HS. Adverse reactions to iodinated contrast media. Eur Radiol 2001; 11:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/49\">",
"      Hong SJ, Wong JT, Bloch KJ. Reactions to radiocontrast media. Allergy Asthma Proc 2002; 23:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/50\">",
"      Cohan RH, Leder RA, Ellis JH. Treatment of adverse reactions to radiographic contrast media in adults. Radiol Clin North Am 1996; 34:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/51\">",
"      Bertrand ME, Esplugas E, Piessens J, Rasch W. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators. Circulation 2000; 101:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/52\">",
"      Fransson SG, Stenport G, Andersson M. Immediate and late adverse reactions in coronary angiography. A comparison between iodixanol and ioxaglate. Acta Radiol 1996; 37:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/53\">",
"      Shehadi WH, Toniolo G. Adverse reactions to contrast media: a report from the Committee on Safety of Contrast Media of the International Society of Radiology. Radiology 1980; 137:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/54\">",
"      Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol 2001; 176:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/55\">",
"      Greenberger PA, Patterson R. The prevention of immediate generalized reactions to radiocontrast media in high-risk patients. J Allergy Clin Immunol 1991; 87:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/56\">",
"      Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. Radiology 1997; 203:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/57\">",
"      Sutton AG, Finn P, Grech ED, et al. Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization. Am Heart J 2001; 141:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/58\">",
"      Sutton AG, Finn P, Campbell PG, et al. Early and late reactions following the use of iopamidol 340, iomeprol 350 and iodixanol 320 in cardiac catheterization. J Invasive Cardiol 2003; 15:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/59\">",
"      Barrett BJ, Parfrey PS, McDonald JR, et al. Nonionic low-osmolality versus ionic high-osmolality contrast material for intravenous use in patients perceived to be at high risk: randomized trial. Radiology 1992; 183:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/60\">",
"      Marshall GD Jr, Lieberman PL. Comparison of three pretreatment protocols to prevent anaphylactoid reactions to radiocontrast media. Ann Allergy 1991; 67:70.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, 5th ed, American College of Radiology, Reston, VA 2004. p.5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/62\">",
"      Katayama H. Adverse reactions to contrast media. What are the risk factors? Invest Radiol 1990; 25 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/63\">",
"      Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 2009; 193:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/64\">",
"      Davenport MS, Cohan RH, Caoili EM, Ellis JH. Repeat contrast medium reactions in premedicated patients: frequency and severity. Radiology 2009; 253:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/65\">",
"      Caro JJ, Trindade E, McGregor M. The risks of death and of severe nonfatal reactions with high- vs low-osmolality contrast media: a meta-analysis. AJR Am J Roentgenol 1991; 156:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/66\">",
"      H&auml;ussler MD. Safety and patient comfort with iodixanol: a postmarketing surveillance study in 9515 patients undergoing diagnostic CT examinations. Acta Radiol 2010; 51:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/67\">",
"      Dewachter P, Mouton-Faivre C, Felden F. Allergy and contrast media. Allergy 2001; 56:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/68\">",
"      Brockow K, Vieluf D, P&uuml;schel K, et al. Increased postmortem serum mast cell tryptase in a fatal anaphylactoid reaction to nonionic radiocontrast medium. J Allergy Clin Immunol 1999; 104:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/69\">",
"      Dewachter P, Laroche D, Mouton-Faivre C, et al. Immediate reactions following iodinated contrast media injection: a study of 38 cases. Eur J Radiol 2011; 77:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/70\">",
"      Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000; 53:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/71\">",
"      Laroche D. Immediate reactions to contrast media: mediator release and value of diagnostic testing. Toxicology 2005; 209:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/72\">",
"      Brockow K, Romano A, Aberer W, et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy 2009; 64:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/73\">",
"      Bartlett MJ, Bynevelt M. Acute contrast reaction management by radiologists: a local audit study. Australas Radiol 2003; 47:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/74\">",
"      Lightfoot CB, Abraham RJ, Mammen T, et al. Survey of radiologists' knowledge regarding the management of severe contrast material-induced allergic reactions. Radiology 2009; 251:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31305/abstract/75\">",
"      Wang CL, Cohan RH, Ellis JH, et al. Frequency, outcome, and appropriateness of treatment of nonionic iodinated contrast media reactions. AJR Am J Roentgenol 2008; 191:409.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2075 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31305=[""].join("\n");
var outline_f30_36_31305=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chemotoxic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypersensitivity reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TYPES OF RADIOCONTRAST MEDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Categories of agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Incidence of reactions by type of RCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PRIMARY PREVENTION OF IHRs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Choice of RCM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Need for premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Attention to asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Investigational tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5020871\">",
"      - Tests performed immediately after reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3065708\">",
"      - Skin testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2063187\">",
"      Acute cardiopulmonary collapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Moderate and severe",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4553345\">",
"      - Treatment errors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Mild",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Reactions during critical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2075\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2075|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?4/56/5006\" title=\"algorithm 1\">",
"      Scheme for classifying RCM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2075|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/61/29662\" title=\"table 1\">",
"      IV contrast media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/26/16813\" title=\"table 2\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18221\" title=\"table 3\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/49/38680?source=related_link\">",
"      Immediate hypersensitivity reactions to radiocontrast media: Prevention of recurrent reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/5/20568?source=related_link\">",
"      Iodine-induced thyroid dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_36_31306="Incidence, etiology, and prevention of stillbirth";
var content_f30_36_31306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Incidence, etiology, and prevention of stillbirth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31306/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31306/contributors\">",
"     Ruth C Fretts, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31306/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31306/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/36/31306/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/36/31306/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/36/31306/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms fetal death, fetal demise, stillbirth, and stillborn all refer to the delivery of a fetus showing no signs of life. The terms will be used interchangeably in this topic review; however, it should be noted that parent groups prefer the term stillbirth to the other terms.",
"   </p>",
"   <p>",
"    The incidence, etiology, and prevention of fetal death will be reviewed here. Diagnosis and management of fetal demise, as well as pathological evaluation of stillborns and counseling parents after stillbirth are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/35/1591?source=see_link\">",
"       \"Diagnosis and management of stillbirth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38839?source=see_link\">",
"       \"Evaluation of stillbirth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38999?source=see_link\">",
"       \"Counseling parents after stillbirth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF STILLBIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminology defining fetal, neonatal, perinatal, and infant death is described in detail separately. A brief synopsis of the definition of stillbirth is provided below. All fetal deaths are not stillbirths, as embryologists define the fetal period as beginning at the end of embryonic period (ie, the eight weeks after conception). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21096?source=see_link&amp;anchor=H2#H2\">",
"     \"Perinatal mortality\", section on 'Terminology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      World Health Organization definition &mdash; The World Health Organization (WHO) defines stillbirth as a \"fetal death late in pregnancy\" and allows each country to define the gestational age at which a fetal death is considered a stillbirth for reporting purposes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/1\">",
"       1",
"      </a>",
"      ]. As a result, some countries define stillbirth as early as 16 weeks of gestation, whereas others use a threshold as late as 28 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/2-4\">",
"       2-4",
"      </a>",
"      ]. Fetal deaths under the threshold are considered products of miscarriage (abortuses).",
"     </li>",
"     <li>",
"      United States National Center for Health Statistics definition &mdash; The standardized definition for fetal mortality used by the United States National Center for Health Statistics (NCHS) is similar to the WHO definition and adds that stillbirth is indicated by the absence of breathing, heart beats, pulsation of the umbilical cord, or definite movements of voluntary muscles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/5\">",
"       5",
"      </a>",
"      ]. The majority of individual states in the United States use 20 weeks of gestation as the threshold for distinguishing a stillbirth from a miscarriage; the International Stillbirth Alliance also suggests this cut-off [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/6\">",
"       6",
"      </a>",
"      ]. The use of this threshold results in a more reliable estimate of the stillbirth rate than estimates using earlier gestational age thresholds because of the difficulty of reliably capturing data on early gestational losses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the gestational age is not known, fetal weight may be used to distinguish a stillbirth from a miscarriage. The threshold weight used varies from &ge;350 to &ge;500 g.",
"   </p>",
"   <p>",
"    Stillbirths can be subclassified according to the gestational age at delivery. Early stillbirths are typically defined as those occurring at 20 to 27 weeks of gestation, while late stillbirths occur at or after 28 weeks of gestation. Although the division is somewhat arbitrary, this stratification allows for relatively reliable international comparison of late fetal losses, and allows division of stillbirths into those that are more difficult to prevent (early losses) from the losses that might potentially be preventable (late losses).",
"   </p>",
"   <p>",
"    Despite these definitions, comparison of stillbirth rates between different countries should be done with caution. Obtaining reliable estimates of the number of stillbirths in developing countries is difficult since most births occur in the home and, in some remote areas, data are completely lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/7\">",
"     7",
"    </a>",
"    ]. In developed countries, there is an inconsistent approach as to whether induced pregnancy terminations for prenatally diagnosed fetal anomalies and induced labor for previable infants due to premature rupture of membranes are categorized as stillbirths.",
"   </p>",
"   <p>",
"    In addition, the ability to call a fetal loss a stillbirth is important as birth and death certificates are not generated after a miscarriage, and parents have reported that they feel less grief support is provided after a miscarriage than after a stillbirth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 2.6 million stillbirths &ge;28 weeks of gestation or 1000 g occur each year worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This figure is likely an underestimation as there are little reliable data from low income regions where most of the stillbirths occur. The number of stillbirths appears to have decreased since 1995 when about 3 million stillbirths were estimated to have occurred worldwide.",
"   </p>",
"   <p>",
"    In the United States, the stillbirth rate is higher than the neonatal death rate and slightly lower than the infant mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/10\">",
"     10",
"    </a>",
"    ]. Antepartum fetal death is much more common than intrapartum fetal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/11\">",
"     11",
"    </a>",
"    ] and unexplained fetal death occurs far more commonly than unexplained infant death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21096?source=see_link\">",
"     \"Perinatal mortality\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=see_link\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2005, the stillbirth rate in the United States was",
"    <span class=\"nowrap\">",
"     6.2/1000",
"    </span>",
"    live births and fetal deaths (ie, total births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/13\">",
"     13",
"    </a>",
"    ]. Since 1990, the rate of early fetal loss (20 to 27 weeks of gestation) has remained stable at about 3.2 per 1000, while the rate of late fetal loss (greater than or equal to 28 weeks of gestation) has decreased by 29 percent such that the current rates of early and late fetal death are about the same. About one-half of late fetal deaths occur at term (",
"    <a class=\"graphic graphic_figure graphicRef75607 \" href=\"mobipreview.htm?3/7/3186\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the United States, it is important to note that black women have twice the rate of stillbirth compared to white women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In 2001-2002, the stillbirth rate in white, Hispanic, and black women was",
"    <span class=\"nowrap\">",
"     1/202,",
"    </span>",
"    <span class=\"nowrap\">",
"     1/183,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/",
"    </span>",
"    87, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/15\">",
"     15",
"    </a>",
"    ]. While some of this increased risk can be attributed to access to, and quality of, medical care, other factors contribute as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/12,15,17-22\">",
"     12,15,17-22",
"    </a>",
"    ]. Even in the setting where black women have adequate access to prenatal care, they experience a higher rate of stillbirth, especially preterm stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/15\">",
"     15",
"    </a>",
"    ]. This increased risk has been attributed to higher rates of diabetes mellitus, hypertension, placental abruption, and premature rupture of membranes in these women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequencies of the various etiologies of stillbirth differ among racial groups. This may be related to genetic, as well as behavioral and environmental, factors. A study from the United Kingdom observed that the most important factor associated with antepartum stillbirth among white women was placental abruption, but among South Asian and black women it was birth weight below 2000 g [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of stillbirth in low income countries are substantially higher (9 to",
"    <span class=\"nowrap\">",
"     34/1000",
"    </span>",
"    births) than in high income countries",
"    <span class=\"nowrap\">",
"     (3.1/1000)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/8,9,24\">",
"     8,9,24",
"    </a>",
"    ]. About 98 percent of stillbirths occur in low and middle income countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/9\">",
"     9",
"    </a>",
"    ]. At least half of the stillbirths in low income countries occur during labor and birth, in large part because of a lack of skilled birthing attendants and facilities for cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/9\">",
"     9",
"    </a>",
"    ]. Antepartum stillbirths are often related to maternal infection or fetal growth restriction. Pregnancy induced hypertension that is not identified and appropriately managed with induction of labor is another common cause of both fetal and maternal death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The study of specific causes of stillbirth has been hindered by the lack of a uniform protocol for evaluating and classifying stillbirths, and from declining autopsy rates. In most cases, fetal death certificates are completed before all results from post-mortem evaluations become available.",
"   </p>",
"   <p>",
"    A system for classifying specific causes of fetal death could serve many purposes. As an example, parents obviously want to know why their baby died, and whether they are at an increased risk for similar losses in the future. Researchers want to understand the pathogenetic mechanisms for stillbirth so they can develop prevention strategies. This information could also be useful for compiling a perinatal database and as a tool for quality improvement.",
"   </p>",
"   <p>",
"    There are more than 35 published systems for classifying perinatal deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/25\">",
"     25",
"    </a>",
"    ]. The rate of unexplained stillbirth depends, in part, on the system used. In one study including 154 stillbirths, the rate of unexplained stillbirth by classification system was RoDeCo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/26\">",
"     26",
"    </a>",
"    ] (14.3 percent), Wigglesworth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/27\">",
"     27",
"    </a>",
"    ] (47.4 percent), de Galan-Roosen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/28\">",
"     28",
"    </a>",
"    ] (18.2 percent), and Tulip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/25\">",
"     25",
"    </a>",
"    ] (16.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/29\">",
"     29",
"    </a>",
"    ]. Mean gestational age at stillbirth in unexplained and explained stillbirth was similar for all four protocols. The rate of",
"    <span class=\"nowrap\">",
"     unexplained/unknown",
"    </span>",
"    cause for the Stockholm classification has been reported as 18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/30\">",
"     30",
"    </a>",
"    ]. This system consists of 17 groups identifying underlying conditions related to stillbirth (primary diagnoses) and associated factors which may have contributed to the death (associated diagnoses).",
"   </p>",
"   <p>",
"    Early classification systems included only a small number of subtypes stratified into normally formed stillbirths, congenital malformations, immaturity, asphyxia, and \"others\" (",
"    <a class=\"graphic graphic_table graphicRef59045 \" href=\"mobipreview.htm?2/63/3069\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/31\">",
"     31",
"    </a>",
"    ]. Subsequent systems attempted to capture more information, including aberrations of fetal growth, placental pathology, and maternal conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/25,32\">",
"     25,32",
"    </a>",
"    ]. There is considerable debate over whether hierarchical systems should be used, and if conditions such as growth restriction and hypertension are causes, or merely risk factors, for stillbirth. Nevertheless, a systematic approach to classifying stillbirth would be a critical step in designing prevention strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Efforts are underway to adopt an international classification system that would indicate maternal conditions and fetal growth status; capture pregnancy terminations for congenital anomalies and late fetal deaths versus intrapartum deaths; and classify deaths in multiple gestations in a useful way, in addition to usual perinatal data (eg, birth weight, gestational age, maternal marital status) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/34\">",
"     34",
"    </a>",
"    ]. Currently, the most useful information about the specific causes of stillbirth comes from hospitals or regions that systematically review and classify these deaths over time (",
"    <a class=\"graphic graphic_table graphicRef54973 \" href=\"mobipreview.htm?22/28/22989\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nevertheless, in developed countries, the strength of any classification system is based on a thorough stillbirth evaluation, including a detailed description of the condition of the mother, baby, cord and placenta at birth, as well as the events leading up to stillbirth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24002174\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequencies of the various etiologies of stillbirth differ between developing and developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/33,35,36\">",
"     33,35,36",
"    </a>",
"    ]. For example, in developing countries",
"    <span class=\"nowrap\">",
"     obstructed/prolonged",
"    </span>",
"    labor, preeclampsia, and infection are common causes of stillbirth, whereas in developed countries congenital or karyotypic anomalies, placental problems associated with growth restriction, and maternal medical diseases are the most common causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/37\">",
"     37",
"    </a>",
"    ]. The following discussion refers primarily to stillbirth occurring in developed countries.",
"   </p>",
"   <p>",
"    In a population-based study of surveillance of stillbirths in the US between 2006 and 2008, 500 women consented to complete postmortem examinations of 512 stillborn neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/38\">",
"     38",
"    </a>",
"    ]. A probable cause of death was found in 60.9 percent of cases and a possible or probable cause was found in 76.2 percent of cases. The most common causes were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obstetric complications (eg, abruption, multiple gestation, preterm birth) (29.3 percent; 95% CI 25.4-33.5)",
"     </li>",
"     <li>",
"      Placental disease (23.6 percent; 95% CI 20.1-27.6)",
"     </li>",
"     <li>",
"      Fetal",
"      <span class=\"nowrap\">",
"       genetic/structural",
"      </span>",
"      abnormalities (13.7 percent; 95% CI 10.9-17.0)",
"     </li>",
"     <li>",
"      Maternal or fetal infection (12.9 percent; 95% CI 10.2-16.2)",
"     </li>",
"     <li>",
"      Umbilical cord abnormalities (10.4 percent; 95% CI 7.9-13.4)",
"     </li>",
"     <li>",
"      Hypertensive disorders (9.2 percent; 95% CI 6.9-12.1)",
"     </li>",
"     <li>",
"      Other maternal medical conditions (7.8 percent; 95% CI 5.7-10.6)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequencies of the various etiologies of stillbirth also vary in relation to gestational age. In one review, the most common causes of stillbirth between 24 and 27 weeks of gestation were infection (19 percent), abruption (14 percent), and fetal anomalies (14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/39\">",
"     39",
"    </a>",
"    ]. After 28 weeks of gestation, the most frequent cause of stillbirth was unexplained fetal loss, which included stillbirths associated with growth restriction and placental abruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Unexplained stillbirth",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unexplained stillbirth is a fetal death that cannot be attributed to an identifiable fetal, placental, maternal, or obstetrical etiology. It accounts for 25 to 60 percent of all fetal deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/38,40-42\">",
"     38,40-42",
"    </a>",
"    ]. Variation in the proportion of stillbirths reported as unexplained generally reflects whether the stillbirth has been fully evaluated, and if the classification system allows risk factors to be included as causes. As an example, the cause of stillbirth in an infant who is small for gestational age may be attributed to fetal growth restriction in some systems, but is considered unexplained in others if the underlying cause of the growth restriction is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stillbirths occurring near term are more likely to be unexplained than stillbirths that occur earlier in gestation. As an example, in one series, two thirds of unexplained fetal deaths occurred after 35 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/40\">",
"     40",
"    </a>",
"    ]. In another series, the rate of unexplained fetal death in pregnancies over 40 weeks of gestation was more than double the rate earlier in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study of unexplained stillbirth (n=196 cases) reported the following characteristics were independent risk factors: maternal prepregnancy weight greater than 68 kg (OR 2.9; 95% CI 1.85-4.68), birth weight ratio (defined as ratio of birth weight to mean weight for gestational age) between 0.75 and 0.85 (OR 2.77, 95% CI 1.48-5.18) or over 1.15 (OR 2.36, 95% CI 1.26-4.44), parity of three or more (OR 2.01, 95% CI 1.26-3.20), primiparity (OR 1.74, 95% CI 1.26-2.40), cord loops (OR 1.75, 95% CI 1.04-2.97), low socioeconomic status (OR 1.59, 95% CI 1.14-2.22), and, for the 1978 to 1996 period only, maternal age 40 years or more (OR 3.69, 95% CI 1.28-0.58) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/40\">",
"     40",
"    </a>",
"    ]. Trimester of first antenatal visit, low maternal weight, postdate pregnancy, fetal-to-placental weight ratio, fetal sex, previous fetal death, previous abortion, cigarette smoking, and alcohol use were not significantly associated with unexplained fetal death in this series. This study excluded stillborns with weight less than 10",
"    <sup>",
"     th",
"    </sup>",
"    centile for gestational age, as these deaths were not considered &ldquo;unexplained,&rdquo; even if the etiology of growth restriction was not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Fetal growth restriction/placental dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal death of a growth-restricted fetus is the second most common type of stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/39\">",
"     39",
"    </a>",
"    ]. Placental dysfunction is the presumed cause of both the growth restriction and the fetal death. The estimated risk of stillbirth for growth restricted fetuses is five to seven times that of the normally grown fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/44-49\">",
"     44-49",
"    </a>",
"    ]. A large Norwegian study determined that mean gestational age at death was 35 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22906?source=see_link\">",
"     \"Diagnosis of fetal growth restriction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10616?source=see_link\">",
"     \"Overview of causes of and risk factors for fetal growth restriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conditions resulting in placental dysfunction can be recurrent, but the placental complications may manifest in different ways in different pregnancies. Growth restriction, preterm delivery, and stillbirth can all be sequelae of impaired placental function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/44,50\">",
"     44,50",
"    </a>",
"    ]. The association between the birth of a small for gestational age (SGA) infant in one pregnancy and stillbirth in a subsequent pregnancy has been reported in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/44,46,51\">",
"     44,46,51",
"    </a>",
"    ]. The risk of stillbirth in a subsequent pregnancy is particularly high if the SGA infant was premature. An analysis of data from the Swedish Birth Register is a representative example of these data (",
"    <a class=\"graphic graphic_table graphicRef56032 \" href=\"mobipreview.htm?18/19/18747\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Placental dysfunction can be related to a number of maternal medical disorders (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Maternal medical disorders'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abruptio placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abruptio placenta occurs in approximately 1 percent of pregnancies, but accounts for 10 and 20 percent of all stillbirths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/39\">",
"     39",
"    </a>",
"    ]. The risk of fetal death is highest when more than 50 percent of the placental surface becomes separated or when the abruption involves the central aspect of the placenta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection accounts for approximately one-half of all stillbirths in low and middle income countries, and 10 to 25 percent of stillbirths in high income countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/52\">",
"     52",
"    </a>",
"    ]. It is the cause of more preterm than term stillbirths.",
"   </p>",
"   <p>",
"    Infection may lead to fetal demise as a result of severe systemic maternal illness (eg, influenza), placental dysfunction due to placental infection (eg, malaria), or fetal systemic illness (eg, Escherichia coli). Fetal infection can be acquired transplacentally (hematogenous dissemination of infectious agents) or transcervically (ascending infection from colonization of the lower genital tract).",
"   </p>",
"   <p>",
"    Viral pathogens are the most common source of hematogenous infection of the placenta, although bacteria, spirochetes, fungi, and protozoa can also cause infection via this route. Almost any systemic infection that occurs during pregnancy can infect the placenta, but fetal death as a result of maternal infection is rare. CMV infection is relatively common and should be considered in stillbirths of unknown etiology after autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic criteria for determining if a fetal death is due to infection are not well-defined, and complicated by the relatively high frequency of asymptomatic maternal vaginal colonization of some potential pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/54\">",
"     54",
"    </a>",
"    ]. In order to attribute infection as a cause of death, there should be histological evidence of placental and fetal infection.",
"   </p>",
"   <p>",
"    In developed countries, the majority of stillbirths related to infection occur in periviable fetuses following premature rupture of membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/39\">",
"     39",
"    </a>",
"    ]. The usual mechanism is ascending infection from the lower genital tract. The rate of these losses has been relatively stable over the past 30 years. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27353?source=see_link\">",
"     \"Midtrimester preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malaria is a common infectious cause of stillbirth in endemic areas. Parvovirus, cytomegalovirus, toxoplasmosis, listeria, and herpes simplex virus are other well-established infectious causes of stillbirth (see individual topic reviews on specific infections). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=see_link\">",
"     \"Placental infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have found that women who have had an unexplained stillbirth have a higher number of \"memory T cells\" (CD45RO) than \"naive T cells\" (CD45RA) compared to mothers of live born controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/55\">",
"     55",
"    </a>",
"    ]. This finding suggests that, in spite of the absence of any overt evidence of clinically significant infection, these women had had prior exposure to infectious agents or other unidentified antigens, which may have played a role in the fetal demise.",
"   </p>",
"   <p>",
"    In addition, the absence of a fetal inflammatory response in the presence of chorioamnionitis in an unexplained stillbirth may reflect the inability of the fetus to mount an immune response sufficient to trigger the onset of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/56\">",
"     56",
"    </a>",
"    ]. This could result in intrauterine death. A large study including 428 stillbirths found histologic chorioamnionitis in 158 (36.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/57\">",
"     57",
"    </a>",
"    ]. A fetal inflammatory response was also present in",
"    <span class=\"nowrap\">",
"     57/158",
"    </span>",
"    (36 percent) and was most likely in cases with intrapartum death after spontaneous onset of labor or after spontaneous rupture of membranes. There was no fetal inflammatory response in",
"    <span class=\"nowrap\">",
"     101/158",
"    </span>",
"    (64 percent) and these cases were more likely to be associated with unexplained fetal death prior to the onset of labor. These findings support a pathophysiologic relationship between fetal inflammation and initiation of parturition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=see_link&amp;anchor=H18#H18\">",
"     \"Intraamniotic infection (chorioamnionitis)\", section on 'Fetal and neonatal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chromosomal and genetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most aneuploidies are lethal in utero. Some aneuploidies, such as trisomy 21, 18, and 13 and monosomy X, are at increased risk of fetal demise, but also occur in livebirths. Death of a karyotypically abnormal embryo or fetus occurs at all stages of pregnancy, but is most common in the first trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=see_link\">",
"     \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One large series that karyotyped a combined group of 823 stillbirths and neonatal deaths reported 6.3 percent had a major chromosomal abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/61\">",
"     61",
"    </a>",
"    ]. The frequency of abnormal karyotype in macerated stillbirths, nonmacerated stillbirths, and neonatal deaths was approximately 12, 4, and 6 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/41\">",
"     41",
"    </a>",
"    ]. The abnormalities reported were mostly comprised of trisomies 18, 13, and 21; sex chromosome aneuploidy; and unbalanced translocations. By comparison, the frequency of chromosomal abnormality in the total population of live born infants was 0.7 percent.",
"   </p>",
"   <p>",
"    The combination of a congenital anomaly and stillbirth increases the likelihood a chromosomal abnormality is present. In one study of 750 stillbirths, chromosomal abnormalities were present in 38 percent of anomalous stillborns versus 4.6 percent of stillborns who were morphologically normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is little information on genetic causes of stillbirth, other than aneuploidy. Single gene defects, confined placental mosaicism, and microdeletions are examples of genetic causes of stillbirth that may be present even though a karyotype determined by conventional cytogenetic analysis is normal. Molecular genetic technology may help to identify these cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Confined placental mosaicism is present in 1 to 2 percent of chorionic villus samples; 15 to 20 percent of these pregnancies abort, develop fetal growth restriction, or end in stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/34\">",
"     34",
"    </a>",
"    ]. Outcome appears to be determined by the specific chromosome involved (2,3,9,14,15,16, and 18 alter outcome), whether the abnormal line persists throughout pregnancy, the percentage of aneuploid cells, the cell line of the aneuploid cells, and whether uniparental disomy is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fifteen to 20 percent of stillbirths have a major malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/39,58\">",
"     39,58",
"    </a>",
"    ]. This rate varies from country to country and is greatly influenced by the availability of prenatal diagnosis and pregnancy termination. Malformations associated with fetal demise, but unrelated to structural chromosomal abnormalities, include abdominal wall defects, neural tube defects, Potter syndrome, achondrogenesis, and amniotic band syndrome.",
"   </p>",
"   <p>",
"    Fetal death can be attributed to a malformation if epidemiologic data support a relationship, the anomaly is rare in liveborns, neonates with the anomaly often die, or there is biologic plausibility for an association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fetomaternal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetomaternal hemorrhage (FMH) sufficiently large to cause fetal death has been reported in up to 5 percent of stillborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Usually there is no identifiable etiology; however, some cases have been associated with abruptio placenta, vasa previa, chorioangioma, choriocarcinoma, maternal trauma, cephalic version, and amniocentesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Umbilical cord complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Umbilical cord complications (eg, nuchal cord, knot, intrinsic cord abnormalities) are often cited as a cause of fetal death in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/66-70\">",
"     66-70",
"    </a>",
"    ]. Although nuchal cords and knots are relatively common, vascular constriction severe enough to kill the fetus rarely occurs. The presence of a nuchal cord or knot may provide the clinician and the patient with an immediate potential explanation for the fetal demise; however, attributing the cause of death to a cord complication should occur only after a thorough search for other causes and when there are other findings supporting this diagnosis. Photographs of the baby with the umbilical cord in situ (eg, around the neck) can help in the assessment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40840?source=see_link&amp;anchor=H4#H4\">",
"     \"Gross examination of the placenta\", section on 'Umbilical cord'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hydrops fetalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrops fetalis may be due to immune or nonimmune etiologies and is often fatal. Diagnosis and management of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34393?source=see_link\">",
"     \"Nonimmune hydrops fetalis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5464?source=see_link\">",
"     \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Platelet alloimmunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe fetal alloimmune thrombocytopenia can result in intracranial hemorrhage and death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/60/12232?source=see_link\">",
"     \"Prenatal management of neonatal alloimmune thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Placental disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross and microscopic examination of the placenta is an integral part of the evaluation of stillbirth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38839?source=see_link\">",
"     \"Evaluation of stillbirth\"",
"    </a>",
"    .) Placental causes of stillbirth include abruptio placenta, vasa previa, placental infection, confined placental mosaicism (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Chromosomal and genetic abnormalities'",
"    </a>",
"    above), neoplasms, structural or vascular malformations, vasculopathy, and infarction. Small placentas are associated with growth restriction and large placentas are associated with large babies; pathological causes of large placentas include hydrops fetalis, maternal diabetes mellitus, and syphilis, which are also causes of stillbirth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Uterine conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common uterine condition associated with stillbirth is uterine rupture. Any uterine abnormality that impairs uteroplacental blood flow can potentially lead to stillbirth, but miscarriage and preterm birth are the more common sequelae of structural uterine abnormalities.",
"   </p>",
"   <p>",
"    Amniotic band sequence causes deformation, but may also result in stillbirth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36902?source=see_link\">",
"     \"Amniotic band sequence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two studies prospective studies, the risk of stillbirth at &ge;24 weeks of gestation among singleton pregnancies with a live fetus at about 11 to 13 weeks of gestation was 0.3 and 0.4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Although risk factors for stillbirth can be identified at the first prenatal visit, these women do not account for the majority of stillbirths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/16\">",
"     16",
"    </a>",
"    ]. A variety of risk factors have been evaluated in an attempt to create models that estimate patient-specific risk for fetal loss, but none performs well enough to be clinically useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Biologic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;No good screening tests are available for clinical assessment of risk of stillbirth in the general obstetrical population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/46/34537?source=see_link&amp;anchor=H23#H23\">",
"     \"Evidence-based approach to prevention\", section on 'Criteria for a good screening test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two laboratory tests commonly obtained in pregnant women have shown some predictive value:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biochemical tests obtained as part of population-based screening programs for Down syndrome, if abnormal, are predictive of adverse pregnancy outcome, including fetal death. The utility of these tests for predicting or preventing stillbirth is low, and is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18329?source=see_link\">",
"       \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7529?source=see_link&amp;anchor=H21#H21\">",
"       \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\", section on 'Adverse pregnancy outcome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemoconcentration has been associated with an elevated risk of stillbirth. Plasma volume expansion and lowered hemoglobin concentration are normal physiologic responses to pregnancy. Plasma volume expansion appears to be important for fetal growth and failure of sufficient hemodilution is associated with an increased risk of stillbirth, even if the fetus is not growth-restricted. This was illustrated in an analysis of a Swedish database that found both an elevated hemoglobin at initial prenatal examination (initial hemoglobin &ge;14.6",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      and failure of significant hemodilution over the course of pregnancy significantly increased the risk of nonanomalous antepartum stillbirth (OR 2.0, 95% C, 1.1-3.8), even after women with preeclampsia and eclampsia were excluded [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/73\">",
"       73",
"      </a>",
"      ]. However, only 5.6 percent of women with stillbirth had an elevated hemoglobin level early in pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common risk factors and medical conditions associated with stillbirth are listed in the table, along with the stillbirth rate associated with these conditions (",
"    <a class=\"graphic graphic_table graphicRef71588 \" href=\"mobipreview.htm?38/21/39261\">",
"     table 4",
"    </a>",
"    ). The prevalence of some risk factors is increasing. As an example, in high income countries, primiparity, maternal age &gt;35 years, obesity, and multiple gestation are becoming more common and are major risk factors for stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/74\">",
"     74",
"    </a>",
"    ]. Many of these risk factors are modifiable. Globally, cigarette smoking is the major modifiable risk factor associated with fetal death. The most common pregnancy-related disorders associated with stillbirth are small for gestational age",
"    <span class=\"nowrap\">",
"     fetus/infant",
"    </span>",
"    and abruptio placentae. The most common medical disorders associated with stillbirth are pre-existing diabetes and hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Race and socioeconomic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, studies have consistently shown that black women have twice the risk of stillbirth as white women, even when only women who received adequate prenatal care were evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/16,19-22,38,75,76\">",
"     16,19-22,38,75,76",
"    </a>",
"    ]. In 2001-2002 in the United States, the stillbirth rates for white, Hispanic and black women were",
"    <span class=\"nowrap\">",
"     1/202,",
"    </span>",
"    <span class=\"nowrap\">",
"     1/83",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1/87.",
"    </span>",
"    Black women had a higher rate of stillbirth throughout gestation, with a peak in relative risk between 20 and 24 weeks. Paradoxically, black women are less likely than women of other races to be induced at term even though they have higher rates of diabetes mellitus, hypertension, placental abruption, and term stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Intimate partner violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Violence against women by their male partner often begins or, if already present, increases during pregnancy and the postpartum period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5784?source=see_link&amp;anchor=H86601695#H86601695\">",
"     \"Intimate partner violence: Epidemiology and health consequences\", section on 'Pregnancy'",
"    </a>",
"    .) The gravida is at risk of emotional and physical trauma, as well as adverse pregnancy outcome, including fetal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/77-81\">",
"     77-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Advanced maternal age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced maternal age is an independent risk factor for stillbirth, even after accounting for medical conditions that are more likely to occur in older women, such as multiple gestation, hypertension, diabetes, previous abortion, and abruptio placenta, all of which are associated with higher rates of stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, stillbirth related to fetal anomalies occurred more often in women 35 years of age or older than in younger women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/84\">",
"     84",
"    </a>",
"    ]. However, after the introduction of routine prenatal screening for fetal anomalies, this risk declined to that observed in their younger counterparts. Currently, the only type of stillbirth that is statistically significantly more common in older women is unexplained fetal demise (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Unexplained stillbirth'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese gravidas (body mass index over 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    are at increased risk of fetal death, especially late fetal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/85\">",
"     85",
"    </a>",
"    ]. The reasons for this association are unknown, but are thought to be due to behavioral, socioeconomic, and obstetrical factors. As an example, obese women are more likely to smoke and to have pregnancies complicated by gestational diabetes and preeclampsia. However, even after controlling for these factors, obesity remains a significant risk factor for stillbirth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stillbirth rate from all causes is higher in fetuses of a multiple gestation than in singletons (19.6 versus 4.7 per 1000 births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/86\">",
"     86",
"    </a>",
"    ]. The increased rate is due to complications specific to twin pregnancy (such as twin-twin transfusion syndrome and twin reverse arterial perfusion [TRAP] sequence) as well as complications, such as fetal anomalies and growth restriction, that can occur in any pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limiting the number of embryos transferred during in vitro fertilization or multifetal pregnancy reduction could reduce the number of stillbirths related to multiple gestation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=see_link\">",
"     \"Strategies to control the rate of high order multiple gestation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39065?source=see_link\">",
"     \"Multifetal pregnancy reduction and selective termination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large case control and cohort studies have shown a relative risk of stillbirth in smokers ranging from 1.2 to 1.4. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27482?source=see_link&amp;anchor=H11#H11\">",
"     \"Smoking and pregnancy\", section on 'Stillbirth'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Maternal medical disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension and diabetes mellitus are among the most common medical conditions that complicate pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/87\">",
"     87",
"    </a>",
"    ]. In the past, these conditions accounted for a significant proportion of fetal deaths related to inadequate medical control of maternal disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36281?source=see_link\">",
"     \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=see_link\">",
"     \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other important medical conditions associated with an increased risk of stillbirth are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef71588 \" href=\"mobipreview.htm?38/21/39261\">",
"     table 4",
"    </a>",
"    ). These conditions are discussed in separate topic reviews on each disorder (see individual topic reviews on pregnancy and renal disease, systemic lupus erythematosus, inherited and acquired thrombophilias, thyroid disease, cardiac disease, specific infections, asthma, cholestasis, hemoglobinopathies, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Past obstetrical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, growth restriction, preterm delivery, and stillbirth can all be sequelae of impaired placental function and there is an association between the birth of a SGA infant in one pregnancy and stillbirth in a subsequent pregnancy (",
"    <a class=\"graphic graphic_table graphicRef56032 \" href=\"mobipreview.htm?18/19/18747\">",
"     table 3",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H7\">",
"     'Fetal growth restriction/placental dysfunction'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    There is a two- to ten-fold risk of recurrent stillbirth, which is affected by multiple factors, including characteristics of the stillbirth and race [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/88\">",
"     88",
"    </a>",
"    ]. The risk of recurrent stillbirth is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38999?source=see_link&amp;anchor=H13#H13\">",
"     \"Counseling parents after stillbirth\", section on 'Recurrence risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/35/1591?source=see_link\">",
"     \"Diagnosis and management of stillbirth\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PREVENTION STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review identified the following ten interventions as those with the best evidence for reducing the burden of stillbirth worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/89\">",
"     89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Periconceptional",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      fortification",
"     </li>",
"     <li>",
"      Prevention of malaria",
"     </li>",
"     <li>",
"      Syphilis detection and treatment",
"     </li>",
"     <li>",
"      Hypertensive disorders of pregnancy detection and management",
"     </li>",
"     <li>",
"      Diabetes of pregnancy detection and management",
"     </li>",
"     <li>",
"      Fetal growth restriction detection and management",
"     </li>",
"     <li>",
"      Postterm pregnancy (&ge;41 weeks of gestation) identification and induction",
"     </li>",
"     <li>",
"      Skilled birth attendant at birth",
"     </li>",
"     <li>",
"      Availability of basic emergency obstetric care",
"     </li>",
"     <li>",
"      Availability of comprehensive emergency obstetric care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This list includes specific interventions that are effective for stillbirth prevention in the developing world, where the risk of stillbirth is high and resources are low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/37,89-93\">",
"     37,89-93",
"    </a>",
"    ]. Most of these interventions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=see_link\">",
"     \"Folic acid for prevention of neural tube defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20695?source=see_link\">",
"     \"Treatment and prevention of malaria in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=see_link\">",
"     \"Syphilis in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16535?source=see_link\">",
"     \"Postterm pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many of these interventions are also applicable to the high income countries. There are no randomized-controlled trials demonstrating an effective method of reducing stillbirth in the general population of these countries. Stillbirth prevention may be possible in some pregnancies at high-risk of stillbirth (eg, fetal growth restriction, decreased fetal movement, postterm pregnancy, maternal medical conditions), if these pregnancies are identified and optimal medical and obstetrical care are provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. Additional interventions for significant modifiable risk factors include preconception weight reduction in obese women, avoidance of delayed childbearing, and smoking cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Recurrence risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrent stillbirth is related to the etiology of the first loss, which reinforces the concept that a thorough stillbirth evaluation is important. Recurrence risks are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38999?source=see_link&amp;anchor=H13#H13\">",
"     \"Counseling parents after stillbirth\", section on 'Recurrence risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Medical and obstetrical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvement in the general health of women, including adequate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    intake; optimum diet and weight; and avoidance of smoking, recreational drugs, and excessive alcohol intake are components of preventative medicine and may reduce stillbirth risk, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies in high income countries suggest that suboptimal medical care accounts for 10 to 60 percent of perinatal deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/96\">",
"     96",
"    </a>",
"    ]. Appropriate medical and obstetrical care can reduce the risk of stillbirth in women with some medical disorders that carry an increased risk of stillbirth, such as poorly controlled pregestational diabetes mellitus or hyperthyroidism. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Maternal medical disorders'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=see_link\">",
"     \"Preconception evaluation and counseling\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    In low income countries, a systematic review found that use of trained versus untrained traditional birth attendants resulted in a lower stillbirth rate (OR 0.69, 95% CI 0.57-0.83), but data were limited to one trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/97\">",
"     97",
"    </a>",
"    ]. There was no evidence that additional training of trained traditional birth attendants led to further reductions in stillbirths.",
"   </p>",
"   <p>",
"    Poor antepartum management of preeclampsia contributes to one third of stillbirths in developing countries. Recognition of these pregnancies and early delivery could prevent some of these deaths. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other strategies include reduction in multiple pregnancy related to assisted reproductive technology and induction to avoid postterm pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=see_link\">",
"     \"Strategies to control the rate of high order multiple gestation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16535?source=see_link\">",
"     \"Postterm pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In population based studies, over 50 percent of fetal deaths have been attributed to either the presence of a fetus that is small for gestational age or placental abruption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/98\">",
"     98",
"    </a>",
"    ]. As an example, in a large cohort study, the stillbirth rate (per 1000 births) was 2.4 in pregnancies without fetal growth restriction, increasing to 9.7 with antenatally detected fetal growth restriction, and 19.8 when it was not detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/49\">",
"     49",
"    </a>",
"    ]. This suggests that strategies should be developed toward risk assessment and management of these two conditions to reduce the number of fetal deaths. For women with a history of a small for gestational age stillbirth, accurate determination of gestational age is important and fetal growth should be monitored with ultrasound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis of fetal anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal screening, diagnostic testing, and elective termination of pregnancies with major congenital anomalies could reduce the proportion of stillbirths related to this etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/99\">",
"     99",
"    </a>",
"    ]. However, pregnancy termination merely results in some potential stillbirths and neonatal deaths to be classified as abortuses, which may not be captured by national vital statistics. As an example, 7 percent of anencephalics in ongoing pregnancies are stillborn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/100\">",
"     100",
"    </a>",
"    ], but pregnancy termination for this diagnosis is common (20 to 70 percent of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/101\">",
"     101",
"    </a>",
"    ]. Routine prenatal screening of low-risk populations has only been proven cost-effective for some abnormalities (eg, Down syndrome, neural tube defects). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43576?source=see_link\">",
"     \"Routine prenatal ultrasonography as a screening tool\"",
"    </a>",
"    .) (Also see individual topic reviews on prenatal diagnosis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Antepartum fetal monitoring and timed delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Theoretically, antepartum fetal monitoring should reduce the risk of stillbirth by identifying fetuses in whom timely intervention will prevent death. The best evidence that antepartum fetal monitoring can play a role in reducing stillbirth rates involves the use of Doppler velocimetry for monitoring the growth restricted fetus. The value of this approach is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .) The rationale for, and the efficacy of, various antepartum fetal monitoring techniques are also reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30121?source=see_link\">",
"     \"Overview of fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The challenge for the clinician is to assess the a priori risk of stillbirth and use antepartum fetal testing wisely. Given that many factors influence the risk of stillbirth, it would be helpful to have an evidence-based interactive model that would estimate the risk of fetal demise in a specific pregnancy. The \"Active Management Of Risk In Pregnancy At Term (AMOR-IPAT)\" model is one such approach under investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the present lack of sufficient data on which to base recommendations, the obstetrical care provider has to use",
"    <span class=\"nowrap\">",
"     her/his",
"    </span>",
"    clinical judgment to decide on the appropriate type and frequency of antepartum monitoring, and to determine when the",
"    <span class=\"nowrap\">",
"     maternal/fetal",
"    </span>",
"    risks of ongoing pregnancy warrant intervention for delivery, even though delivery may result in the birth of a preterm infant or require cesarean birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/87\">",
"     87",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists recommends the initiation of antepartum testing between 32 and 34 weeks of gestation in otherwise healthy women with a previous stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/104\">",
"     104",
"    </a>",
"    ]. Antepartum fetal testing should begin one to two weeks prior to the gestational age of the previous stillbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For reassurance, many practitioners offer early delivery (eg, 38 to 39 weeks) to provide the couple with some psychological reassurance and a measure of control over the pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. An amniocentesis should be performed before any elective delivery &lt;39 weeks, and fetal lung maturity should be confirmed before proceeding with the delivery. We agree with an expert consensus guideline that suggested avoiding scheduled delivery before 39 weeks if the previous stillbirth was unexplained and the current pregnancy is uncomplicated (ie, reassuring fetal testing and no maternal or fetal complications such as preeclampsia or growth restriction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complexity of these decisions was illustrated in a decision-analysis of the risks and benefits of antepartum testing late in pregnancy for women 35 years of age or older using the McGill Obstetrical Neonatal Database to obtain risk estimates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/109\">",
"     109",
"    </a>",
"    ]. This decision analysis considered only late unexplained stillbirth, which comprise the majority of late stillbirths. The model assumed that there was no measurable long-term adverse effect of being born at 36 weeks of gestation or later, so the analysis was begun during the 37th week. It also assumed that the major risk of antepartum testing after 36 weeks was induction of labor and its associated down-stream effects (eg, increased potential for cesarean delivery, morbidity associated with induction and surgery) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sensitivity analysis was used to estimate the effects of this strategy late in pregnancy and found that antepartum testing was successful in reducing the number of unexplained stillbirths, but was also associated with a high risk of labor induction. For nulliparous women 35 years of age or older with an estimated risk of late stillbirth of",
"    <span class=\"nowrap\">",
"     5.2/1000",
"    </span>",
"    pregnancies, the number of fetal deaths averted late in pregnancy was 3.9 per 1000 pregnancies. It would take 863 antepartum tests, 71 additional inductions, and 14 additional cesarean deliveries to prevent one unexplained stillbirth. By comparison, if the estimated risk of late stillbirth was 1 to",
"    <span class=\"nowrap\">",
"     2/1000",
"    </span>",
"    pregnancies, then a strategy of antepartum testing would be expected to avert 1.2 late fetal deaths per 1000 pregnancies, at a cost of 2862 antepartum tests, 233 additional inductions, and 44 additional cesareans per fetal death averted.",
"   </p>",
"   <p>",
"    This model illustrates that any strategy to reduce the risk of late stillbirth depends on the patient's underlying risk and that the number needed to treat to prevent one fetal death will be lower in those women at increased risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Monitoring fetal movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who report decreased fetal movement are at increased risk of having an adverse pregnancy outcome, including stillbirth. Monitoring fetal movement has been suggested as a means of identifying fetuses in whom timely intervention will prevent death. Trials comparing",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    outcome in mixed risk populations of women randomly assigned to follow a formal program of fetal movement counting or routine care have not yielded conclusive results. Observational studies suggest monitoring fetal movement and promptly evaluating women with decreased fetal activity may improve pregnancy outcome. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15959?source=see_link\">",
"     \"Evaluation of decreased fetal movements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Perinatal audit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developing strategies for stillbirth reduction requires an ongoing audit process to evaluate the specific causes of stillbirth and the results of intervention programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/96\">",
"     96",
"    </a>",
"    ]. As an example, perinatal audits have identified stillbirths resulting from deficiencies in intrapartum care, and quality improvement processes have been initiated to prevent recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/92,111\">",
"     92,111",
"    </a>",
"    ]. An audit by the Confidential Inquiry into Stillbirths and Infant Death of Northern Ireland found that failure to diagnose and appropriately manage fetal growth restriction was the most common error leading to stillbirth, followed by failure to recognize additional maternal medical risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/112\">",
"     112",
"    </a>",
"    ]. As discussed above, there is some evidence that antepartum identification and optimal management of these disorders might lower stillbirth rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Elective delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies consistently show that the risk of stillbirth increases late in pregnancy, especially after 38 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/42,113-118\">",
"     42,113-118",
"    </a>",
"    ]. A life-table analysis found that the risk of antepartum stillbirth increased from 1 in 2000 women per week at 37 weeks of gestation, to 1 in 500 at 42 weeks, and 1 in 200 by 43 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/119\">",
"     119",
"    </a>",
"    ]. Theoretically, elective delivery of women at term should prevent some stillbirths since fetal demise can only occur in an ongoing pregnancy. This theory is supported by indirect evidence from an analysis of management of postterm pregnancy over time in Canada [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/36/31306/abstract/120\">",
"     120",
"    </a>",
"    ]. Between 1980 and 1995 there was a marked decrease in pregnancies reaching 42 or more weeks of gestation and a decrease in the rate of stillbirth, presumably related, at least in part, to the increased prevalence of inducing labor at 41 weeks of gestation.",
"   </p>",
"   <p>",
"    There are insufficient data to support a policy of routine elective induction of labor at term. Large, randomized trials with emphasis on maternal and neonatal safety, determination of neonatal benefit as a reflection of reduced unexplained fetal death, and",
"    <span class=\"nowrap\">",
"     cost-effectiveness/cost-benefit",
"    </span>",
"    analyses are needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=see_link&amp;anchor=H5#H5\">",
"     \"Principles of labor induction\", section on 'Elective induction at term'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a strategy of elective induction might be useful in situations associated with an increased risk of stillbirth, such as monoamniotic twin pregnancy, poor glycemic control in a pregnancy complicated by diabetes mellitus, or postterm pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5306?source=see_link\">",
"     \"Twin pregnancy: Labor and delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16535?source=see_link\">",
"     \"Postterm pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/3/29745?source=see_link\">",
"       \"Patient information: Stillbirth (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The definition of stillbirth varies around the world. In the United States, the most common gestational age threshold for distinguishing a stillbirth from a miscarriage is 20 weeks of gestation. Early stillbirths are defined as those occurring at 20 to 27 weeks of gestation, while late stillbirths occur at or after 28 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition of stillbirth'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The stillbirth rate in the United States in 2003 was",
"      <span class=\"nowrap\">",
"       6.23/1000",
"      </span>",
"      live births and fetal deaths. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence and epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of stillbirth include placental pathology associated with fetal growth restriction, infection, placental abruption, fetal anomalies (with and without chromosomal abnormalities), fetomaternal hemorrhage, constriction of the umbilical cord, and hydrops fetalis, but a large proportion are unexplained, especially late in gestation. Variation in the proportion of stillbirths reported as unexplained generally reflects whether the stillbirth has been fully evaluated, and if the classification system allows risk factors to be included as causes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for stillbirth include black race, older maternal age, obesity, multiple gestation, concurrent medical disorders, smoking, and pregnancy complications. Many of these risk factors are modifiable. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No intervention has been proven to significantly reduce the rate of stillbirth in the general obstetrical population. Interventions such as achieving good glycemic control, induction of labor, and Doppler velocimetry are useful in selected high risk populations. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prevention strategies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization. Definitions and indicators in Family Planning Maternal &amp; Child Health and Reproductive Health. Geneva: WHO Press, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/2\">",
"      Sachs BP, Fretts RC, Gardner R, et al. The impact of extreme prematurity and congenital anomalies on the interpretation of international comparisons of infant mortality. Obstet Gynecol 1995; 85:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/3\">",
"      Cartlidge PH, Stewart JH. Effect of changing the stillbirth definition on evaluation of perinatal mortality rates. Lancet 1995; 346:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/4\">",
"      Wilson AL, Fenton LJ, Munson DP. State reporting of live births of newborns weighing less than 500 grams: impact on neonatal mortality rates. Pediatrics 1986; 78:850.",
"     </a>",
"    </li>",
"    <li>",
"     Procedures for coding fetal cause of death (2003 revision). Available at www.cdc.gov/nchs/about/major/fetaldth/abfetal.htm#Data percent20Highlights. (Accessed 2/28/07).",
"    </li>",
"    <li>",
"     www.stillbirthalliance.org. (Accessed 2/28/07).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/7\">",
"      Setel PW, Sankoh O, Rao C, et al. Sample registration of vital events with verbal autopsy: a renewed commitment to measuring and monitoring vital statistics. Bull World Health Organ 2005; 83:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/8\">",
"      Cousens S, Blencowe H, Stanton C, et al. National, regional, and worldwide estimates of stillbirth rates in 2009 with trends since 1995: a systematic analysis. Lancet 2011; 377:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/9\">",
"      Lawn JE, Blencowe H, Pattinson R, et al. Stillbirths: Where? When? Why? How to make the data count? Lancet 2011; 377:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/10\">",
"      Hamilton BE, Mini&ntilde;o AM, Martin JA, et al. Annual summary of vital statistics: 2005. Pediatrics 2007; 119:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/11\">",
"      Getahun D, Ananth CV, Kinzler WL. Risk factors for antepartum and intrapartum stillbirth: a population-based study. Am J Obstet Gynecol 2007; 196:499.",
"     </a>",
"    </li>",
"    <li>",
"     CDC, National Center for Health Statistics (NCHS), National Vital Statistics Report (NversusR) 54(16) May 3, 2006. file://www.cdc.gov/nchs/data/nversusr/nversusr54/nversusr54_16.pdf. (Accessed 2/28/07).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/13\">",
"      MacDorman MF, Kirmeyer S. Fetal and perinatal mortality, United States, 2005. Natl Vital Stat Rep 2009; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     MacDorman MF, Munson ML, Kirmeyer S. Fetal and perinatal mortality, United States, 2004. Natl Vital Stat Rep 2007;56(3). Available at www.cdc.gov/nchs/products/pubs/pubd/nvsr/nvsr.htm#vol56 (Accessed December 17, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/15\">",
"      Willinger M, Ko CW, Reddy UM. Racial disparities in stillbirth risk across gestation in the United States. Am J Obstet Gynecol 2009; 201:469.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/16\">",
"      Stillbirth Collaborative Research Network Writing Group. Association between stillbirth and risk factors known at pregnancy confirmation. JAMA 2011; 306:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/17\">",
"      Copper RL, Goldenberg RL, DuBard MB, Davis RO. Risk factors for fetal death in white, black, and Hispanic women. Collaborative Group on Preterm Birth Prevention. Obstet Gynecol 1994; 84:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/18\">",
"      Sharma PP, Salihu HM, Oyelese Y, et al. Is race a determinant of stillbirth recurrence? Obstet Gynecol 2006; 107:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/19\">",
"      Salihu HM, Kinniburgh BA, Aliyu MH, et al. Racial disparity in stillbirth among singleton, twin, and triplet gestations in the United States. Obstet Gynecol 2004; 104:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/20\">",
"      Healy AJ, Malone FD, Sullivan LM, et al. Early access to prenatal care: implications for racial disparity in perinatal mortality. Obstet Gynecol 2006; 107:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/21\">",
"      Vintzileos AM, Ananth CV, Smulian JC, et al. Prenatal care and black-white fetal death disparity in the United States: heterogeneity by high-risk conditions. Obstet Gynecol 2002; 99:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/22\">",
"      Kallan JE. Rates of fetal death by maternal race, ethnicity, and nativity: New Jersey, 1991-1998. JAMA 2001; 285:2978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/23\">",
"      Balchin I, Whittaker JC, Patel RR, et al. Racial variation in the association between gestational age and perinatal mortality: prospective study. BMJ 2007; 334:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/24\">",
"      McClure EM, Wright LL, Goldenberg RL, et al. The global network: a prospective study of stillbirths in developing countries. Am J Obstet Gynecol 2007; 197:247.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/25\">",
"      Korteweg FJ, Gordijn SJ, Timmer A, et al. The Tulip classification of perinatal mortality: introduction and multidisciplinary inter-rater agreement. BJOG 2006; 113:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/26\">",
"      Gardosi J, Kady SM, McGeown P, et al. Classification of stillbirth by relevant condition at death (ReCoDe): population based cohort study. BMJ 2005; 331:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/27\">",
"      Wigglesworth JS. Classification of perinatal deaths. Soz Praventivmed 1994; 39:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/28\">",
"      de Galan-Roosen AE, Kuijpers JC, Oei YB, et al. [Discrepancy between results of registration of perinatal cause of death by the CBS (Central Bureau of Statistics) and by personal studies in the Delft-Westland-Oostland region]. Ned Tijdschr Geneeskd 1997; 141:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/29\">",
"      Vergani P, Cozzolino S, Pozzi E, et al. Identifying the causes of stillbirth: a comparison of four classification systems. Am J Obstet Gynecol 2008; 199:319.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/30\">",
"      Varli IH, Petersson K, Bottinga R, et al. The Stockholm classification of stillbirth. Acta Obstet Gynecol Scand 2008; 87:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/31\">",
"      Wigglesworth JS. Monitoring perinatal mortality. A pathophysiological approach. Lancet 1980; 2:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/32\">",
"      Chan A, King JF, Flenady V, et al. Classification of perinatal deaths: development of the Australian and New Zealand classifications. J Paediatr Child Health 2004; 40:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/33\">",
"      Silver RM, Varner MW, Reddy U, et al. Work-up of stillbirth: a review of the evidence. Am J Obstet Gynecol 2007; 196:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/34\">",
"      Reddy UM, Goldenberg R, Silver R, et al. Stillbirth classification--developing an international consensus for research: executive summary of a National Institute of Child Health and Human Development workshop. Obstet Gynecol 2009; 114:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/35\">",
"      Lawn J, Shibuya K, Stein C. No cry at birth: global estimates of intrapartum stillbirths and intrapartum-related neonatal deaths. Bull World Health Organ 2005; 83:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/36\">",
"      Di Mario S, Say L, Lincetto O. Risk factors for stillbirth in developing countries: a systematic review of the literature. Sex Transm Dis 2007; 34:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/37\">",
"      McClure EM, Nalubamba-Phiri M, Goldenberg RL. Stillbirth in developing countries. Int J Gynaecol Obstet 2006; 94:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/38\">",
"      Stillbirth Collaborative Research Network Writing Group. Causes of death among stillbirths. JAMA 2011; 306:2459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/39\">",
"      Fretts RC, Boyd ME, Usher RH, Usher HA. The changing pattern of fetal death, 1961-1988. Obstet Gynecol 1992; 79:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/40\">",
"      Huang DY, Usher RH, Kramer MS, et al. Determinants of unexplained antepartum fetal deaths. Obstet Gynecol 2000; 95:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/41\">",
"      Fr&oslash;en JF, Arnestad M, Frey K, et al. Risk factors for sudden intrauterine unexplained death: epidemiologic characteristics of singleton cases in Oslo, Norway, 1986-1995. Am J Obstet Gynecol 2001; 184:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/42\">",
"      Yudkin PL, Wood L, Redman CW. Risk of unexplained stillbirth at different gestational ages. Lancet 1987; 1:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/43\">",
"      Alessandri LM, Stanley FJ, Newnham J, Walters BN. The epidemiological characteristics of unexplained antepartum stillbirths. Early Hum Dev 1992; 30:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/44\">",
"      Cnattingius S, Haglund B, Kramer MS. Differences in late fetal death rates in association with determinants of small for gestational age fetuses: population based cohort study. BMJ 1998; 316:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/45\">",
"      Fr&oslash;en JF, Gardosi JO, Thurmann A, et al. Restricted fetal growth in sudden intrauterine unexplained death. Acta Obstet Gynecol Scand 2004; 83:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/46\">",
"      Surkan PJ, Stephansson O, Dickman PW, Cnattingius S. Previous preterm and small-for-gestational-age births and the subsequent risk of stillbirth. N Engl J Med 2004; 350:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/47\">",
"      Zhang J, Klebanoff MA. Small-for-gestational-age infants and risk of fetal death in subsequent pregnancies. N Engl J Med 2004; 350:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/48\">",
"      Gilbert WM, Danielsen B. Pregnancy outcomes associated with intrauterine growth restriction. Am J Obstet Gynecol 2003; 188:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/49\">",
"      Gardosi J, Madurasinghe V, Williams M, et al. Maternal and fetal risk factors for stillbirth: population based study. BMJ 2013; 346:f108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/50\">",
"      Raymond EG, Cnattingius S, Kiely JL. Effects of maternal age, parity, and smoking on the risk of stillbirth. Br J Obstet Gynaecol 1994; 101:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/51\">",
"      Atterwill CK, Meakin JM. Delayed treatment with nerve growth factor (NGF) reverses ECMA-induced cholinergic lesions in rat brain reaggregate cultures. Biochem Pharmacol 1990; 39:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/52\">",
"      Goldenberg RL, McClure EM, Saleem S, Reddy UM. Infection-related stillbirths. Lancet 2010; 375:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/53\">",
"      Iwasenko JM, Howard J, Arbuckle S, et al. Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy. J Infect Dis 2011; 203:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/54\">",
"      Gibbs RS. The origins of stillbirth: infectious diseases. Semin Perinatol 2002; 26:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/55\">",
"      Blackwell S, Romero R, Chaiworapongsa T, et al. Unexplained fetal death is associated with changes in the adaptive limb of the maternal immune response consistent with prior antigenic exposure. J Matern Fetal Neonatal Med 2003; 14:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/56\">",
"      Blackwell S, Romero R, Chaiworapongsa T, et al. Maternal and fetal inflammatory responses in unexplained fetal death. J Matern Fetal Neonatal Med 2003; 14:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/57\">",
"      Lahra MM, Gordon A, Jeffery HE. Chorioamnionitis and fetal response in stillbirth. Am J Obstet Gynecol 2007; 196:229.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/58\">",
"      Morrison I, Olsen J. Weight-specific stillbirths and associated causes of death: an analysis of 765 stillbirths. Am J Obstet Gynecol 1985; 152:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/59\">",
"      Strom CM, Ginsberg N, Applebaum M, et al. Analyses of 95 first-trimester spontaneous abortions by chorionic villus sampling and karyotype. J Assist Reprod Genet 1992; 9:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/60\">",
"      Angell RR, Sandison A, Bain AD. Chromosome variation in perinatal mortality: a survey of 500 cases. J Med Genet 1984; 21:39.",
"     </a>",
"    </li>",
"    <li>",
"     Hsu LYF. Prenatal diagnosis of chromosomal abnormalities through amniocentesis. In: Genetic disorders and the fetus, 4th ed, Milunsky A (Ed), The Johns Hopkins University Press, Baltimore 1998. p.179.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/62\">",
"      Korteweg FJ, Bouman K, Erwich JJ, et al. Cytogenetic analysis after evaluation of 750 fetal deaths: proposal for diagnostic workup. Obstet Gynecol 2008; 111:865.",
"     </a>",
"    </li>",
"    <li>",
"     Am J Med Genet 1998; 44:338.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/64\">",
"      Owen J, Stedman CM, Tucker TL. Comparison of predelivery versus postdelivery Kleihauer-Betke stains in cases of fetal death. Am J Obstet Gynecol 1989; 161:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/65\">",
"      Giacoia GP. Severe fetomaternal hemorrhage: a review. Obstet Gynecol Surv 1997; 52:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/66\">",
"      S&oslash;rnes T. Umbilical cord knots. Acta Obstet Gynecol Scand 2000; 79:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/67\">",
"      Carey JC, Rayburn WF. Nuchal cord encirclements and risk of stillbirth. Int J Gynaecol Obstet 2000; 69:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/68\">",
"      Sch&auml;ffer L, Burkhardt T, Zimmermann R, Kurmanavicius J. Nuchal cords in term and postterm deliveries--do we need to know? Obstet Gynecol 2005; 106:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/69\">",
"      Clapp JF 3rd, Stepanchak W, Hashimoto K, et al. The natural history of antenatal nuchal cords. Am J Obstet Gynecol 2003; 189:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/70\">",
"      Larson JD, Rayburn WF, Crosby S, Thurnau GR. Multiple nuchal cord entanglements and intrapartum complications. Am J Obstet Gynecol 1995; 173:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/71\">",
"      Akolekar R, Bower S, Flack N, et al. Prediction of miscarriage and stillbirth at 11-13 weeks and the contribution of chorionic villus sampling. Prenat Diagn 2011; 31:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/72\">",
"      Dugoff L, Cuckle HS, Hobbins JC, et al. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers. Am J Obstet Gynecol 2008; 199:290.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/73\">",
"      Stephansson O, Dickman PW, Johansson A, Cnattingius S. Maternal hemoglobin concentration during pregnancy and risk of stillbirth. JAMA 2000; 284:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/74\">",
"      Flenady V, Koopmans L, Middleton P, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. Lancet 2011; 377:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/75\">",
"      Salihu HM, Sharma PP, Aliyu MH, et al. Is small for gestational age a marker of future fetal survival in utero? Obstet Gynecol 2006; 107:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/76\">",
"      Reddy UM, Laughon SK, Sun L, et al. Prepregnancy risk factors for antepartum stillbirth in the United States. Obstet Gynecol 2010; 116:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/77\">",
"      Alio AP, Nana PN, Salihu HM. Spousal violence and potentially preventable single and recurrent spontaneous fetal loss in an African setting: cross-sectional study. Lancet 2009; 373:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/78\">",
"      Janssen PA, Holt VL, Sugg NK, et al. Intimate partner violence and adverse pregnancy outcomes: a population-based study. Am J Obstet Gynecol 2003; 188:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/79\">",
"      Jejeebhoy SJ. Associations between wife-beating and fetal and infant death: impressions from a survey in rural India. Stud Fam Plann 1998; 29:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/80\">",
"      Coker AL, Sanderson M, Dong B. Partner violence during pregnancy and risk of adverse pregnancy outcomes. Paediatr Perinat Epidemiol 2004; 18:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/81\">",
"      Ahmed S, Koenig MA, Stephenson R. Effects of domestic violence on perinatal and early-childhood mortality: evidence from north India. Am J Public Health 2006; 96:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/82\">",
"      Fretts RC, Schmittdiel J, McLean FH, et al. Increased maternal age and the risk of fetal death. N Engl J Med 1995; 333:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/83\">",
"      Cnattingius S, Forman MR, Berendes HW, Isotalo L. Delayed childbearing and risk of adverse perinatal outcome. A population-based study. JAMA 1992; 268:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/84\">",
"      Fretts RC, Usher RH. Causes of fetal death in women of advanced maternal age. Obstet Gynecol 1997; 89:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/85\">",
"      Stephansson O, Dickman PW, Johansson A, Cnattingius S. Maternal weight, pregnancy weight gain, and the risk of antepartum stillbirth. Am J Obstet Gynecol 2001; 184:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/86\">",
"      Bell R, Glinianaia SV, Rankin J, et al. Changing patterns of perinatal death, 1982-2000: a retrospective cohort study. Arch Dis Child Fetal Neonatal Ed 2004; 89:F531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/87\">",
"      Fretts RC. Etiology and prevention of stillbirth. Am J Obstet Gynecol 2005; 193:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/88\">",
"      Reddy UM. Prediction and prevention of recurrent stillbirth. Obstet Gynecol 2007; 110:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/89\">",
"      Bhutta ZA, Yakoob MY, Lawn JE, et al. Stillbirths: what difference can we make and at what cost? Lancet 2011; 377:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/90\">",
"      Adam T, Lim SS, Mehta S, et al. Cost effectiveness analysis of strategies for maternal and neonatal health in developing countries. BMJ 2005; 331:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/91\">",
"      Jokhio AH, Winter HR, Cheng KK. An intervention involving traditional birth attendants and perinatal and maternal mortality in Pakistan. N Engl J Med 2005; 352:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/92\">",
"      Goffinet F, Combier E, Bucourt M, et al. [Epidemiology of fetal deaths in the Seine-Saint-Denis perinatal survey]. J Gynecol Obstet Biol Reprod (Paris) 1996; 25:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/93\">",
"      Pattinson R, Kerber K, Buchmann E, et al. Stillbirths: how can health systems deliver for mothers and babies? Lancet 2011; 377:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/94\">",
"      Saastad E, Vangen S, Fr&oslash;en JF. Suboptimal care in stillbirths - a retrospective audit study. Acta Obstet Gynecol Scand 2007; 86:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/95\">",
"      Richardus JH, Graafmans WC, Verloove-Vanhorick SP, et al. Differences in perinatal mortality and suboptimal care between 10 European regions: results of an international audit. BJOG 2003; 110:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/96\">",
"      Flenady V, Middleton P, Smith GC, et al. Stillbirths: the way forward in high-income countries. Lancet 2011; 377:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/97\">",
"      Sibley LM, Sipe TA, Barry D. Traditional birth attendant training for improving health behaviours and pregnancy outcomes. Cochrane Database Syst Rev 2012; 8:CD005460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/98\">",
"      Smulian JC, Ananth CV, Vintzileos AM, et al. Fetal deaths in the United States. Influence of high-risk conditions and implications for management. Obstet Gynecol 2002; 100:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/99\">",
"      Liu S, Joseph KS, Kramer MS, et al. Relationship of prenatal diagnosis and pregnancy termination to overall infant mortality in Canada. JAMA 2002; 287:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/100\">",
"      Jaquier M, Klein A, Boltshauser E. Spontaneous pregnancy outcome after prenatal diagnosis of anencephaly. BJOG 2006; 113:951.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov/mmwR/preview/mmwrhtml/00038567.htm (accessed March 8, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/102\">",
"      Nicholson JM, Caughey AB, Stenson MH, et al. The active management of risk in multiparous pregnancy at term: association between a higher preventive labor induction rate and improved birth outcomes. Am J Obstet Gynecol 2009; 200:250.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/103\">",
"      Nicholson JM, Stenson MH, Kellar LC, et al. Active management of risk in nulliparous pregnancy at term: association between a higher preventive labor induction rate and improved birth outcomes. Am J Obstet Gynecol 2009; 200:254.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/104\">",
"      ACOG Practice Bulletin No. 102: management of stillbirth. Obstet Gynecol 2009; 113:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/105\">",
"      Spong CY. Add stillbirth to the list of outcomes to worry about in a pregnant woman with a history of preterm birth or fetal growth restriction. Obstet Gynecol 2012; 119:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/106\">",
"      Eller AG, Branch DW, Byrne JL. Stillbirth at term. Obstet Gynecol 2006; 108:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/107\">",
"      Weeks JW, Asrat T, Morgan MA, et al. Antepartum surveillance for a history of stillbirth: when to begin? Am J Obstet Gynecol 1995; 172:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/108\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/109\">",
"      Fretts RC, Elkin EB, Myers ER, Heffner LJ. Should older women have antepartum testing to prevent unexplained stillbirth? Obstet Gynecol 2004; 104:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/110\">",
"      Heffner LJ, Elkin E, Fretts RC. Impact of labor induction, gestational age, and maternal age on cesarean delivery rates. Obstet Gynecol 2003; 102:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/111\">",
"      Sachs BP. A 38-year-old woman with fetal loss and hysterectomy. JAMA 2005; 294:833.",
"     </a>",
"    </li>",
"    <li>",
"     Confidential Enquiry into Maternal and Child Health. Perinatal Mortality Surveillance, 2004: England, Wales and Northern Ireland. London: CEMACH, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/113\">",
"      Cotzias CS, Paterson-Brown S, Fisk NM. Prospective risk of unexplained stillbirth in singleton pregnancies at term: population based analysis. BMJ 1999; 319:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/114\">",
"      Hilder L, Costeloe K, Thilaganathan B. Prolonged pregnancy: evaluating gestation-specific risks of fetal and infant mortality. Br J Obstet Gynaecol 1998; 105:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/115\">",
"      Caughey AB, Musci TJ. Complications of term pregnancies beyond 37 weeks of gestation. Obstet Gynecol 2004; 103:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/116\">",
"      Stallmach T, Hebisch G, Meier K, et al. Rescue by birth: defective placental maturation and late fetal mortality. Obstet Gynecol 2001; 97:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/117\">",
"      Divon MY, Haglund B, Nisell H, et al. Fetal and neonatal mortality in the postterm pregnancy: the impact of gestational age and fetal growth restriction. Am J Obstet Gynecol 1998; 178:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/118\">",
"      Campbell MK, Ostbye T, Irgens LM. Post-term birth: risk factors and outcomes in a 10-year cohort of Norwegian births. Obstet Gynecol 1997; 89:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/119\">",
"      Smith GC. Life-table analysis of the risk of perinatal death at term and post term in singleton pregnancies. Am J Obstet Gynecol 2001; 184:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/36/31306/abstract/120\">",
"      Sue-A-Quan AK, Hannah ME, Cohen MM, et al. Effect of labour induction on rates of stillbirth and cesarean section in post-term pregnancies. CMAJ 1999; 160:1145.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6827 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-119.36.87.26-D553724FC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31306=[""].join("\n");
var outline_f30_36_31306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF STILLBIRTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24002174\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Unexplained stillbirth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Fetal growth restriction/placental dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abruptio placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chromosomal and genetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Umbilical cord complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Platelet alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Placental disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Uterine conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Biologic markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Race and socioeconomic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Advanced maternal age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Maternal medical disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Past obstetrical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      DIAGNOSIS AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PREVENTION STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Recurrence risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Medical and obstetrical care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Prenatal diagnosis of fetal anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Antepartum fetal monitoring and timed delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Monitoring fetal movement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Perinatal audit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Elective delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6827\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6827|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/7/3186\" title=\"figure 1\">",
"      Stillbirth risk by GA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6827|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/63/3069\" title=\"table 1\">",
"      Wigglesworth classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/28/22989\" title=\"table 2\">",
"      Etiology fetal death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/19/18747\" title=\"table 3\">",
"      SGA stillbirth association",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/21/39261\" title=\"table 4\">",
"      Risk factors stillbirth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36902?source=related_link\">",
"      Amniotic band sequence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/5/38999?source=related_link\">",
"      Counseling parents after stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/35/1591?source=related_link\">",
"      Diagnosis and management of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/23/22906?source=related_link\">",
"      Diagnosis of fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/37/15959?source=related_link\">",
"      Evaluation of decreased fetal movements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38839?source=related_link\">",
"      Evaluation of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/61/5081?source=related_link\">",
"      Folic acid for prevention of neural tube defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40840?source=related_link\">",
"      Gross examination of the placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5784?source=related_link\">",
"      Intimate partner violence: Epidemiology and health consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27353?source=related_link\">",
"      Midtrimester preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39065?source=related_link\">",
"      Multifetal pregnancy reduction and selective termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10616?source=related_link\">",
"      Overview of causes of and risk factors for fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=related_link\">",
"      Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/3/29745?source=related_link\">",
"      Patient information: Stillbirth (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21096?source=related_link\">",
"      Perinatal mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16535?source=related_link\">",
"      Postterm pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18329?source=related_link\">",
"      Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/60/12232?source=related_link\">",
"      Prenatal management of neonatal alloimmune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/35/43576?source=related_link\">",
"      Routine prenatal ultrasonography as a screening tool",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/27/43449?source=related_link\">",
"      Strategies to control the rate of high order multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/61/4057?source=related_link\">",
"      Syphilis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5306?source=related_link\">",
"      Twin pregnancy: Labor and delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_36_31307="Treatment of painful diabetic neuropathy";
var content_f30_36_31307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for painful diabetic neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tricyclics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amitriptyline 25 to 100 mg at night",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nortriptyline 25 to 100 mg at night",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxepin 25 to 100 mg at night",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duloxetine 60 to 120 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venlafaxine 75 to 225 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Anticonvulsants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregabalin 300 to 600 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium valproate 500 to 1200 mg daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capsaicin topical cream 0.075 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine patch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha-lipoic acid 600 mg once daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isosorbide dinitrate spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transcutaneous electrical nerve stimulation (TENS)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31307=[""].join("\n");
var outline_f30_36_31307=null;
var title_f30_36_31308="Guidelines opioid rotation";
var content_f30_36_31308=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for opioid rotation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Step 1:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Consider opioid rotation as a strategy to address the scenario of poor opioid responsiveness following dose titration.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The decision about the drug to which the patient is switched is empirical, based on prior experience of the patient and physician, availability, cost, and other factors.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       When the new drug is selected, calculate the equianalgesic dose from an equianalgesic dose table.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If switching to any opioid other than methadone or fentanyl, identify an \"automatic dose reduction window\" equal to a reduction of 25-50 percent below the calculated equianalgesic dose.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If switching to methadone, the \"automatic dose reduction window\" should be a 75-90 percent reduction below the calculated equianalgesic dose. Great caution should be exercised in converting to methadone at doses of 100 mg or greater per day; consider inpatient monitoring, including serial EKG monitoring.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If switching to transdermal fentanyl, do not do an automatic dose reduction and use the calculated equianalgesic dose included in the FDA-approved manufacturer's labeling for these formulations.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Select a dose closer to the lower boundary (25 percent reduction) or the upper boundary (50 percent reduction) of the \"automatic dose reduction window\" on the basis of a clinical judgment that the equianalgesic dose table is relatively more or less applicable, respectively, to the specific characteristics of the opioid regimen or patient:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       - Select a dose closer to the upper boundary (50 percent reduction) of the reduction if the patient is receiving a relatively high dose of the current opioid regimen, is not Caucasian, or is elderly or medically frail.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       - Select a dose closer to the lower boundary (25 percent reduction) of the reduction if the patient does not have these characteristics or is undergoing a switch to a different route of systemic drug administration using the same drug.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Step 2:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Before finally selecting the starting dose of the new opioid, perform a second assessment of pain severity and other medical or psychosocial characteristics to determine whether to apply an additional increase or decrease of 15-30 percent to enhance the likelihood that the initial dose will be effective for pain, or conversely, unlikely to cause withdrawal or opioid-related side effects.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       After the initial doses, assess response and titrate the dose of the new opioid regimen to optimize outcomes.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If a supplemental \"rescue dose\" is used for titration, calculate this at 5 to 15 percent of the total daily opioid dose and administer at an appropriate interval; an exception are the oral transmucosal fentanyl formulations, which should be initiated at one of the lower available doses irrespective of the baseline opioid dose.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31308=[""].join("\n");
var outline_f30_36_31308=null;
var title_f30_36_31309="Rates of recovery in hibernating myocardium";
var content_f30_36_31309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F55431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F55431&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rates of recovery in hibernating myocardium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is the possible range of acute, subacute, and chronic myocardial hibernation, based on the rate of recovery of ventricular function after increasing coronary artery blood flow. The role of stunned myocardium (S) and structural changes (SC) in the myocardium can also be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from: Rahimtoola SH. Am J Cardiol 1995; 75:16E.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31309=[""].join("\n");
var outline_f30_36_31309=null;
var title_f30_36_31310="Factors affecting neonatal oxygen dissociation curve";
var content_f30_36_31310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59739&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Factors that affect the neonatal oxygen-dissociation curve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 393px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The oxygen-dissociation curve of human blood and the effects of changes in the H",
"    <sup>",
"     +",
"    </sup>",
"    ion concentration, Pco",
"    <sub>",
"     2",
"    </sub>",
"    temperature and level of 2,3-diposphoglycerate (2,3-DPG) are depicted above. For fetal hemoglobin, the normal curve (a) is shifted to the left (b).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Levin AR. Management of the cyanotic newborn. Ped Ann 1981; 10:127. Copyright &copy; 1981 SLACK, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31310=[""].join("\n");
var outline_f30_36_31310=null;
var title_f30_36_31311="Adult shoulder scapular Y";
var content_f30_36_31311=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Scapular Y-view of the shoulder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This radiograph utilizes a scapular Y-view of the shoulder to assess the location of the humeral head. Anterior or posterior dislocation are excluded by a normal position of the humeral head (HH) relative to the coracoid (C) and the acromion process (A). The inferior portion of the \"Y\" is formed by the body of the scapula (S).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_36_31311=[""].join("\n");
var outline_f30_36_31311=null;
